CUMULATIVE
SUPPLEMENT 5
MAY 2001



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

21ST EDITION

Department of Health and Human Services
Public Health Service
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Information Technology
Division of Data Management and Services

2001

Prepared By
Division of Data Management and Services
Office of Information Technology
Center for Drug Evaluation and Research
Food and Drug Administration

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

21ST EDITION

Cumulative Supplement 5

May 2001

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

21ST EDITION

CUMULATIVE SUPPLEMENT 5
MAY 2001

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 21st Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 21st Edition List will then be added to the "Discontinued Drug Product List" appearing in the 22nd Edition. The current edition Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >**A**>. The Patent and Exclusivity Data are indicated by the symbol >**ADD**> to the left of the line on which new information exists. The >**ADD**> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >**D**> (DELETE) to the left of the line. The information line with the >**D**> symbol is dropped in subsequent Cumulative Supplements for that item.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated

Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
CAMALL CO INC (CAMALL)	ABC HOLDING CORPORATION (ABC HOLDING)
KNOLL PHARMACEUTICAL COMPANY (KNOLL PHARM)	ABBOTT LABORATORIES PHARMACEUTICAL PRODUCTS (ABBOTT)
MEDEVA AMERICAS INC (MEDEVA)	CELLTECH PHARMACEUTICALS INC (CELLTECH PHARMS)
MEDEVA PHARMACEUTICALS INC (MEDEVA)	CELLTECH PHARMACEUTICALS INC (CELLTECH PHARMS)
MEDEVA INC (MEDEVA)	CELLTECH PHARMACEUTICALS INC (CELLTECH PHARMS)
MEDEVA PHARMACEUTICALS CA INC (MEDEVA PHARMS CA)	CELLTECH MANUFACTURING CA INC (CELLTECH MFG CA INC)
MEDEVA PHARMACEUTICALS MA INC (MEDEVA PHARMS MA)	CELLTECH MANUFACTURING INC (CELLTECH MFG)
NOVOPHARM LTD (NOVOPHARM)	TEVA PHARMACEUTICALS USA (TEVA)
NOVOPHARM PHARMACEUTICAL CO (NOVOPHARM PHARM)	TEVA PHARMACEUTICALS USA (TEVA)
NOVOPHARM NC INC (NOVOPHARM NC)	TEVA PHARMACEUTICALS USA (TEVA)

1.3 AVAILABILITY OF THE EDITION

The 21st Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents
Government Printing Office
P.O. Box 371954
Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800. The cost is $101.00 annually.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related drug information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

There is an Electronic Orange Book Query (EOB) at http://www.fda.gov/cder/ob. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the annual edition or monthly cumulative supplements.

The Internet version of the hard copy Orange Book annual edition is at
http://www.fda.gov/cder/orange/adp.htm.

The Internet version of the hard copy monthly supplement is at
http://www.fda.gov/cder/orange/supplement/cspreface.htm. Changes to the annual edition are listed separately by month.

There are ASCII text files of the Orange Book drug product data at
http://www.fda.gov/cder/orange/obreadme.htm. The drug product text files are zipped into zipobtxt.exe. The files are updated concurrently with the publication of the annual edition or monthly cumulative supplements. Appendix A and Appendix B are updated quarterly.

The 21st annual edition of the 2000 Orange Book Patent and Exclusivity List is at
http://www.fda.gov/cder/orange/21bookpub.pdf.

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at http://www.fda.gov/cder/orange/supplement/patents.pdf.

The Patent Term Extension and new Patents, Docket Number *95S-0117, is at
http://www.fda.gov/cder/orange/docket.pdf. It is updated monthly as soon as available and as otherwise needed.

The Drug Price Competition and Patent Term Restoration Act requires that patent information be filed with all newly submitted Section 505 drug applications. To facilitate industry submission of the information, a patent submission sample format is available in HTML and PDF format at:
http://www.fda.gov/cder/orange/patdecl.pdf
http://www.fda.gov/cder/orange/patdecl.html

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.4 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2000) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2000	MAR 2001	JUN 2001	SEP 2001
	10360	10372		
DRUG PRODUCTS LISTED	2682 (25.9%)	2696 (26.0%)		
SINGLE SOURCE	7568 (73.1%)	7566 (72.9%)		
MULTISOURCE	7257 (70.0%)	7263 (70.0%)		
THERAPEUTICALLY EQUIVALENT				
NOT THERAPEUTICALLY EQUIVALENT	311 (3.0%)	303 (2.9%)		
EXCEPTIONS[1]	110 (1.1%)	110 (1.1%)		
NEW MOLECULAR ENTITIES APPROVED	2	6		
NUMBER OF APPLICANTS	594	582		

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

Please Note

1.5 CUMULATIVE SUPPLEMENT LEGEND

The 21st Edition Orange book (OB) Cumulative Supplement (CS) layout has changed. The new format follows the Annual Edition and previous CS format. The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form;Route and then by trade name. The manner of displaying the individual product information has changed.

The individual product record follows the previous format layout for Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Approval number, product number, and approval date. Two new columns have been added to provide more information. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form;route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product throuth the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.
CTNA	Change. Trade Name.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
WDRP	Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition.

ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE

CAPSULE; ORAL

ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE

>D>		+ MIKART	150MG;180MG;15MG	N81095 001	OCT 26, 1990	MAY	DISC	
>A>		@	150MG;180MG;15MG	N81095 001	OCT 26, 1990	MAY	DISC	
>D>		+	150MG;180MG;60MG	N81097 001	OCT 26, 1990	MAY	DISC	
>A>		@	150MG;180MG;60MG	N81097 001	OCT 26, 1990	MAY	DISC	

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL

TRIAPRIN

		@ DUNHALL	325MG;50MG	N89268 001	JUL 02, 1987	FEB	WDRP	

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

ANOQUAN

		@ ROBERTS AND HAUCK	325MG;50MG;40MG	N87628 001	OCT 01, 1986	FEB	WDRP	

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL; ACETAMINOPHEN; AND CAFFEINE WITH CODEINE PHOSPHATE

	AB	WEST WARD	325MG;50MG;40MG;30MG	N75618 001	MAR 23, 2001	MAR	NEWA	

FIORICET W/ CODEINE

	AB	+ NOVARTIS	325MG;50MG;40MG;30MG	N20232 001	JUL 30, 1992	MAR	CFTG	

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

TABLET; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

		+ MIKART	712.8MG;60MG;32MG	N40316 001	APR 28, 1999	JAN	CTNA	

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

>A>	AA	MALLINCKRODT	300MG;15MG	N40419 001	MAY 31, 2001	MAY	NEWA	
>A>	AA		300MG;30MG	N40419 002	MAY 31, 2001	MAY	NEWA	
>A>	AA		300MG;60MG	N40419 003	MAY 31, 2001	MAY	NEWA	

CAPITAL WITH CODEINE

		@ CARNRICK	325MG;30MG	N83643 001	MAY 31, 1974	FEB	WDRP	

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

		+ WATSON LABS	750MG;10MG	N40094 004	MAR 22, 1999	APR	NEWA	

LORTAB

	AA	+ WATSON LABS	325MG;5MG	N40099 001	JUN 25, 1997	JAN	CAHN	

NORCO

	AA	WATSON LABS	325MG;7.5MG	N40148 003	SEP 12, 2000	APR	NEWA	

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

>D>	AB	HALSEY	325MG;50MG	N70115 001	JUN 12, 1985	MAY	DISC	

>A>		@		325MG;50MG	N70115 001	JUN 12, 1985	MAY	DISC
>D>	AB			650MG;100MG	N70116 001	JUN 12, 1985	MAY	DISC
>A>		@		650MG;100MG	N70116 001	JUN 12, 1985	MAY	DISC
	AB		MALLINCKRODT	650MG;100MG	N75738 001	FEB 02, 2001	FEB	NEWA
	AB		VINTAGE PHARMS	325MG;50MG	N74843 002	FEB 15, 2001	FEB	NEWA

ACYCLOVIR SODIUM
INJECTABLE; INJECTION
ACYCLOVIR

	AP		GENSIA SICOR PHARMS	EQ 50MG BASE/ML	N75627 001	MAR 28, 2001	MAR	NEWA

ALBUTEROL SULFATE
AEROSOL, METERED; INHALATION
VENTOLIN HFA

	+		GLAXO	EQ 0.09MG BASE/INH	N20983 001	APR 19, 2001	APR	NEWA

SOLUTION; INHALATION
ACCUNEB

	+		DEY	EQ 0.021% BASE	N20949 002	APR 30, 2001	APR	NEWA
	+			EQ 0.042% BASE	N20949 001	APR 30, 2001	APR	NEWA
			ALBUTEROL SULFATE					
	AN		ROXANE	EQ 0.083% BASE	N75129 001	FEB 13, 2001	FEB	NEWA

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE
SOLUTION; INHALATION
DUONEB

	+		DEY	EQ 0.083% BASE;0.017%	N20950 001	MAR 21, 2001	MAR	NEWA

ALLOPURINOL
TABLET; ORAL
ZYLOPRIM

>D>	AB		FARO PHARMS	100MG	N16084 001	AUG 19, 1966	MAY	CAHN
>D>	AB	+		300MG	N16084 002	JAN 14, 1974	MAY	CAHN
>A>	AB		PROMETHEUS LABS	100MG	N16084 001	AUG 19, 1966	MAY	CAHN
>A>	AB	+		300MG	N16084 002	JAN 14, 1974	MAY	CAHN

ALMOTRIPTAN MALATE
TABLET; ORAL
AXERT

>A>			PHARMACIA AND UPJOHN	EQ 6.25MG BASE	N21001 001	MAY 07, 2001	MAY	NEWA
>A>		+		EQ 12.5MG BASE	N21001 002	MAY 07, 2001	MAY	NEWA

AMIKACIN SULFATE
INJECTABLE; INJECTION
AMIKACIN SULFATE

		@	ABBOTT	EQ 250MG BASE/ML	N63265 001	NOV 30, 1994	APR	DISC
		@		EQ 250MG BASE/ML	N63266 001	OCT 31, 1994	APR	DISC
>D>	AP			EQ 250MG BASE/ML	N64099 001	JUN 20, 1995	MAY	DISC
>A>		@		EQ 250MG BASE/ML	N64099 001	JUN 20, 1995	MAY	DISC
		@	ELKINS SINN	EQ 250MG BASE/ML	N63275 001	MAY 18, 1992	APR	DISC

AMINOCAPROIC ACID
TABLET; ORAL

>A>		AMICAR						
>D>	+	IMMUNEX	500MG	N15197 001	JUN 03, 1964	MAY	CFTG	
>A>	AB +		500MG	N15197 001	JUN 03, 1964	MAY	CFTG	
>A>		AMINOCAPROIC						
>A>	AB	MIKART	500MG	N75602 001	MAY 24, 2001	MAY	NEWA	

AMIODARONE HYDROCHLORIDE
TABLET; ORAL
AMIODARONE HCL

AB	BARR	200MG	N75389 001	JAN 25, 2001	JAN	NEWA	
AB	TARO	200MG	N75424 001	MAR 30, 2001	MAR	NEWA	

AMOXICILLIN
CAPSULE; ORAL
AMOXICILLIN

@	LABS ATRAL	250MG	N62528 001	AUG 07, 1985	FEB	WDRP
@		500MG	N62528 002	AUG 07, 1985	FEB	WDRP
@	MYLAN	250MG	N62067 001	AUG 14, 1980	APR	DISC
@		500MG	N62067 002	AUG 14, 1980	APR	DISC
@	TEVA	250MG	N63030 001	FEB 28, 1989	APR	DISC
@		500MG	N63031 001	FEB 28, 1989	APR	DISC

TRIMOX

@	APOTHECON	250MG	N63099 001	MAR 20, 1992	APR	DISC
@		500MG	N63099 002	MAR 20, 1992	APR	DISC

WYMOX

@	WYETH AYERST	250MG	N62120 001	APR 28, 1978	APR	DISC
@		500MG	N62120 002	APR 28, 1978	APR	DISC

FOR SUSPENSION; ORAL
TRIMOX

>D>	AB	APOTHECON	50MG/ML	N61886 001	DEC 09, 1974	MAY	DISC
>A>		@	50MG/ML	N61886 001	DEC 09, 1974	MAY	DISC
>D>	AB		125MG/5ML	N61886 002	DEC 09, 1974	MAY	DISC
>A>		@	125MG/5ML	N61886 002	DEC 09, 1974	MAY	DISC
>D>	AB		250MG/5ML	N61886 003	DEC 09, 1974	MAY	DISC
>A>		@	250MG/5ML	N61886 003	DEC 09, 1974	MAY	DISC

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE
TABLET; ORAL
ADDERALL 7.5

SHIRE PHARM	1.875MG;1.875MG;1.875MG;1.875MG	N11522 011	AUG 31, 2000	APR	CTEC	

AMPHOTERICIN B
INJECTABLE; INJECTION
AMPHOTERICIN B

>D>	AP	ABBOTT	50MG/VIAL	N64141 001	DEC 23, 1996	MAY	DISC	
>A>		@	50MG/VIAL	N64141 001	DEC 23, 1996	MAY	DISC	

INJECTABLE, LIPID COMPLEX; INJECTION
AMPHOTEC

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX; INJECTION

		AMPHOTEC				
+		INTERMUNE PHARMS	50MG/VIAL	N50729 001	NOV 22, 1996	FEB CAHN
+			100MG/VIAL	N50729 002	NOV 22, 1996	FEB CAHN

AMPICILLIN SODIUM

INJECTABLE; INJECTION

		AMPICILLIN SODIUM				
>D>	AP	ELKINS SINN	EQ 125MG BASE/VIAL	N62692 001	JUN 24, 1986	MAY DISC
>A>		@	EQ 125MG BASE/VIAL	N62692 001	JUN 24, 1986	MAY DISC
>D>	AP		EQ 250MG BASE/VIAL	N62692 002	JUN 24, 1986	MAY DISC
>A>		@	EQ 250MG BASE/VIAL	N62692 002	JUN 24, 1986	MAY DISC
>D>	AP		EQ 500MG BASE/VIAL	N62692 003	JUN 24, 1986	MAY DISC
>A>		@	EQ 500MG BASE/VIAL	N62692 003	JUN 24, 1986	MAY DISC
>D>	AP		EQ 1GM BASE/VIAL	N62692 004	JUN 24, 1986	MAY DISC
>A>		@	EQ 1GM BASE/VIAL	N62692 004	JUN 24, 1986	MAY DISC
>D>	AP		EQ 2GM BASE/VIAL	N62692 005	JUN 24, 1986	MAY DISC
>A>		@	EQ 2GM BASE/VIAL	N62692 005	JUN 24, 1986	MAY DISC
>D>	AP		EQ 10GM BASE/VIAL	N62692 006	JUN 24, 1986	MAY DISC
>A>		@	EQ 10GM BASE/VIAL	N62692 006	JUN 24, 1986	MAY DISC
		@ HANFORD GC	EQ 125MG BASE/VIAL	N63143 001	APR 15, 1993	APR DISC
		@	EQ 250MG BASE/VIAL	N63145 001	APR 15, 1993	APR DISC
		@	EQ 500MG BASE/VIAL	N63146 001	APR 15, 1993	APR DISC
		@	EQ 500MG BASE/VIAL	N63147 001	APR 15, 1993	APR DISC
>D>	AP		EQ 1GM BASE/VIAL	N62772 001	APR 15, 1993	MAY DISC
>A>		@	EQ 1GM BASE/VIAL	N62772 001	APR 15, 1993	MAY DISC
		@	EQ 1GM BASE/VIAL	N63139 001	APR 15, 1993	APR DISC
		@	EQ 2GM BASE/VIAL	N63140 001	APR 15, 1993	APR DISC
		@	EQ 2GM BASE/VIAL	N63141 001	APR 15, 1993	APR DISC
		@	EQ 10GM BASE/VIAL	N63142 001	APR 15, 1993	APR DISC
>D>	AP	IBI	EQ 125MG BASE/VIAL	N62797 001	JUL 12, 1993	MAY DISC
>A>		@	EQ 125MG BASE/VIAL	N62797 001	JUL 12, 1993	MAY DISC
>D>	AP		EQ 2GM BASE/VIAL	N62797 002	JUL 12, 1993	MAY DISC
>A>		@	EQ 2GM BASE/VIAL	N62797 002	JUL 12, 1993	MAY DISC
		OMNIPEN-N				
>D>	AP	WYETH AYERST	EQ 125MG BASE/VIAL	N62718 001	DEC 16, 1986	MAY DISC
>A>		@	EQ 125MG BASE/VIAL	N62718 001	DEC 16, 1986	MAY DISC
>D>	AP		EQ 250MG BASE/VIAL	N62718 002	DEC 16, 1986	MAY DISC
>A>		@	EQ 250MG BASE/VIAL	N62718 002	DEC 16, 1986	MAY DISC
>D>	AP		EQ 500MG BASE/VIAL	N62718 003	DEC 16, 1986	MAY DISC
>A>		@	EQ 500MG BASE/VIAL	N62718 003	DEC 16, 1986	MAY DISC
>D>	AP		EQ 1GM BASE/VIAL	N62718 004	DEC 16, 1986	MAY DISC
>A>		@	EQ 1GM BASE/VIAL	N62718 004	DEC 16, 1986	MAY DISC
>D>	AP		EQ 2GM BASE/VIAL	N62718 005	DEC 16, 1986	MAY DISC
>A>		@	EQ 2GM BASE/VIAL	N62718 005	DEC 16, 1986	MAY DISC

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

		AMPICILLIN TRIHYDRATE				
>D>	AB	BIOCHEMIE	EQ 250MG BASE	N64082 001	AUG 29, 1995	MAY DISC
>A>		@	EQ 250MG BASE	N64082 001	AUG 29, 1995	MAY DISC
>D>	AB		EQ 500MG BASE	N64082 002	AUG 29, 1995	MAY DISC

>A>		@	EQ 500MG BASE	N64082 002	AUG 29, 1995	MAY	DISC
		FOR SUSPENSION; ORAL					
>D>	AB	MYLAN	EQ 125MG BASE/5ML	N61829 002	JUL 29, 1974	MAY	DISC
>A>		@	EQ 125MG BASE/5ML	N61829 002	JUL 29, 1974	MAY	DISC
>D>	AB		EQ 250MG BASE/5ML	N61829 001	JUL 29, 1974	MAY	DISC
>A>		@	EQ 250MG BASE/5ML	N61829 001	JUL 29, 1974	MAY	DISC
		TOTACILLIN					
		@ SMITHKLINE BEECHAM	EQ 125MG BASE/5ML	N60666 001	MAY 07, 1970	FEB	WDRP
		@	EQ 250MG BASE/5ML	N60666 002	MAY 07, 1970	FEB	WDRP
	AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID						
>D>		FOR SUSPENSION; ORAL					
>D>		PROBAMPACIN					
>D>	+	TEVA	EQ 3.5GM BASE/BOT;1GM/BOT	N61741 001	OCT 10, 1973	MAY	DISC
>A>		@	EQ 3.5GM BASE/BOT;1GM/BOT	N61741 001	OCT 10, 1973	MAY	DISC
	ARBUTAMINE HYDROCHLORIDE						
		INJECTABLE; INJECTION					
		GENESA					
		@ GENSIA AUTOMEDICS	0.05MG/ML	N20420 001	SEP 12, 1997	MAR	DISC
	ARDEPARIN SODIUM						
>D>		INJECTABLE; INJECTION					
>D>		NORMIFLO					
>D>	+	WYETH AYERST	5,000 UNITS/0.5ML	N20227 002	MAY 23, 1997	MAY	DISC
>A>		@	5,000 UNITS/0.5ML	N20227 002	MAY 23, 1997	MAY	DISC
>D>	+		10,000 UNITS/0.5ML	N20227 001	MAY 23, 1997	MAY	DISC
>A>		@	10,000 UNITS/0.5ML	N20227 001	MAY 23, 1997	MAY	DISC
	ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K						
		INJECTABLE; IV (INFUSION)					
		INFUVITE PEDIATRIC					
	+	SABEX	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N21265 001	FEB 21, 2001	FEB	NEWA
	ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E						
		FOR SOLUTION; IV (INFUSION)					
		M.V.I. PEDIATRIC					
	+	ASTRAZENECA	80MG/VIAL;0.02MG/VIAL;0.00 1MG/VIAL;5MG/VIAL;0.01MG/VIAL;0.14MG/VIAL;17MG/VIAL;0.2MG/VIAL;1MG/VIAL;1.4MG/VIAL;EQ 1.2MG BASE/VIAL;0.7MG/VIAL;7MG/VIAL	N18920 001	SEP 21, 2000	FEB	NEWA

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

INVAGESIC

AB	GENEVA PHARMS TECH	385MG;30MG;25MG	N74817 001	NOV 27, 1996	JAN	CAHN

INVAGESIC FORTE

AB	GENEVA PHARMS TECH	770MG;60MG;50MG	N74817 002	NOV 27, 1996	JAN	CAHN

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

PROPOXYPHENE COMPOUND 65

>D> AA	EON	389MG;32.4MG;65MG	N80044 002	SEP 16, 1983	MAY	DISC
>A>	@	389MG;32.4MG;65MG	N80044 002	SEP 16, 1983	MAY	DISC

PROPOXYPHENE COMPOUND-65

>D> AA	GENEVA PHARMS	389MG;32.4MG;65MG	N83101 002	JUN 24, 1985	MAY	DISC
>A>	@	389MG;32.4MG;65MG	N83101 002	JUN 24, 1985	MAY	DISC

ATORVASTATIN CALCIUM

TABLET; ORAL

LIPITOR

PFIZER

		EQ 10MG BASE	N20702 001	DEC 17, 1996	MAR	CAHN
		EQ 20MG BASE	N20702 002	DEC 17, 1996	MAR	CAHN
		EQ 40MG BASE	N20702 003	DEC 17, 1996	MAR	CAHN
+		EQ 80MG BASE	N20702 004	APR 07, 2000	MAR	CAHN

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

DIPHENOXYLATE HCL AND ATROPINE SULFATE

	@ INWOOD LABS	0.025MG;2.5MG	N85509 001	MAR 09, 1978	FEB	WDRP
>D> AA	R AND S PHARMA	0.025MG;2.5MG	N85035 001	JUL 05, 1977	MAY	DISC
>A>	@	0.025MG;2.5MG	N85035 001	JUL 05, 1977	MAY	DISC

DIPHENOXYLATE HCL W/ ATROPINE SULFATE

>D> AA	PVT FORM	0.025MG;2.5MG	N85766 001	DEC 22, 1978	MAY	DISC
>A>	@	0.025MG;2.5MG	N85766 001	DEC 22, 1978	MAY	DISC

AURANOFIN

CAPSULE; ORAL

RIDAURA

>D>	+ CONNETICS	3MG	N18689 001	MAY 24, 1985	MAY	CAHN
>A>	+ PROMETHEUS LABS	3MG	N18689 001	MAY 24, 1985	MAY	CAHN

AZATHIOPRINE

TABLET; ORAL

IMURAN

>D>	@ FARO PHARMS	25MG	N16324 002	MAR 21, 1980	MAY	CAHN
>D> AB	+	50MG	N16324 001	MAR 20, 1968	MAY	CAHN
>A>	@ PROMETHEUS LABS	25MG	N16324 002	MAR 21, 1980	MAY	CAHN
>A> AB	+	50MG	N16324 001	MAR 20, 1968	MAY	CAHN

AZITHROMYCIN DIHYDRATE; TROVAFLOXACIN MESYLATE

>D>	FOR SUSPENSION; TABLET; ORAL					
>D>	TROVAN/ZITHROMAX COMPLIANCE PAK					
>D>	@ PFIZER	EQ 1GM BASE;EQ 100MG BASE	N50762 001	DEC 18, 1998	MAY	DISC

>A>		@	EQ 1GM BASE;EQ 100MG BASE	N50762 001	DEC 18, 1998	MAY	DISC
		BACITRACIN ZINC					
		POWDER; FOR RX COMPOUNDING					
		ZIBA-RX					
>D>		PHARMA TEK	500,000 UNITS/BOT	N61737 001	APR 26, 1973	MAY	DISC
>A>		@	500,000 UNITS/BOT	N61737 001	APR 26, 1973	MAY	DISC
		BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE					
		OINTMENT; OPHTHALMIC					
		NEO-POLYCIN					
		@ DOW PHARM	500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N60647 001	APR 19, 1954	FEB	WDRP
		BENZQUINAMIDE HYDROCHLORIDE					
		INJECTABLE; INJECTION					
		EMETE-CON					
>A>	+	PFIZER	EQ 50MG BASE/VIAL	N16820 001	MAR 20, 1974	MAY	CAHN
>D>	+	ROERIG	EQ 50MG BASE/VIAL	N16820 001	MAR 20, 1974	MAY	CAHN
		BETAMETHASONE DIPROPIONATE					
		CREAM; TOPICAL					
		BETAMETHASONE DIPROPIONATE					
		@ CLAY PARK	EQ 0.05% BASE	N74579 001	NOV 26, 1997	APR	DISC
		BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE					
		CREAM; TOPICAL					
>A>		CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE					
>A>	AB	TARO	EQ 0.05% BASE;1%	N75673 001	MAY 29, 2001	MAY	NEWA
>A>		LOTRISONE					
>D>	+	SCHERING	EQ 0.05% BASE;1%	N18827 001	JUL 10, 1984	MAY	CFTG
>A>	AB +		EQ 0.05% BASE;1%	N18827 001	JUL 10, 1984	MAY	CFTG
		BETAXOLOL HYDROCHLORIDE					
		SOLUTION/DROPS; OPHTHALMIC					
		BETAXOLOL HCL					
	AT	BAUSCH AND LOMB	EQ 0.5% BASE	N75630 001	APR 12, 2001	APR	NEWA
		BIMATOPROST					
		SOLUTION/DROPS; OPHTHALMIC					
		LUMIGAN					
	+	ALLERGAN	0.03%	N21275 001	MAR 16, 2001	MAR	NEWA
		BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE					
		CAPSULE; TABLET; TABLET, CHEWABLE, TABLET, CAPSULE; ORAL					
		HELIDAC					
>D>	+	PROMETHEUS LABS	262.4MG;250MG;500MG	N50719 001	AUG 15, 1996	MAY	DISC
>A>	+		262.4MG;250MG;500MG	N50719 001	AUG 15, 1996	MAY	DISC
		BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE					
		TABLET; ORAL					
		BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE					
	AB	TEVA	2.5MG;6.25MG	N75686 001	JAN 19, 2001	JAN	NEWA

AB		5MG;6.25MG	N75686 002	JAN 19, 2001	JAN	NEWA
AB		10MG;6.25MG	N75686 003	JAN 19, 2001	JAN	NEWA

BRIMONIDINE TARTRATE
SOLUTION/DROPS; OPHTHALMIC

	ALPHAGAN					
	@ ALLERGAN	0.5%	N20490 001	MAR 13, 1997	APR	DISC
	ALPHAGAN P					
+	ALLERGAN	0.15%	N21262 001	MAR 16, 2001	MAR	NEWA

BUPROPION HYDROCHLORIDE
TABLET, EXTENDED RELEASE; ORAL

	WELLBUTRIN SR					
	GLAXO WELLCOME	50MG	N20358 001	OCT 04, 1996	APR	CTEC
		100MG	N20358 002	OCT 04, 1996	APR	CTEC

BUSPIRONE HYDROCHLORIDE
TABLET; ORAL

	BUSPAR					
AB	BRISTOL MYERS SQUIBB	5MG	N18731 001	SEP 29, 1986	MAR	CFTG
AB		10MG	N18731 002	SEP 29, 1986	MAR	CFTG
AB		15MG	N18731 003	APR 22, 1996	MAR	NEWA
	BUSPIRONE HCL					
AB	DANBURY PHARMA	5MG	N74253 001	MAR 28, 2001	MAR	NEWA
AB		10MG	N74253 002	MAR 28, 2001	MAR	NEWA
AB	MYLAN	15MG	N75272 003	MAR 28, 2001	MAR	NEWA
AB	PAR PHARM	7.5MG	N75467 002	MAR 28, 2001	MAR	NEWA

BUTABARBITAL SODIUM
TABLET; ORAL

		BUTISOL SODIUM					
>D>	AA	+ WALLACE LABS	15MG	N00793 002	JUN 05, 1939	MAY	CTEC
>A>		+	15MG	N00793 002	JUN 05, 1939	MAY	CTEC
		SODIUM BUTABARBITAL					
>D>	AA	LANNETT	15MG	N85849 001	AUG 21, 1978	MAY	DISC
>A>		@	15MG	N85849 001	AUG 21, 1978	MAY	DISC
>D>	AA		30MG	N85866 001	JUL 20, 1978	MAY	DISC
>A>		@	30MG	N85866 001	JUL 20, 1978	MAY	DISC

CALCIUM ACETATE
CAPSULE; ORAL

	PHOSLO					
	BRAINTREE	EQ 84.5MG CALCIUM	N21160 001	APR 02, 2001	APR	NEWA
		EQ 169MG CALCIUM	N21160 002	APR 02, 2001	APR	NEWA
+						

CAPTOPRIL
TABLET; ORAL

	CAPTOPRIL					
AB	GENEVA PHARMS TECH	12.5MG	N74481 001	FEB 13, 1996	JAN	CAHN
AB		25MG	N74481 002	FEB 13, 1996	JAN	CAHN
AB		50MG	N74481 003	FEB 13, 1996	JAN	CAHN
AB		100MG	N74481 004	FEB 13, 1996	JAN	CAHN

CARBACHOL
SOLUTION; INTRAOCULAR
CARBASTAT

AT	NOVARTIS	0.01%	N73677 001	APR 28, 1995	FEB	CAHN

CARBIDOPA; LEVODOPA
TABLET; ORAL
CARBIDOPA AND LEVODOPA

	@ SCS	10MG;100MG	N74080 001	MAR 25, 1994	FEB	WDRP
	@	25MG;100MG	N74080 002	MAR 25, 1994	FEB	WDRP
	@	25MG;250MG	N74080 003	MAR 25, 1994	FEB	WDRP

CASPOFUNGIN ACETATE
INJECTABLE; IV (INFUSION)
CANCIDAS

+	MERCK RES	50MG/VIAL	N21227 001	JAN 26, 2001	JAN	NEWA
+		70MG/VIAL	N21227 002	JAN 26, 2001	JAN	NEWA

CEFACLOR
FOR SUSPENSION; ORAL
CEFACLOR

>D>	AB	ZENITH GOLDLINE	EQ 125MG BASE/5ML	N64087 001	APR 28, 1995	MAY	DISC
>A>		@	EQ 125MG BASE/5ML	N64087 001	APR 28, 1995	MAY	DISC
>D>	AB		EQ 187MG BASE/5ML	N64086 001	APR 28, 1995	MAY	DISC
>A>		@	EQ 187MG BASE/5ML	N64086 001	APR 28, 1995	MAY	DISC
>D>	AB		EQ 250MG BASE/5ML	N64085 001	APR 28, 1995	MAY	DISC
>A>		@	EQ 250MG BASE/5ML	N64085 001	APR 28, 1995	MAY	DISC

TABLET, EXTENDED RELEASE; ORAL
CECLOR CD

		LILLY	EQ 375MG BASE	N50673 001	JUN 28, 1996	APR	CTEC
	AB	+	EQ 500MG BASE	N50673 002	JUN 28, 1996	JAN	CFTG

CEFACLOR

	AB	ZENITH GOLDLINE	EQ 500MG BASE	N65057 001	JAN 05, 2001	JAN	NEWA

CEFADROXIL/CEFADROXIL HEMIHYDRATE
TABLET; ORAL
CEFADROXIL

>D>	AB	ZENITH GOLDLINE	EQ 1GM BASE	N62774 001	APR 08, 1987	MAY	DISC
>A>		@	EQ 1GM BASE	N62774 001	APR 08, 1987	MAY	DISC

CEFAMANDOLE NAFATE
INJECTABLE; INJECTION
MANDOL

>D>		LILLY	EQ 1GM BASE/VIAL	N62560 001	SEP 10, 1985	MAY	DISC
>A>		@	EQ 1GM BASE/VIAL	N62560 001	SEP 10, 1985	MAY	DISC
>D>			EQ 2GM BASE/VIAL	N62560 002	SEP 10, 1985	MAY	DISC
>A>		@	EQ 2GM BASE/VIAL	N62560 002	SEP 10, 1985	MAY	DISC

CEFAZOLIN SODIUM
INJECTABLE; INJECTION
CEFAZOLIN SODIUM

		@ TEVA	EQ 250MG BASE/VIAL	N63016 001	MAR 14, 1989	APR	DISC

		@	EQ 500MG BASE/VIAL	N63016 002	MAR 14, 1989	APR	DISC
		@	EQ 1GM BASE/VIAL	N63016 003	MAR 14, 1989	APR	DISC
		KEFZOL					
>D>	AP	LILLY	EQ 500MG BASE/VIAL	N62557 001	SEP 10, 1985	MAY	DISC
>A>		@	EQ 500MG BASE/VIAL	N62557 001	SEP 10, 1985	MAY	DISC
>D>	AP		EQ 1GM BASE/VIAL	N62557 002	SEP 10, 1985	MAY	DISC
>A>		@	EQ 1GM BASE/VIAL	N62557 002	SEP 10, 1985	MAY	DISC
		CEFONICID SODIUM					
		INJECTABLE; INJECTION					
		MONOCID					
		@ SMITHKLINE BEECHAM	EQ 1GM BASE/VIAL	N63295 001	JUL 26, 1993	APR	DISC
		CEFOPERAZONE SODIUM					
		INJECTABLE; INJECTION					
		CEFOBID					
>D>		PFIZER	EQ 1GM BASE/VIAL	N63333 001	MAR 31, 1995	MAY	DISC
>A>		@	EQ 1GM BASE/VIAL	N63333 001	MAR 31, 1995	MAY	DISC
>D>			EQ 2GM BASE/VIAL	N63333 002	MAR 31, 1995	MAY	DISC
>A>		@	EQ 2GM BASE/VIAL	N63333 002	MAR 31, 1995	MAY	DISC
		CEFORANIDE					
		INJECTABLE; INJECTION					
		PRECEF					
>D>		APOTHECON	500MG/VIAL	N62579 001	NOV 26, 1984	MAY	DISC
>A>		@	500MG/VIAL	N62579 001	NOV 26, 1984	MAY	DISC
>D>			1GM/VIAL	N62579 002	NOV 26, 1984	MAY	DISC
>A>		@	1GM/VIAL	N62579 002	NOV 26, 1984	MAY	DISC
>D>			2GM/VIAL	N62579 003	NOV 26, 1984	MAY	DISC
>A>		@	2GM/VIAL	N62579 003	NOV 26, 1984	MAY	DISC
>D>			10GM/VIAL	N62579 004	NOV 26, 1984	MAY	DISC
>A>		@	10GM/VIAL	N62579 004	NOV 26, 1984	MAY	DISC
>D>			20GM/VIAL	N62579 005	NOV 26, 1984	MAY	DISC
>A>		@	20GM/VIAL	N62579 005	NOV 26, 1984	MAY	DISC
		CEFTAZIDIME					
		INJECTABLE; INJECTION					
		TAZICEF					
	AP	ABBOTT	500MG/VIAL	N62662 001	MAR 06, 1986	JAN	CAHN
	AP		1GM/VIAL	N62662 002	MAR 06, 1986	JAN	CAHN
	AP		1GM/VIAL	N64032 001	OCT 31, 1993	JAN	CAHN
	AP		2GM/VIAL	N62662 003	MAR 06, 1986	JAN	CAHN
	AP		2GM/VIAL	N64032 002	OCT 31, 1993	JAN	CAHN
	AP		6GM/VIAL	N62662 004	MAR 06, 1986	JAN	CAHN
>D>		TAZIDIME IN PLASTIC CONTAINER					
>D>	AP	LILLY	1GM/VIAL	N62739 001	JUL 10, 1986	MAY	DISC
>A>		@	1GM/VIAL	N62739 001	JUL 10, 1986	MAY	DISC
>D>	AP		2GM/VIAL	N62739 002	JUL 10, 1986	MAY	DISC
>A>		@	2GM/VIAL	N62739 002	JUL 10, 1986	MAY	DISC

CEFUROXIME SODIUM

INJECTABLE; IM-IV

CEFUROXIME

>A>	AB		AM PHARM PARTNERS	EQ 750MG BASE/VIAL	N65001	001	MAY 30, 2001	MAY	NEWA
>D>	AB		TEVA	EQ 750MG BASE/VIAL	N64192	002	APR 16, 1998	MAY	CDFR
>A>	AB			EQ 750MG BASE/VIAL	N64192	002	APR 16, 1998	MAY	CDFR

CEFUROXIME SODIUM

>D>	AB		HANFORD GC	EQ 750MG BASE/VIAL	N64125	001	MAY 30, 1997	MAY	CDFR
>A>	AB			EQ 750MG BASE/VIAL	N64125	001	MAY 30, 1997	MAY	CDFR

KEFUROX

>D>	AB		LILLY	EQ 750MG BASE/VIAL	N62591	001	JAN 10, 1986	MAY	CDFR
>A>	AB			EQ 750MG BASE/VIAL	N62591	001	JAN 10, 1986	MAY	CDFR

ZINACEF

>D>	AB	+	GLAXO WELLCOME	EQ 750MG BASE/VIAL	N50558	002	OCT 19, 1983	MAY	CDFR
>A>	AB	+		EQ 750MG BASE/VIAL	N50558	002	OCT 19, 1983	MAY	CDFR

INJECTABLE; INJECTION

CEFUROXIME

>A>	AP		AM PHARM PARTNERS	EQ 1.5GM BASE/VIAL	N65001	002	MAY 30, 2001	MAY	NEWA

CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER

		+	B BRAUN	EQ 15MG BASE/ML	N50780	001	FEB 21, 2001	FEB	NEWA
		+		EQ 30MG BASE/ML	N50780	002	FEB 21, 2001	FEB	NEWA

KEFUROX IN PLASTIC CONTAINER

>D>	AP		LILLY	EQ 1.5GM BASE/VIAL	N62590	002	JAN 10, 1986	MAY	DISC
>A>			@	EQ 1.5GM BASE/VIAL	N62590	002	JAN 10, 1986	MAY	DISC

INJECTABLE; INTRAVENOUS

>D>	AP		LILLY	EQ 750MG BASE/VIAL	N62590	001	JAN 10, 1986	MAY	DISC
>A>			@	EQ 750MG BASE/VIAL	N62590	001	JAN 10, 1986	MAY	DISC

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

>D>	AB		TEVA	EQ 500MG BASE	N62823	001	FEB 05, 1988	MAY	DISC
>A>			@	EQ 500MG BASE	N62823	001	FEB 05, 1988	MAY	DISC

FOR SUSPENSION; ORAL

>D>	AB		BARR	EQ 125MG BASE/5ML	N62778	001	AUG 06, 1987	MAY	DISC
>A>			@	EQ 125MG BASE/5ML	N62778	001	AUG 06, 1987	MAY	DISC

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION

KEFLIN IN PLASTIC CONTAINER

			@ LILLY	EQ 1GM BASE/VIAL	N62549	001	SEP 10, 1985	APR	DISC
			@	EQ 2GM BASE/VIAL	N62549	002	SEP 10, 1985	APR	DISC

CHLORAMPHENICOL

CAPSULE; ORAL

>D>			CHLORAMPHENICOL						
>D>	AB		ZENITH GOLDLINE	250MG	N62247	001	APR 28, 1980	MAY	DISC
>A>			@	250MG	N62247	001	APR 28, 1980	MAY	DISC
>D>			CHLOROMYCETIN						
>D>			PARKEDALE	50MG	N60591	001	DEC 08, 1950	MAY	DISC
>A>			@	50MG	N60591	001	DEC 08, 1950	MAY	DISC
>D>				100MG	N60591	003	DEC 08, 1950	MAY	DISC

>A>		@	100MG	N60591 003	DEC 08, 1950	MAY	DISC
>D>	AB	+	250MG	N60591 002	DEC 08, 1950	MAY	DISC
>A>		@	250MG	N60591 002	DEC 08, 1950	MAY	DISC
		MYCHEL					
>D>	AB	ARMENPHARM	250MG	N60851 001	JUN 20, 1967	MAY	CRLD
>A>		+	250MG	N60851 001	JUN 20, 1967	MAY	CRLD
		SOLUTION/DROPS; OPHTHALMIC					
		CHLORAMPHENICOL					
		@ AKORN	0.5%	N62042 001	AUG 31, 1981	FEB	WDRP
>D>	AT	ALCON	0.5%	N62628 001	SEP 25, 1985	MAY	DISC
>A>		@	0.5%	N62628 001	SEP 25, 1985	MAY	DISC
		CHLOROPTIC					
>D>	AT	+ ALLERGAN	0.5%	N50091 001	MAR 20, 1968	MAY	CTEC
>A>		+	0.5%	N50091 001	MAR 20, 1968	MAY	CTEC
		CHLORDIAZEPOXIDE HYDROCHLORIDE					
		CAPSULE; ORAL					
		CHLORDIAZACHEL					
		@ RACHELLE	5MG	N85086 001	MAY 11, 1976	FEB	WDRP
		@	10MG	N84639 001	MAY 11, 1976	FEB	WDRP
		@	25MG	N85087 001	MAY 11, 1976	FEB	WDRP
		CHLORDIAZEPOXIDE HCL					
		@ FERRANTE	5MG	N85118 001	SEP 02, 1981	FEB	WDRP
		@	10MG	N85119 001	SEP 02, 1976	FEB	WDRP
		@	25MG	N85120 001	SEP 02, 1976	FEB	WDRP
>D>	AB	GENEVA PHARMS	10MG	N84041 001	JUN 15, 1976	MAY	DISC
>A>		@	10MG	N84041 001	JUN 15, 1976	MAY	DISC
>D>	AB		25MG	N84679 002	SEP 07, 1976	MAY	DISC
>A>		@	25MG	N84679 002	SEP 07, 1976	MAY	DISC
>D>	AB	ROSEMONT	5MG	N84644 001	FEB 24, 1976	MAY	DISC
>A>		@	5MG	N84644 001	FEB 24, 1976	MAY	DISC
		CHLOROTHIAZIDE					
		TABLET; ORAL					
		CHLOROTHIAZIDE					
>D>	AB	ABC HOLDING	250MG	N85569 001	MAR 08, 1978	MAY	DISC
>A>		@	250MG	N85569 001	MAR 08, 1978	MAY	DISC
>D>	AB	DANBURY PHARMA	250MG	N85173 001	NOV 04, 1977	MAY	DISC
>A>		@	250MG	N85173 001	NOV 04, 1977	MAY	DISC
		CHLORPHENIRAMINE MALEATE					
		TABLET; ORAL					
		CHLORPHENIRAMINE MALEATE					
>D>	AA	+ GENEVA PHARMS	4MG	N80961 001	DEC 20, 1972	MAY	DISC
>A>		@	4MG	N80961 001	DEC 20, 1972	MAY	DISC
>D>	AA	ICN	4MG	N80598 001	FEB 11, 1972	MAY	CRLD
>A>	AA	+	4MG	N80598 001	FEB 11, 1972	MAY	CRLD
		@ PHARMAVITE	4MG	N85104 001	FEB 11, 1977	FEB	WDRP
		@ WEST WARD	4MG	N83787 001	OCT 18, 1973	FEB	WDRP

CHLORPROMAZINE HYDROCHLORIDE
INJECTABLE; INJECTION
CHLORPROMAZINE HCL

>D>	AP	STERIS	25MG/ML	N80365 001	FEB 13, 1974	MAY	DISC
>A>		@	25MG/ML	N80365 001	FEB 13, 1974	MAY	DISC

CHLORZOXAZONE
TABLET; ORAL
CHLORZOXAZONE

>D>	AA	DANBURY PHARMA	500MG	N81019 001	JUL 29, 1991	MAY	DISC
>A>		@	500MG	N81019 001	JUL 29, 1991	MAY	DISC

CIMETIDINE
TABLET; ORAL
CIMETIDINE

AB	GENEVA PHARMS TECH	200MG	N74506 001	JAN 24, 1996	JAN	CAHN
AB		300MG	N74506 002	JAN 24, 1996	JAN	CAHN
AB		400MG	N74506 003	JAN 24, 1996	JAN	CAHN
AB		800MG	N74506 004	JAN 24, 1996	JAN	CAHN

CLINDAMYCIN HYDROCHLORIDE
CAPSULE; ORAL
CLEOCIN HCL

AB	+ PHARMACIA AND UPJOHN	EQ 300MG BASE	N50162 003	APR 14, 1988	FEB	CFTG

CLINDAMYCIN HCL

AB	RANBAXY	EQ 150MG BASE	N65061 001	FEB 02, 2001	FEB	NEWA
AB		EQ 300MG BASE	N65061 002	FEB 02, 2001	FEB	NEWA

CLINDAMYCIN PHOSPHATE
INJECTABLE; INJECTION
CLINDAMYCIN PHOSPHATE

>D>	AP	ABBOTT	EQ 150MG BASE/ML	N62943 001	SEP 29, 1988	MAY	DISC
>A>		@	EQ 150MG BASE/ML	N62943 001	SEP 29, 1988	MAY	DISC
>D>	AP	ELKINS SINN	EQ 150MG BASE/ML	N62806 001	OCT 15, 1987	MAY	DISC
>A>		@	EQ 150MG BASE/ML	N62806 001	OCT 15, 1987	MAY	DISC
>D>	AP		EQ 150MG BASE/ML	N62953 001	APR 21, 1988	MAY	DISC
>A>		@	EQ 150MG BASE/ML	N62953 001	APR 21, 1988	MAY	DISC
		@ GENSIA SICOR PHARMS	EQ 150MG BASE/ML	N63041 001	DEC 29, 1989	APR	DISC
		@	EQ 150MG BASE/ML	N63282 001	MAY 29, 1992	APR	DISC
>D>	AP	LEDERLE	EQ 150MG BASE/ML	N63068 001	AUG 28, 1989	MAY	DISC
>A>		@	EQ 150MG BASE/ML	N63068 001	AUG 28, 1989	MAY	DISC

SOLUTION; TOPICAL

>D>	AT	COPLEY PHARM	EQ 1% BASE	N62944 001	JAN 11, 1989	MAY	DISC
>A>		@	EQ 1% BASE	N62944 001	JAN 11, 1989	MAY	DISC
>D>	AT	TEVA	EQ 1% BASE	N62930 001	JUN 28, 1989	MAY	DISC
>A>		@	EQ 1% BASE	N62930 001	JUN 28, 1989	MAY	DISC

CLOBETASOL PROPIONATE
CREAM; TOPICAL
CLOBETASOL PROPIONATE

AB1	STIEFEL	0.05%	N75338 001	FEB 09, 2001	FEB	NEWA

CLONAZEPAM
TABLET; ORAL
CLONAZEPAM

AB	CARACO	0.5MG	N75423 001	APR 27, 2001	APR	NEWA
AB		1MG	N75423 002	APR 27, 2001	APR	NEWA
AB		2MG	N75423 003	APR 27, 2001	APR	NEWA

CLORAZEPATE DIPOTASSIUM
CAPSULE; ORAL
CLORAZEPATE DIPOTASSIUM

@	ABLE	3.75MG	N71777 001	JUL 14, 1987	JAN	DISC
@		7.5MG	N71778 001	JUL 14, 1987	JAN	DISC
@		15MG	N71779 001	JUL 14, 1987	JAN	DISC

CORTISONE ACETATE
TABLET; ORAL
CORTISONE ACETATE

>D>	BP	CHELSEA LABS	25MG	N85884 001	MAY 15, 1978	MAY	DISC
>A>		@	25MG	N85884 001	MAY 15, 1978	MAY	DISC

CROMOLYN SODIUM
SOLUTION/DROPS; OPHTHALMIC
CROMOLYN SODIUM

AT		NOVEX	4%	N75615 001	JAN 26, 2001	JAN	NEWA

CYCLACILLIN

>D>		TABLET; ORAL					
>D>		CYCLACILLIN					
>D>		TEVA	250MG	N62895 001	AUG 04, 1988	MAY	DISC
>A>		@	250MG	N62895 001	AUG 04, 1988	MAY	DISC
>D>		+	500MG	N62895 002	AUG 04, 1988	MAY	DISC
>A>		@	500MG	N62895 002	AUG 04, 1988	MAY	DISC

DESERPIDINE; HYDROCHLOROTHIAZIDE
TABLET; ORAL

ORETICYL 25						
@	ABBOTT	0.125MG;25MG	N12148 001	DEC 14, 1959	MAR	DISC
ORETICYL 50						
@	ABBOTT	0.125MG;50MG	N12148 003	DEC 14, 1959	MAR	DISC
ORETICYL FORTE						
@	ABBOTT	0.25MG;25MG	N12148 002	DEC 14, 1959	MAR	DISC

DESONIDE
OINTMENT; TOPICAL
DESONIDE

AB	ALTANA	0.05%	N75751 001	MAR 12, 2001	MAR	NEWA

DEXAMETHASONE
TABLET; ORAL
DEXAMETHASONE

>D>	BP	DANBURY PHARMA	0.75MG	N80968 001	MAY 03, 1973	MAY	DISC
>A>		@	0.75MG	N80968 001	MAY 03, 1973	MAY	DISC

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

		@ DELL LABS	EQ 4MG PHOSPHATE/ML	N83161 001	JUN 06, 1978	FEB	WDRP
>D>	AP	GENSIA SICOR PHARMS	EQ 4MG PHOSPHATE/ML	N81125 001	AUG 31, 1990	MAY	DISC
>A>		@	EQ 4MG PHOSPHATE/ML	N81125 001	AUG 31, 1990	MAY	DISC

OINTMENT; OPHTHALMIC

DECADRON

>D>	AT +	MERCK	EQ 0.05% PHOSPHATE	N11977 001	SEP 02, 1959	MAY	DISC
>A>		@	EQ 0.05% PHOSPHATE	N11977 001	SEP 02, 1959	MAY	DISC

MAXIDEX

>D>	AT	ALCON	EQ 0.05% PHOSPHATE	N83342 001	OCT 23, 1973	MAY	CTEC
>A>	+		EQ 0.05% PHOSPHATE	N83342 001	OCT 23, 1973	MAY	CTEC

SOLUTION/DROPS; OTIC

DEXAMETHASONE SODIUM PHOSPHATE

		@ AKORN	EQ 0.1% PHOSPHATE	N84855 001	JUN 29, 1976	FEB	WDRP

DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE

SOLUTION/DROPS; OPHTHALMIC

NEODECADRON

>D>	AT +	MERCK	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	N50322 001	JUL 06, 1959	MAY	CTEC
>A>	+		EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	N50322 001	JUL 06, 1959	MAY	CTEC

NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE

>D>	AT	ALCON UNIVERSAL	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	N62714 001	JUL 21, 1986	MAY	DISC
>A>		@	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	N62714 001	JUL 21, 1986	MAY	DISC

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

DEXACIDIN

>D>	AT	NOVARTIS	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N62566 001	FEB 22, 1985	MAY	DISC
>A>		@	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N62566 001	FEB 22, 1985	MAY	DISC
	AT		0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N62566 001	FEB 22, 1985	FEB	CAHN

SUSPENSION/DROPS; OPHTHALMIC

	AT	NOVARTIS	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62544 001	OCT 29, 1984	FEB	CAHN

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

	AA	BARR	5MG	N40361 001	JAN 31, 2001	JAN	NEWA
	AA		10MG	N40361 002	JAN 31, 2001	JAN	NEWA

DEXTROSTAT

	AA +	SHIRE RICHWOOD	10MG	N84051 002	MAY 29, 1975	JAN	CFTG

DICLOFENAC POTASSIUM
TABLET; ORAL
DICLOFENAC POTASSIUM

AB	EON	50MG	N75582 001	FEB 23, 2001	FEB	NEWA

DICLOFENAC SODIUM
GEL; TOPICAL
SOLARAZE

+	BIOGLAN PHARMA PLC	3%	N21005 001	OCT 16, 2000	MAR	CAHN

DICLOXACILLIN SODIUM
CAPSULE; ORAL
DYCILL

@	SMITHKLINE BEECHAM	EQ 250MG BASE	N62238 001	DEC 31, 1979	APR	DISC
@		EQ 500MG BASE	N62238 002	DEC 31, 1979	APR	DISC

DICYCLOMINE HYDROCHLORIDE
CAPSULE; ORAL
DICYCLOMINE HCL

>D>	AB	HALSEY	10MG	N84505 001	OCT 21, 1986	MAY	DISC
>A>	@		10MG	N84505 001	OCT 21, 1986	MAY	DISC

DILTIAZEM HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE; ORAL
DILTIAZEM HCL

AB2	MYLAN	120MG	N75124 002	MAR 18, 1998	MAR	CTEC

DIPHENHYDRAMINE HYDROCHLORIDE
CAPSULE; ORAL
DIPHENHYDRAMINE HCL

>D>	AA	CHELSEA LABS	50MG	N85083 001	JUN 29, 1976	MAY	DISC
>A>	@		50MG	N85083 001	JUN 29, 1976	MAY	DISC
	@	NEWTRON PHARMS	25MG	N86543 001	FEB 08, 1979	FEB	WDRP
	@		50MG	N86544 001	FEB 08, 1979	FEB	WDRP

DISULFIRAM
TABLET; ORAL
ANTABUSE

	ODYSSEY PHARMS	250MG	N88482 001	DEC 08, 1983	JAN	CAHN
+		500MG	N88483 001	DEC 08, 1983	JAN	CAHN
@	SIDMAK LABS	250MG	N07883 003	NOV 03, 1970	MAR	CAHN
@		500MG	N07883 002	JUN 01, 1953	MAR	CAHN

DOXAZOSIN MESYLATE
TABLET; ORAL
DOXAZOSIN MESYLATE

AB	TEVA	EQ 1MG BASE	N75353 001	JAN 12, 2001	JAN	NEWA
AB		EQ 2MG BASE	N75353 002	JAN 12, 2001	JAN	NEWA
AB		EQ 4MG BASE	N75353 003	JAN 12, 2001	JAN	NEWA
AB		EQ 8MG BASE	N75353 004	JAN 12, 2001	JAN	NEWA

		DOXYCYCLINE						
		FOR SUSPENSION; ORAL						
		DOXYCHEL						
		@ RACHELLE	EQ 25MG BASE/5ML	N61720 001	JUN 18, 1973	FEB	WDRP	
		VIBRAMYCIN						
		+ PFIZER	EQ 25MG BASE/5ML	N50006 001	DEC 06, 1967	FEB	CTEC	
		DOXYCYCLINE HYCLATE						
		CAPSULE; ORAL						
		DOXY-LEMMON						
		@ TEVA	EQ 50MG BASE	N62497 001	AUG 23, 1984	APR	DISC	
		@	EQ 100MG BASE	N62497 002	JUN 15, 1984	APR	DISC	
		DOXYCYCLINE HYCLATE						
		@ CHELSEA LABS	EQ 50MG BASE	N62142 001	AUG 12, 1981	APR	DISC	
		@	EQ 100MG BASE	N62142 002	AUG 12, 1981	APR	DISC	
		@ HALSEY	EQ 50MG BASE	N62418 001	JAN 28, 1983	APR	DISC	
		@	EQ 100MG BASE	N62418 002	JAN 28, 1983	APR	DISC	
		CAPSULE, COATED PELLETS; ORAL						
>D>		DOXYCYCLINE HYCLATE						
>D>	AB	SIDMAK LABS NJ	EQ 100MG BASE	N63187 001	JUN 30, 1992	MAY	DISC	
>A>		@	EQ 100MG BASE	N63187 001	JUN 30, 1992	MAY	DISC	
		INJECTABLE; INJECTION						
		DOXYCHEL HYCLATE						
		@ RACHELLE	EQ 100MG BASE/VIAL	N61953 001	SEP 10, 1980	FEB	WDRP	
>D>		DOXYCYCLINE						
>D>	AP	BEDFORD	EQ 100MG BASE/VIAL	N62569 001	MAR 09, 1988	MAY	DISC	
>A>		@	EQ 100MG BASE/VIAL	N62569 001	MAR 09, 1988	MAY	DISC	
>D>	AP		EQ 200MG BASE/VIAL	N62569 002	MAR 09, 1988	MAY	DISC	
>A>		@	EQ 200MG BASE/VIAL	N62569 002	MAR 09, 1988	MAY	DISC	
		@ ELKINS SINN	EQ 100MG BASE/VIAL	N62450 001	OCT 27, 1983	APR	DISC	
		@	EQ 200MG BASE/VIAL	N62450 002	OCT 27, 1983	APR	DISC	
>D>		DOXYCYCLINE HYCLATE						
>D>	AP	LEDERLE	EQ 100MG BASE/VIAL	N62992 001	FEB 16, 1989	MAY	DISC	
>A>		@	EQ 100MG BASE/VIAL	N62992 001	FEB 16, 1989	MAY	DISC	
>D>	AP		EQ 200MG BASE/VIAL	N62992 002	FEB 16, 1989	MAY	DISC	
>A>		@	EQ 200MG BASE/VIAL	N62992 002	FEB 16, 1989	MAY	DISC	
		TABLET; ORAL						
>D>		DOXY-LEMMON						
>D>	AB	TEVA	EQ 100MG BASE	N62581 001	MAR 15, 1985	MAY	DISC	
>A>		@	EQ 100MG BASE	N62581 001	MAR 15, 1985	MAY	DISC	
		DOXYCYCLINE HYCLATE						
		@ HALSEY	EQ 100MG BASE	N62391 001	SEP 30, 1982	APR	DISC	
		PERIOSTAT						
		+ COLLAGENEX PHARMS	20MG	N50783 001	FEB 02, 2001	FEB	NEWA	
>A>		DROSPIRENONE; ETHINYL ESTRADIOL						
>A>		TABLET; ORAL-28						
>A>		YASMIN						
>A>		+ BERLEX LABS	3MG;0.03MG	N21098 001	MAY 11, 2001	MAY	NEWA	

ENALAPRIL MALEATE
TABLET; ORAL
ENALAPRIL MALEATE

AB	TARO	2.5MG	N75657 001	JAN 23, 2001	JAN	NEWA	>D>
AB		5MG	N75657 002	JAN 23, 2001	JAN	NEWA	>A>
AB		10MG	N75657 003	JAN 23, 2001	JAN	NEWA	
AB		20MG	N75657 004	JAN 23, 2001	JAN	NEWA	
AB	TORPHARM	2.5MG	N75178 002	MAR 23, 2001	MAR	NEWA	
AB		5MG	N75178 001	MAR 23, 2001	MAR	NEWA	
AB		10MG	N75178 003	MAR 23, 2001	MAR	NEWA	>D>
AB		20MG	N75178 004	MAR 23, 2001	MAR	NEWA	>D>
							>A>

ENFLURANE
LIQUID; INHALATION
ENFLURANE

							>D>
AN	MINRAD	99.9%	N74396 001	JUL 29, 1994	FEB	CAHN	>D>
							>D>
							>A>

ENOXAPARIN SODIUM
INJECTABLE; SUBCUTANEOUS
LOVENOX

							>D>
+	AVENTIS	30MG/0.3ML	N20164 001	MAR 29, 1993	APR	CAHN	>D>
+		40MG/0.4ML	N20164 002	JAN 30, 1998	APR	CAHN	>A>
+		60MG/0.6ML	N20164 003	MAR 27, 1998	APR	CAHN	>D>
+		80MG/0.8ML	N20164 004	MAR 27, 1998	APR	CAHN	>A>
+		90MG/0.6ML	N20164 006	JUN 02, 2000	APR	CAHN	>D>
+		100MG/ML	N20164 005	MAR 27, 1998	APR	CAHN	>D>
+		120MG/0.8ML	N20164 007	JUN 02, 2000	APR	CAHN	>D>
+		150MG/ML	N20164 008	JUN 02, 2000	APR	CAHN	>A>

EPINEPHRINE BITARTRATE; ETIDOCAINE HYDROCHLORIDE
INJECTABLE; INJECTION
DURANEST

+	DENTSPLY PHARM	0.005MG/ML;1%	N17751 006	AUG 30, 1976	APR	CAHN	
+		0.005MG/ML;1.5%	N17751 007	AUG 30, 1976	APR	CAHN	>D>
							>A>

EPINEPHRINE; ETIDOCAINE HYDROCHLORIDE
INJECTABLE; INJECTION

							>D>
@	DENTSPLY PHARM	0.005MG/ML;0.5%	N17751 004	AUG 30, 1976	APR	CAHN	>A>

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE
INJECTABLE; INJECTION
LIDOCATON

							>D>
@	PHARMATON	0.02MG/ML;2%	N84728 001	AUG 17, 1983	FEB	WDRP	>A>

ERGOCALCIFEROL
CAPSULE; ORAL
VITAMIN D

@	IMPAX LABS	50,000 IU	N80951 001	JUL 13, 1973	FEB	DISC	>D>
							>A>
							>D>
							>A>
							>D>
							>A>

		ERYTHROMYCIN						
		SOLUTION; TOPICAL						
		ERYTHROMYCIN						
>D>		@ CLAY PARK	2%	N63038	001	JAN 11, 1991	MAY	CMFD
>A>	AT		2%	N63038	001	JAN 11, 1991	MAY	CMFD
		@	2%	N63038	001	JAN 11, 1991	APR	DISC
		TABLET, DELAYED RELEASE; ORAL						
		E-BASE						
		@ BARR	333MG	N63028	001	MAY 15, 1990	APR	DISC
>D>		ILOTYCIN						
>D>	AB	DISTA	250MG	N61910	001	FEB 27, 1975	MAY	DISC
>A>		@	250MG	N61910	001	FEB 27, 1975	MAY	DISC
		ERYTHROMYCIN ESTOLATE						
>D>		CAPSULE; ORAL						
>D>		ERYTHROMYCIN ESTOLATE						
>D>	AB	BARR	EQ 250MG BASE	N62162	002	JUN 15, 1981	MAY	CTEC
>A>		+	EQ 250MG BASE	N62162	002	JUN 15, 1981	MAY	CTEC
		@ DANBURY PHARMA	EQ 250MG BASE	N62087	001	JUN 14, 1979	APR	DISC
>D>		ILOSONE						
>D>		LILLY	EQ 125MG BASE	N61897	001	JAN 06, 1975	MAY	DISC
>A>		@	EQ 125MG BASE	N61897	001	JAN 06, 1975	MAY	DISC
>D>	AB	+	EQ 250MG BASE	N61897	002	JAN 06, 1975	MAY	DISC
>A>		@	EQ 250MG BASE	N61897	002	JAN 06, 1975	MAY	DISC
>D>		FOR SUSPENSION; ORAL						
>D>		ILOSONE						
>D>		+ DISTA	EQ 125MG BASE/5ML	N61893	001	JAN 06, 1975	MAY	DISC
>A>		@	EQ 125MG BASE/5ML	N61893	001	JAN 06, 1975	MAY	DISC
		SUSPENSION/DROPS; ORAL						
		@ LILLY	EQ 100MG BASE/ML	N61894	003	JAN 07, 1975	APR	DISC
		TABLET; ORAL						
		@ LILLY	EQ 500MG BASE	N61896	001	JAN 03, 1975	APR	DISC
		TABLET, CHEWABLE; ORAL						
>D>		DISTA	EQ 125MG BASE	N61895	001	JAN 03, 1975	MAY	DISC
>A>		@	EQ 125MG BASE	N61895	001	JAN 03, 1975	MAY	DISC
>D>		+	EQ 250MG BASE	N61895	002	JAN 03, 1975	MAY	DISC
>A>		@	EQ 250MG BASE	N61895	002	JAN 03, 1975	MAY	DISC
		ERYTHROMYCIN ETHYLSUCCINATE						
		TABLET; ORAL						
		ERYTHROMYCIN ETHYLSUCCINATE						
>D>	AB	BARR	EQ 400MG BASE	N62256	001	APR 28, 1980	MAY	DISC
>A>		@	EQ 400MG BASE	N62256	001	APR 28, 1980	MAY	DISC
		ERYTHROMYCIN STEARATE						
		TABLET; ORAL						
		ERYTHROMYCIN STEARATE						
>D>	AB	BARR	EQ 500MG BASE	N63179	001	MAY 15, 1990	MAY	DISC
>A>		@	EQ 500MG BASE	N63179	001	MAY 15, 1990	MAY	DISC
>D>	AB	ZENITH GOLDLINE	EQ 250MG BASE	N61461	001	SEP 04, 1971	MAY	DISC
>A>		@	EQ 250MG BASE	N61461	001	SEP 04, 1971	MAY	DISC
>D>	AB		EQ 500MG BASE	N61461	002	APR 11, 1980	MAY	DISC
>A>		@	EQ 500MG BASE	N61461	002	APR 11, 1980	MAY	DISC

ERYTHROMYCIN STEARATE

TABLET; ORAL

WYAMYCIN S

@ WYETH AYERST	EQ 250MG BASE	N61675 001	OCT 06, 1972	APR	DISC
@	EQ 500MG BASE	N61675 002	JUL 13, 1973	APR	DISC

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL

NEXIUM

+ ASTRAZENECA	EQ 20MG BASE	N21153 001	FEB 20, 2001	FEB	NEWA
+	EQ 40MG BASE	N21153 002	FEB 20, 2001	FEB	NEWA

ESTRADIOL; NORETHINDRONE ACETATE

FILM, EXTENDED RELEASE; TRANSDERMAL

COMBIPATCH

NOVARTIS	0.05MG/24HR;0.14MG/24HR	N20870 001	AUG 07, 1998	MAR	CAHN
+	0.05MG/24HR;0.25MG/24HR	N20870 002	AUG 07, 1998	MAR	CAHN

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET; ORAL-28

PREMPRO

+ WYETH AYERST	0.625MG;0.625MG;2.5MG;2.5MG	N20527 001	NOV 17, 1995	JAN	CTNA
+	0.625MG;0.625MG;5MG;5MG	N20527 003	JAN 09, 1998	JAN	CTNA

PREMPRO (PREMARIN;CYCRIN)

+ WYETH AYERST	0.625MG;0.625MG;2.5MG;2.5MG	N20303 001	DEC 30, 1994	JAN	CTNA

ESTROPIPATE

TABLET; ORAL

ORTHO-EST

AB WOMEN FIRST HLTHCARE	0.75MG	N89567 001	FEB 27, 1991	JAN	CAHN
AB	1.5MG	N89582 001	JUL 17, 1991	JAN	CAHN

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21

ALESSE

AB + WYETH AYERST	0.02MG;0.1MG	N20683 001	MAR 27, 1997	APR	CTEC

AVIANE-21

AB DURAMED	0.02MG;0.1MG	N75796 002	APR 30, 2001	APR	NEWA

TABLET; ORAL-28

ALESSE

AB WYETH AYERST	0.02MG;0.1MG	N20683 002	MAR 27, 1997	APR	CTEC

AVIANE-28

AB DURAMED	0.02MG;0.1MG	N75796 001	APR 30, 2001	APR	NEWA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-28

LOESTRIN FE 1.5/30

AB + PARKE DAVIS	0.03MG;1.5MG	N17355 001	APR 30, 1973	FEB	CFTG

LOESTRIN FE 1/20

AB + PARKE DAVIS	0.02MG;1MG	N17354 001	APR 30, 1973	FEB	CFTG

MICROGESTIN FE 1.5/30

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-28

MICROGESTIN FE 1.5/30

AB	WATSON LABS	0.03MG;1.5MG	N75548 001	FEB 05, 2001	FEB	NEWA

MICROGESTIN FE 1/20

AB	WATSON LABS	0.02MG;1MG	N75647 001	FEB 05, 2001	FEB	NEWA

ETHOSUXIMIDE

SYRUP; ORAL

ZARONTIN

AA +	PARKE DAVIS	250MG/5ML	N80258 001	FEB 13, 1974	JAN	CRLD

ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST

	@ DENTSPLY PHARM	0.5%	N17751 003	AUG 30, 1976	APR	CAHN
	+	1%	N17751 005	AUG 30, 1976	APR	CAHN

ETODOLAC

TABLET, EXTENDED RELEASE; ORAL

ETODOLAC

AB	TEVA	400MG	N75665 003	FEB 05, 2001	FEB	NEWA

FAMCICLOVIR

TABLET; ORAL

FAMVIR

	NOVARTIS	125MG	N20363 003	DEC 11, 1995	JAN	CAHN
		250MG	N20363 001	APR 26, 1996	JAN	CAHN
	+	500MG	N20363 002	JUN 29, 1994	JAN	CAHN

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE

AP	AM PHARM PARTNERS	10MG/ML	N75709 001	APR 16, 2001	APR	NEWA
>D> AP	APOTHECON	10MG/ML	N75707 001	APR 16, 2001	MAY	DISC
>A>	@	10MG/ML	N75707 001	APR 16, 2001	MAY	DISC
AP		10MG/ML	N75707 001	APR 16, 2001	APR	NEWA
AP	BEDFORD	10MG/ML	N75651 001	APR 16, 2001	APR	NEWA
AP		10MG/ML	N75684 001	APR 16, 2001	APR	NEWA
AP	ESI LEDERLE	10MG/ML	N75488 001	APR 16, 2001	APR	NEWA
AP	FAULDING	10MG/ML	N75705 001	APR 16, 2001	APR	NEWA

FAMOTIDINE PRESERVATIVE FREE

AP	AM PHARM PARTNERS	10MG/ML	N75813 001	APR 16, 2001	APR	NEWA
>D> AP	APOTHECON	10MG/ML	N75708 001	APR 16, 2001	MAY	DISC
>A>	@	10MG/ML	N75708 001	APR 16, 2001	MAY	DISC
AP		10MG/ML	N75708 001	APR 16, 2001	APR	NEWA
AP	BEDFORD	10MG/ML	N75622 001	APR 16, 2001	APR	NEWA
AP	BEN VENUE	10MG/ML	N75825 001	APR 17, 2001	APR	NEWA
AP	ESI LEDERLE	10MG/ML	N75486 001	APR 16, 2001	APR	NEWA
AP	FAULDING	10MG/ML	N75669 001	APR 16, 2001	APR	NEWA

FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER

>A> AP	BAXTER HLTHCARE	0.4MG/ML	N75591 001	MAY 10, 2001	MAY	NEWA

PEPCID

FAMOTIDINE

INJECTABLE; INJECTION

		PEPCID						
	AP	+ MERCK	10MG/ML	N19510 001	NOV 04, 1986	APR	CFTG
		PEPCID PRESERVATIVE FREE						
	AP	+ MERCK	10MG/ML	N19510 004	NOV 04, 1986	APR	CFTG
		PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER						
>D>		+ MERCK	0.4MG/ML	N20249 001	FEB 18, 1994	MAY	CFTG
>A>	AP	+	0.4MG/ML	N20249 001	FEB 18, 1994	MAY	CFTG

TABLET; ORAL

		FAMOTIDINE						
	AB	CARLSBAD	20MG	N75805 001	APR 16, 2001	APR	NEWA
	AB		40MG	N75805 002	APR 16, 2001	APR	NEWA
	AB	DANBURY PHARMA	20MG	N75062 002	APR 16, 2001	APR	NEWA
	AB		40MG	N75062 001	APR 16, 2001	APR	NEWA
	AB	DR REDDYS LABS LTD	20MG	N75718 001	APR 16, 2001	APR	NEWA
	AB		40MG	N75718 002	APR 16, 2001	APR	NEWA
	AB	EON	20MG	N75793 001	APR 16, 2001	APR	NEWA
	AB		40MG	N75793 002	APR 16, 2001	APR	NEWA
	AB	GENEVA PHARMS	20MG	N75302 001	APR 16, 2001	APR	NEWA
	AB		40MG	N75302 002	APR 16, 2001	APR	NEWA
	AB	GENPHARM	20MG	N75457 001	APR 18, 2001	APR	NEWA
	AB		40MG	N75457 002	APR 18, 2001	APR	NEWA
>A>	AB	INVAMED	20MG	N75607 001	MAY 10, 2001	MAY	NEWA
>A>	AB		40MG	N75607 002	MAY 10, 2001	MAY	NEWA
	AB	MYLAN	20MG	N75704 001	APR 16, 2001	APR	NEWA
	AB		40MG	N75704 002	APR 16, 2001	APR	NEWA
	AB	TEVA	20MG	N75311 001	APR 16, 2001	APR	NEWA
	AB		40MG	N75311 002	APR 16, 2001	APR	NEWA
	AB	WOCKHARDT	20MG	N75786 001	APR 16, 2001	APR	NEWA
	AB		40MG	N75786 002	APR 16, 2001	APR	NEWA
	AB	ZENITH GOLDLINE	20MG	N75511 001	APR 16, 2001	APR	NEWA
	AB		40MG	N75511 002	APR 16, 2001	APR	NEWA
		PEPCID						
	AB	MERCK	20MG	N19462 001	OCT 15, 1986	APR	CFTG
	AB	+	40MG	N19462 002	OCT 15, 1986	APR	CFTG

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

		DURAGESIC						
>D>		+ ALZA	1.2MG/24HR	N19813 003	AUG 07, 1990	MAY	CTEC
>A>			1.2MG/24HR	N19813 003	AUG 07, 1990	MAY	CTEC
>D>		+	1.8MG/24HR	N19813 002	AUG 07, 1990	MAY	CTEC
>A>			1.8MG/24HR	N19813 002	AUG 07, 1990	MAY	CTEC
>D>		+	2.4MG/24HR	N19813 001	AUG 07, 1990	MAY	CTEC
>A>			2.4MG/24HR	N19813 001	AUG 07, 1990	MAY	CTEC

FENTANYL CITRATE

INJECTABLE; INJECTION

		FENTANYL CITRATE PRESERVATIVE FREE						
		@ MARSAM	EQ 0.05MG BASE/ML	N74917 001	FEB 03, 1998	JAN	DISC

FLOXURIDINE
INJECTABLE; INJECTION
FLOXURIDINE

AP	AM PHARM PARTNERS	500MG/VIAL	N75837	001	FEB 22, 2001	FEB	NEWA

FLUOCINOLONE ACETONIDE
CREAM; TOPICAL
FLUOCINOLONE ACETONIDE

	@ CLAY PARK	0.01%	N86810	001	MAR 04, 1982	APR	DISC
	@	0.025%	N86811	001	MAR 04, 1982	APR	DISC

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE
CREAM; TOPICAL
NEO-SYNALAR

>D>	+ MEDICIS	0.025%;EQ 3.5MG BASE/GM	N60700	001	JUN 11, 1963	MAY	DISC
>A>	@	0.025%;EQ 3.5MG BASE/GM	N60700	001	JUN 11, 1963	MAY	DISC

FLUOROMETHOLONE
SUSPENSION; OPHTHALMIC
FLUOR-OP

AB	NOVARTIS	0.1%	N70185	001	FEB 27, 1986	FEB	CAHN

FLUOROURACIL
CREAM; TOPICAL
FLUOROURACIL
CARAC

>D>	+ DERMIK LABS	0.5%	N20985	001	OCT 27, 2000	MAY	CTNA
>A>	+	0.5%	N20985	001	OCT 27, 2000	MAY	CTNA

FLUOXETINE HYDROCHLORIDE
CAPSULE, DELAYED REL PELLETS; ORAL
PROZAC WEEKLY

	+ LILLY	EQ 90MG BASE	N21235	001	FEB 26, 2001	FEB	NEWA

FLURBIPROFEN
TABLET; ORAL
FLURBIPROFEN

AB	CARACO	50MG	N75058	001	APR 27, 2001	APR	NEWA
AB		100MG	N75058	002	APR 27, 2001	APR	NEWA

FLUVOXAMINE MALEATE
TABLET; ORAL
FLUVOXAMINE MALEATE

AB	BARR	25MG	N75897	001	JAN 25, 2001	JAN	NEWA
AB		50MG	N75897	002	JAN 25, 2001	JAN	NEWA
AB		100MG	N75897	003	JAN 25, 2001	JAN	NEWA
AB	INVAMED	25MG	N75887	001	JAN 05, 2001	JAN	NEWA
AB		50MG	N75887	002	JAN 05, 2001	JAN	NEWA
AB		100MG	N75887	003	JAN 05, 2001	JAN	NEWA
AB	SYNTHON PHARMS	25MG	N75899	001	JAN 17, 2001	JAN	NEWA
AB		50MG	N75899	002	JAN 17, 2001	JAN	NEWA
AB		100MG	N75899	003	JAN 17, 2001	JAN	NEWA
>A> AB	TORPHARM	25MG	N75902	001	MAY 07, 2001	MAY	NEWA

>A>	AB		50MG	N75902 002	MAY 07, 2001	MAY	NEWA
>A>	AB		100MG	N75902 003	MAY 07, 2001	MAY	NEWA
	AB	WATSON LABS	25MG	N75894 001	APR 18, 2001	APR	NEWA
	AB		50MG	N75894 002	APR 18, 2001	APR	NEWA
	AB		100MG	N75894 003	APR 18, 2001	APR	NEWA
	AB	ZENITH GOLDLINE	25MG	N75898 001	MAR 12, 2001	MAR	NEWA
	AB		50MG	N75898 002	MAR 12, 2001	MAR	NEWA
	AB		100MG	N75898 003	MAR 12, 2001	MAR	NEWA

FORMOTEROL FUMARATE
CAPSULE; INHALATION
FORADIL

+	NOVARTIS	0.012MG/INH	N20831 001	FEB 16, 2001	FEB	NEWA

GABAPENTIN
CAPSULE; ORAL
NEURONTIN

	PFIZER	100MG	N20235 001	DEC 30, 1993	MAR	CAHN
		300MG	N20235 002	DEC 30, 1993	MAR	CAHN
+		400MG	N20235 003	DEC 30, 1993	MAR	CAHN

GALANTAMINE HYDROBROMIDE
TABLET; ORAL
REMINYL

	JANSSEN	EQ 4MG BASE	N21169 001	FEB 28, 2001	FEB	NEWA
		EQ 8MG BASE	N21169 002	FEB 28, 2001	FEB	NEWA
+		EQ 12MG BASE	N21169 003	FEB 28, 2001	FEB	NEWA

GEMFIBROZIL
TABLET; ORAL
GEMFIBROZIL

AB	GENEVA PHARMS TECH	600MG	N74615 001	SEP 29, 1995	JAN	CAHN

GENTAMICIN SULFATE
CREAM; TOPICAL
GENTAMICIN SULFATE

>D>	AT	BAUSCH AND LOMB	EQ 0.1% BASE	N64056 001	APR 29, 1994	MAY	DISC
>A>		@	EQ 0.1% BASE	N64056 001	APR 29, 1994	MAY	DISC

INJECTABLE; INJECTION

>D>		@ GENSIA SICOR PHARMS	EQ 10MG BASE/ML	N63149 001	NOV 21, 1991	MAY	DISC
>A>		@	EQ 10MG BASE/ML	N63149 001	NOV 21, 1991	MAY	DISC
		@	EQ 40MG BASE/ML	N63106 002	NOV 21, 1991	APR	DISC
		@ STERIS	EQ 10MG BASE/ML	N62318 002	AUG 20, 1981	APR	DISC
		@	EQ 40MG BASE/ML	N62318 001	JUN 02, 1981	APR	DISC
		U-GENCIN					
		@ PHARMACIA AND UPJOHN	EQ 10MG BASE/ML	N62248 001	MAY 02, 1980	FEB	WDRP
		@	EQ 40MG BASE/ML	N62248 002	MAY 02, 1980	FEB	WDRP

INJECTABLE; INTRATHECAL
GARAMYCIN

		@ SCHERING	EQ 2MG BASE/ML	N50505 001	OCT 01, 1979	APR	DISC

OINTMENT; OPHTHALMIC
GENTACIDIN

>D>							
>D>	AT	NOVARTIS	EQ 0.3% BASE	N62501 001	JUL 26, 1984	MAY	DISC

>A>		@	EQ 0.3% BASE	N62501 001	JUL 26, 1984	MAY	DISC
	AT		EQ 0.3% BASE	N62501 001	JUL 26, 1984	FEB	CAHN
		OINTMENT; TOPICAL					
		GENTAMICIN SULFATE					
>D>	AT	BAUSCH AND LOMB	EQ 0.1% BASE	N64054 001	APR 29, 1994	MAY	DISC
>A>		@	EQ 0.1% BASE	N64054 001	APR 29, 1994	MAY	DISC
		SOLUTION/DROPS; OPHTHALMIC					
		GENTACIDIN					
	AT	NOVARTIS	EQ 0.3% BASE	N62480 001	MAR 30, 1984	FEB	CAHN
		GENTAMICIN SULFATE					
		@ ALCON UNIVERSAL	EQ 0.3% BASE	N62523 001	NOV 25, 1985	APR	DISC
		GLIPIZIDE					
		TABLET; ORAL					
		GLIPIZIDE					
	AB	GENEVA PHARMS TECH	5MG	N74542 001	JUN 20, 1995	JAN	CAHN
	AB		10MG	N74542 002	JUN 20, 1995	JAN	CAHN
		GLYCOPYRROLATE					
		INJECTABLE; INJECTION					
		GLYCOPYRROLATE					
>D>	AP	GENSIA SICOR PHARMS	0.2MG/ML	N81169 001	SEP 10, 1991	MAY	DISC
>A>		@	0.2MG/ML	N81169 001	SEP 10, 1991	MAY	DISC
		GRISEOFULVIN, MICROCRYSTALLINE					
		SUSPENSION; ORAL					
		GRIFULVIN V					
	+	J AND J	125MG/5ML	N62483 001	JAN 26, 1984	MAR	CRLD
		@ JOHNSON AND JOHNSON	125MG/5ML	N50448 001	MAY 19, 1972	MAR	DISC
		GRISEOFULVIN, ULTRAMICROCRYSTALLINE					
		TABLET; ORAL					
		GRISACTIN ULTRA					
		@ WYETH AYERST	125MG	N62178 001	MAR 13, 1980	APR	DISC
		@	250MG	N62178 002	MAR 13, 1980	APR	DISC
>D>		ULTRAGRIS-165					
>D>	AB	SIDMAK LABS NJ	165MG	N62645 001	JUN 30, 1992	MAY	DISC
>A>		@	165MG	N62645 001	JUN 30, 1992	MAY	DISC
>D>		ULTRAGRIS-330					
>D>	AB	SIDMAK LABS NJ	330MG	N62646 001	JUN 30, 1992	MAY	DISC
>A>		@	330MG	N62646 001	JUN 30, 1992	MAY	DISC
		HALOPERIDOL LACTATE					
		INJECTABLE; INJECTION					
		HALOPERIDOL LACTATE					
	AP	AM PHARM PARTNERS	EQ 5MG BASE/ML	N75689 001	MAR 09, 2001	MAR	NEWA
		HALOTHANE					
		LIQUID; INHALATION					
		HALOTHANE					
		@ BH	99.99%	N84977 001	JUL 14, 1976	JAN	DISC

HEPARIN SODIUM
INJECTABLE; INJECTION
HEPARIN SODIUM

>D>	AP	ABBOTT	10,000 UNITS/ML	N40095 001	JUL 26, 1996	MAY	DISC
>A>		@	10,000 UNITS/ML	N40095 001	JUL 26, 1996	MAY	DISC

HEPARIN SODIUM PRESERVATIVE FREE

	@ PHARMA SERVE NY	1,000 UNITS/ML	N86129 001	FEB 22, 1980	FEB	WDRP

HYDRALAZINE HYDROCHLORIDE
INJECTABLE; INJECTION
HYDRALAZINE HCL

AP	AM PHARM PARTNERS	20MG/ML	N40388 001	MAR 13, 2001	MAR	NEWA

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE
TABLET; ORAL
RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE

>D>	BP	DANBURY PHARMA	25MG;15MG;0.1MG	N85549 001	SEP 29, 1977	MAY	DISC
>A>		@	25MG;15MG;0.1MG	N85549 001	SEP 29, 1977	MAY	DISC

HYDROCHLOROTHIAZIDE
TABLET; ORAL
HYDROCHLOROTHIAZIDE

>D>	AB	DANBURY PHARMA	50MG	N83232 001	JAN 24, 1975	MAY	DISC
>A>		@	50MG	N83232 001	JAN 24, 1975	MAY	DISC
>D>	AB	HALSEY	25MG	N83972 001	OCT 03, 1974	MAY	DISC
>A>		@	25MG	N83972 001	OCT 03, 1974	MAY	DISC
>D>	AB		50MG	N83972 002	OCT 03, 1974	MAY	DISC
>A>		@	50MG	N83972 002	OCT 03, 1974	MAY	DISC
>D>	AB	IMPAX LABS	25MG	N84029 001	JUL 05, 1977	MAY	DISC
>A>		@	25MG	N84029 001	JUL 05, 1977	MAY	DISC
>D>	AB		50MG	N83607 002	JUN 06, 1977	MAY	DISC
>A>		@	50MG	N83607 002	JUN 06, 1977	MAY	DISC
>D>	AB	PHARMERAL	25MG	N84325 001	JUN 24, 1976	MAY	DISC
>A>		@	25MG	N84325 001	JUN 24, 1976	MAY	DISC
>D>	AB		50MG	N84324 001	JUN 24, 1976	MAY	DISC
>A>		@	50MG	N84324 001	JUN 24, 1976	MAY	DISC
>D>	AB	WEST WARD	50MG	N84878 001	JAN 31, 1977	MAY	DISC
>A>		@	50MG	N84878 001	JAN 31, 1977	MAY	DISC

HYDROCHLOROTHIAZIDE; RESERPINE
TABLET; ORAL
HYDRO-RESERP

>D>	BP	ABC HOLDING	50MG;0.125MG	N84714 002	JUN 29, 1982	MAY	DISC
>A>		@	50MG;0.125MG	N84714 002	JUN 29, 1982	MAY	DISC

HYDROCHLOROTHIAZIDE W/ RESERPINE

>D>	BP	DANBURY PHARMA	25MG;0.125MG	N84466 001	JAN 07, 1977	MAY	DISC
>A>		@	25MG;0.125MG	N84466 001	JAN 07, 1977	MAY	DISC
>D>	BP		50MG;0.125MG	N84467 001	JAN 07, 1977	MAY	DISC
>A>		@	50MG;0.125MG	N84467 001	JAN 07, 1977	MAY	DISC

RESERPINE AND HYDROCHLOROTHIAZIDE-50

	@ WEST WARD	50MG;0.125MG	N88189 001	MAY 10, 1984	FEB	WDRP

		HYDROCORTISONE						
		CREAM; TOPICAL						
		HC (HYDROCORTISONE)						
		@ C AND M PHARMA	0.5%	N80482 003	MAR 20, 1973	FEB	WDRP
		@	1%	N80482 004	MAR 20, 1973	FEB	WDRP
		HYDROCORTISONE						
		@ TOPIDERM	1%	N89273 001	FEB 17, 1989	FEB	WDRP
		PROCTOCORT						
		@ MONARCH PHARMS	1%	N83011 001	APR 26, 1973	FEB	DISC
		LOTION; TOPICAL						
		BETA-HC						
		@ BETA DERMAC	1%	N89495 001	JAN 25, 1988	FEB	WDRP
		GLYCORT						
		@ HERAN	1%	N87489 001	OCT 03, 1983	FEB	WDRP
		HYDROCORTISONE						
>D>	AT	MERICON	0.5%	N85282 001	JUN 05, 1978	MAY	DISC
>A>		@	0.5%	N85282 001	JUN 05, 1978	MAY	DISC
>D>	AT		1%	N85282 002	FEB 26, 1987	MAY	DISC
>A>		@	1%	N85282 002	FEB 26, 1987	MAY	DISC
		OINTMENT; TOPICAL						
		HC (HYDROCORTISONE)						
		@ C AND M PHARMA	1%	N80481 002	MAR 20, 1973	FEB	WDRP
		POWDER; FOR RX COMPOUNDING						
		H-CORT						
		@ TORCH	100%	N87834 001	MAR 29, 1982	FEB	WDRP
		SOLUTION; TOPICAL						
		TEXACORT						
>D>		+ BIOGLAN PHARMA	2.5%	N81271 001	APR 17, 1992	MAY	CAHN
>A>		+ SIRIUS LABS	2.5%	N81271 001	APR 17, 1992	MAY	CAHN
		TABLET; ORAL						
		HYDROCORTISONE						
>D>	BP	LANNETT	20MG	N85070 001	MAY 07, 1976	MAY	DISC
>A>		@	20MG	N85070 001	MAY 07, 1976	MAY	DISC
		HYDROCORTISONE ACETATE						
		CREAM; TOPICAL						
		MICORT-HC						
		FERNDALE LABS	2.5%	N40396 001	FEB 27, 2001	FEB	NEWA
		HYDROCORTISONE ACETATE; NEOMYCIN SULFATE						
		OINTMENT; TOPICAL						
		NEO-CORTEF						
		@ PHARMACIA AND UPJOHN	1%;EQ 3.5MG BASE/GM	N60751 002	MAY 18, 1965	APR	DISC
		SUSPENSION/DROPS; OPHTHALMIC						
		COR-OTICIN						
		@ AKORN	1.5%;EQ 3.5MG BASE/ML	N60188 001	OCT 26, 1968	FEB	WDRP
		HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE						
		SOLUTION/DROPS; OTIC						
		NEO-OTOSOL-HC						
		@ ALCON	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62423 001	AUG 25, 1983	APR	DISC

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OPHTHALMIC

NEO-OTOSOL-HC

SUSPENSION/DROPS; OPHTHALMIC

CORTISPORIN

>D>	AT	+	MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N50169 001	DEC 18, 1964	MAY	CTEC
>A>		+		1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N50169 001	DEC 18, 1964	MAY	CTEC

>D>

>A>

>D> NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

>D>	AT		ALCON UNIVERSAL	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62874 001	MAY 11, 1988	MAY	DISC
>A>		@		1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62874 001	MAY 11, 1988	MAY	DISC

>D>

>A>

SUSPENSION/DROPS; OTIC

		@	ALCON UNIVERSAL	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62488 001	NOV 06, 1985	APR	DISC

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE HCL

>D>	AP		STERIS	25MG/ML	N85778 001	OCT 05, 1979	MAY	DISC
>A>		@		25MG/ML	N85778 001	OCT 05, 1979	MAY	DISC

>D>

HYDROXYZINE PAMOATE

>D>

>A>

CAPSULE; ORAL

HYDROXYZINE PAMOATE

>D>	AB		GENEVA PHARMS	EQ 50MG HCL	N81128 001	JUN 28, 1991	MAY	DISC
>A>		@		EQ 50MG HCL	N81128 001	JUN 28, 1991	MAY	DISC
>D>	AB			EQ 100MG HCL	N81129 001	JUN 28, 1991	MAY	DISC
>A>		@		EQ 100MG HCL	N81129 001	JUN 28, 1991	MAY	DISC
		@	VANGARD	EQ 50MG HCL	N88393 001	SEP 19, 1983	FEB	WDRP

>D>

>D>

>A>

>D>

>A>

>A> IMATINIB MESYLATE

>A> CAPSULE; ORAL

>A> GLEEVEC

>A>			NOVARTIS	50MG	N21335 001	MAY 10, 2001	MAY	NEWA
>A>		+		100MG	N21335 002	MAY 10, 2001	MAY	NEWA

>A>

>D>

>A>

>D>

>A>

INDAPAMIDE

TABLET; ORAL

INDAPAMIDE

	AB		GENEVA PHARMS TECH	1.25MG	N74594 001	MAY 23, 1996	JAN	CAHN
	AB			2.5MG	N74594 002	MAY 23, 1996	JAN	CAHN

>D>

>A>

>D>

>A>

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

IPRATROPIUM BROMIDE

	AN		ASLUNG PHARM	0.02%	N75693 001	JAN 26, 2001	JAN	NEWA
	AN		NOVEX	0.02%	N75441 001	MAR 28, 2001	MAR	NEWA
	AN		WARRICK PHARMS	0.02%	N75507 001	JAN 19, 2001	JAN	NEWA

>D>

>A>

ISOFLURANE
LIQUID; INHALATION
ISOFLURANE

	AN		MINRAD	99.9%	N74416 001	SEP 30, 1994	FEB	CAHN

ISONIAZID
SYRUP; ORAL
ISONIAZID

>D>	AA	+	CAROLINA MEDCL	50MG/5ML	N88235 001	NOV 10, 1983	MAY	CTEC
>A>		+		50MG/5ML	N88235 001	NOV 10, 1983	MAY	CTEC
>D>	AA		MIKART	50MG/5ML	N81118 001	JUL 21, 1997	MAY	DISC
>A>			@	50MG/5ML	N81118 001	JUL 21, 1997	MAY	DISC

TABLET; ORAL

>D>	AA		HALSEY	100MG	N80136 001	NOV 13, 1970	MAY	DISC
>A>			@	100MG	N80136 001	NOV 13, 1970	MAY	DISC

ISOTRETINOIN
CAPSULE; ORAL
ACCUTANE

		+	HLR	20MG	N18662 004	MAR 28, 1983	APR	CTEC

KANAMYCIN SULFATE
INJECTABLE; INJECTION
KANAMYCIN SULFATE

>D>								
>D>	AP		LOCH	EQ 75MG BASE/2ML	N63021 001	JUL 31, 1992	MAY	DISC
>A>			@	EQ 75MG BASE/2ML	N63021 001	JUL 31, 1992	MAY	DISC
>D>	AP			EQ 500MG BASE/2ML	N63022 001	JUL 31, 1992	MAY	DISC
>A>			@	EQ 500MG BASE/2ML	N63022 001	JUL 31, 1992	MAY	DISC
			@	EQ 1GM BASE/3ML	N63025 001	JUL 31, 1992	APR	DISC
>D>	AP		STERIS	EQ 1GM BASE/3ML	N62520 003	MAY 09, 1985	MAY	DISC
>A>			@	EQ 1GM BASE/3ML	N62520 003	MAY 09, 1985	MAY	DISC

KANTREX

>D>	AP	+	APOTHECON	EQ 75MG BASE/2ML	N61901 003	MAR 06, 1975	MAY	CTEC
>A>		+		EQ 75MG BASE/2ML	N61901 003	MAR 06, 1975	MAY	CTEC
>D>	AP	+		EQ 500MG BASE/2ML	N61901 001	MAR 06, 1975	MAY	CTEC
>A>		+		EQ 500MG BASE/2ML	N61901 001	MAR 06, 1975	MAY	CTEC
>D>	AP	+		EQ 1GM BASE/3ML	N61901 002	MAR 06, 1975	MAY	CTEC
>A>		+		EQ 1GM BASE/3ML	N61901 002	MAR 06, 1975	MAY	CTEC

KETOROLAC TROMETHAMINE
INJECTABLE; INJECTION
KETOROLAC TROMETHAMINE

>D>	AP		APOTHECON	15MG/ML	N75348 001	NOV 28, 2000	MAY	DISC
>A>			@	15MG/ML	N75348 001	NOV 28, 2000	MAY	DISC
>D>	AP			30MG/ML	N75348 002	NOV 28, 2000	MAY	DISC
>A>			@	30MG/ML	N75348 002	NOV 28, 2000	MAY	DISC

LABETALOL HYDROCHLORIDE
INJECTABLE; INJECTION
LABETALOL HCL

>D>	AP		APOTHECON	5MG/ML	N75355 001	NOV 29, 1999	MAY	DISC
>A>			@	5MG/ML	N75355 001	NOV 29, 1999	MAY	DISC

		LABETALOL HYDROCHLORIDE							
		INJECTABLE; INJECTION							
		TRANDATE							
>D>	AP +	FARO PHARMS	5MG/ML	N19425 001	DEC 31, 1985	MAY	CAHN		
>A>	AP +	PROMETHEUS LABS	5MG/ML	N19425 001	DEC 31, 1985	MAY	CAHN		
		LAMOTRIGINE							
		TABLET, CHEWABLE; ORAL							
		LAMICTAL CD							
		GLAXO WELLCOME	2MG	N20764 004	SEP 08, 2000	MAR	NEWA		
		LANSOPRAZOLE							
		FOR SUSPENSION, EXTENDED RELEASE; ORAL							
		PREVACID							
>A>		TAP PHARM	15MG/PACKET	N21281 001	MAY 03, 2001	MAY	NEWA		
>A>	+		30MG/PACKET	N21281 002	MAY 03, 2001	MAY	NEWA		
		LEUCOVORIN CALCIUM							
		INJECTABLE; INJECTION							
		LEUCOVORIN CALCIUM PRESERVATIVE FREE							
	AP	LUITPOLD	EQ 50MG BASE/VIAL	N40338 001	JAN 31, 2001	JAN	NEWA		
		LEVOCARNITINE							
		INJECTABLE; INJECTION							
		CARNITOR							
	AP +	SIGMA TAU	200MG/ML	N20182 001	DEC 16, 1992	MAR	CFTG		
		LEVOCARNITINE							
	AP	BEDFORD	200MG/ML	N75567 001	MAR 29, 2001	MAR	NEWA		
	AP	GENSIA SICOR PHARMS	200MG/ML	N75881 001	MAR 29, 2001	MAR	NEWA		
		LEVODOPA							
		CAPSULE; ORAL							
		DOPAR							
>D>	+	ROBERTS LABS	250MG	N16913 001	JUN 04, 1970	MAY	DISC		
>A>	@	SHIRE LABS	250MG	N16913 001	JUN 04, 1970	MAY	DISC		
		LEVOTHYROXINE SODIUM							
		TABLET; ORAL							
		LEVOXYL							
>A>	BX +	JONES PHARMA	0.025MG	N21301 001	MAY 25, 2001	MAY	NEWA		
>A>	BX		0.05MG	N21301 002	MAY 25, 2001	MAY	NEWA		
>A>	BX		0.075MG	N21301 003	MAY 25, 2001	MAY	NEWA		
>A>	BX		0.088MG	N21301 004	MAY 25, 2001	MAY	NEWA		
>A>	BX		0.1MG	N21301 005	MAY 25, 2001	MAY	NEWA		
>A>	BX		0.112MG	N21301 006	MAY 25, 2001	MAY	NEWA		
>A>	BX		0.125MG	N21301 007	MAY 25, 2001	MAY	NEWA		
>A>	BX		0.137MG	N21301 008	MAY 25, 2001	MAY	NEWA		
>A>	BX		0.15MG	N21301 009	MAY 25, 2001	MAY	NEWA		
>A>	BX		0.175MG	N21301 010	MAY 25, 2001	MAY	NEWA		
>A>	BX		0.2MG	N21301 011	MAY 25, 2001	MAY	NEWA		
>A>	BX		0.3MG	N21301 012	MAY 25, 2001	MAY	NEWA		
		UNITHROID							
>D>		STEVENS J	0.025MG	N21210 001	AUG 21, 2000	MAY	CTEC		

>A>	BX		0.025MG	N21210 001	AUG 21, 2000	MAY	CTEC
>D>			0.05MG	N21210 002	AUG 21, 2000	MAY	CTEC
>A>	BX		0.05MG	N21210 002	AUG 21, 2000	MAY	CTEC
>D>			0.075MG	N21210 003	AUG 21, 2000	MAY	CTEC
>A>	BX		0.075MG	N21210 003	AUG 21, 2000	MAY	CTEC
>D>			0.088MG	N21210 004	AUG 21, 2000	MAY	CTEC
>A>	BX		0.088MG	N21210 004	AUG 21, 2000	MAY	CTEC
>D>			0.1MG	N21210 005	AUG 21, 2000	MAY	CTEC
>A>	BX		0.1MG	N21210 005	AUG 21, 2000	MAY	CTEC
>D>			0.112MG	N21210 006	AUG 21, 2000	MAY	CTEC
>A>	BX		0.112MG	N21210 006	AUG 21, 2000	MAY	CTEC
>D>			0.125MG	N21210 007	AUG 21, 2000	MAY	CTEC
>A>	BX		0.125MG	N21210 007	AUG 21, 2000	MAY	CTEC
>D>			0.15MG	N21210 008	AUG 21, 2000	MAY	CTEC
>A>	BX		0.15MG	N21210 008	AUG 21, 2000	MAY	CTEC
>D>			0.175MG	N21210 009	AUG 21, 2000	MAY	CTEC
>A>	BX		0.175MG	N21210 009	AUG 21, 2000	MAY	CTEC
>D>			0.2MG	N21210 010	AUG 21, 2000	MAY	CTEC
>A>	BX		0.2MG	N21210 010	AUG 21, 2000	MAY	CTEC
>D>		+	0.3MG	N21210 011	AUG 21, 2000	MAY	CTEC
>A>	BX	+	0.3MG	N21210 011	AUG 21, 2000	MAY	CTEC

LIDOCAINE HYDROCHLORIDE
INJECTABLE; INJECTION
LIDOCATON
@ PHARMATON — 2% — N84727 001 AUG 17, 1983 FEB WDRP

LINCOMYCIN HYDROCHLORIDE
INJECTABLE; INJECTION
LINCOCIN

>D>	AP	+	PHARMACIA AND UPJOHN	EQ 300MG BASE/ML	N50317 001	DEC 29, 1964	MAY	CTEC
>A>		+		EQ 300MG BASE/ML	N50317 001	DEC 29, 1964	MAY	CTEC

LINCOMYCIN HCL

>D>	AP		STERIS	EQ 300MG BASE/ML	N63180 001	APR 16, 1991	MAY	DISC
>A>			@	EQ 300MG BASE/ML	N63180 001	APR 16, 1991	MAY	DISC

LISINOPRIL
TABLET; ORAL
ZESTRIL

	AB		ASTRAZENECA	10MG	N19777 002	MAY 19, 1988	APR	CTEC

MECLIZINE HYDROCHLORIDE
TABLET; ORAL
MECLIZINE HCL

>D>	AA		CHELSEA LABS	12.5MG	N85269 001	NOV 11, 1976	MAY	DISC
>A>			@	12.5MG	N85269 001	NOV 11, 1976	MAY	DISC

MEPROBAMATE
TABLET; ORAL
AMOSENE
@ FERNDALE LABS — 400MG — N84030 001 MAY 10, 1974 FEB WDRP
MEPROBAMATE

>D>	AA		HALSEY	400MG	N80699 002	OCT 16, 1972	MAY	DISC

>A>		@		400MG	N80699 002	OCT 16, 1972	MAY	DISC
		MESALAMINE						
		SUPPOSITORY; RECTAL						
		CANASA						
		+ AXCAN SCANDIPHARM		500MG	N21252 001	JAN 05, 2001	JAN	NEWA
		MESNA						
		INJECTABLE; INTRAVENOUS						
		MESNA						
	AP	AM PHARM PARTNERS		100MG/ML	N75811 001	APR 26, 2001	APR	NEWA
	AP	GENSIA SICOR PHARMS		100MG/ML	N75764 001	APR 27, 2001	APR	NEWA
		MESNEX						
	AP	+ ASTA		100MG/ML	N19884 001	DEC 30, 1988	APR	CFTG
		METAPROTERENOL SULFATE						
		SOLUTION; INHALATION						
		METAPROTERENOL SULFATE						
	AN	NOVEX		0.4%	N75402 001	FEB 28, 2001	FEB	NEWA
	AN			0.6%	N75403 001	FEB 28, 2001	FEB	NEWA
		METHAZOLAMIDE						
		TABLET; ORAL						
		METHAZOLAMIDE						
>D>	AB	APPLIED ANAL		25MG	N40011 001	JUL 17, 1997	MAY	DISC
>A>		@		25MG	N40011 001	JUL 17, 1997	MAY	DISC
>D>	AB			50MG	N40011 002	JUL 17, 1997	MAY	DISC
>A>		@		50MG	N40011 002	JUL 17, 1997	MAY	DISC
		METHIMAZOLE						
		TABLET; ORAL						
		METHIMAZOLE						
	AB	EON		5MG	N40411 001	MAR 27, 2001	MAR	NEWA
	AB			10MG	N40411 002	MAR 27, 2001	MAR	NEWA
		METHOTREXATE SODIUM						
		TABLET; ORAL						
		TREXALL						
		BARR		EQ 5MG BASE	N40385 001	MAR 21, 2001	MAR	NEWA
				EQ 7.5MG BASE	N40385 002	MAR 21, 2001	MAR	NEWA
				EQ 10MG BASE	N40385 003	MAR 21, 2001	MAR	NEWA
		+		EQ 15MG BASE	N40385 004	MAR 21, 2001	MAR	NEWA
		METHSCOPOLAMINE BROMIDE						
		TABLET; ORAL						
>D>		METHSCOPOLAMINE BROMIDE						
>D>	AA	PVT FORM		2.5MG	N80970 001	OCT 18, 1976	MAY	DISC
>A>		@		2.5MG	N80970 001	OCT 18, 1976	MAY	DISC
		PAMINE						
>D>	AA	+ BRADLEY PHARMS		2.5MG	N08848 001	APR 09, 1953	MAY	CTEC
>A>		+		2.5MG	N08848 001	APR 09, 1953	MAY	CTEC

		METHYLDOPA						
		TABLET; ORAL						
		METHYLDOPA						
>D>	AB	LEDERLE	125MG	N70070	003	OCT 15, 1985	MAY	DISC
>A>		@	125MG	N70070	003	OCT 15, 1985	MAY	DISC
		METHYLPHENIDATE HYDROCHLORIDE						
		CAPSULE, EXTENDED RELEASE; ORAL						
		METADATE CD						
	+	CELLTECH PHARMS	20MG	N21259	001	APR 03, 2001	APR	NEWA
		TABLET; ORAL						
		METHYLPHENIDATE HCL						
	AB	ABLE	5MG	N40404	001	MAR 29, 2001	MAR	NEWA
	AB		10MG	N40404	002	MAR 29, 2001	MAR	NEWA
	AB		20MG	N40404	003	MAR 29, 2001	MAR	NEWA
		TABLET, EXTENDED RELEASE; ORAL						
		METADATE ER						
	AB	CELLTECH PHARMS	10MG	N40306	001	OCT 20, 1999	APR	CTEC
		METHYLPHENIDATE HCL						
>A>	AB	ABLE	20MG	N76032	001	MAY 09, 2001	MAY	NEWA
	AB	DANBURY PHARMA	20MG	N40410	001	FEB 09, 2001	FEB	NEWA
		METHYLPREDNISOLONE ACETATE						
		INJECTABLE; INJECTION						
		DEPO-MEDROL						
>D>	BP	PHARMACIA AND UPJOHN	40MG/ML	N11757	001	APR 27, 1959	MAY	CTEC
>A>			40MG/ML	N11757	001	APR 27, 1959	MAY	CTEC
		METHYLPREDNISOLONE ACETATE						
>D>	BP	STERIS	40MG/ML	N85600	001	MAR 14, 1979	MAY	DISC
>A>		@	40MG/ML	N85600	001	MAR 14, 1979	MAY	DISC
		METHYLPREDNISOLONE ACETATE; NEOMYCIN SULFATE						
>D>		CREAM; TOPICAL						
>D>		NEO-MEDROL ACETATE						
>D>	+	PHARMACIA AND UPJOHN	0.25%;EQ 3.5MG BASE/GM	N60611	002	DEC 07, 1964	MAY	DISC
>A>		@	0.25%;EQ 3.5MG BASE/GM	N60611	002	DEC 07, 1964	MAY	DISC
>D>			1%;EQ 3.5MG BASE/GM	N60611	001	DEC 07, 1964	MAY	DISC
>A>		@	1%;EQ 3.5MG BASE/GM	N60611	001	DEC 07, 1964	MAY	DISC
		METHYLPREDNISOLONE SODIUM SUCCINATE						
		INJECTABLE; INJECTION						
		METHYLPREDNISOLONE SODIUM SUCCINATE						
>D>	AP	GENSIA SICOR PHARMS	EQ 500MG BASE/VIAL	N81267	001	NOV 30, 1992	MAY	DISC
>A>		@	EQ 500MG BASE/VIAL	N81267	001	NOV 30, 1992	MAY	DISC
>D>	AP		EQ 1GM BASE/VIAL	N81268	001	NOV 30, 1992	MAY	DISC
>A>		@	EQ 1GM BASE/VIAL	N81268	001	NOV 30, 1992	MAY	DISC
		METHYLTESTOSTERONE						
		TABLET; BUCCAL						
		ORETON						
		@ SCHERING	10MG	N80281	001	AUG 03, 1979	FEB	DISC

		METOCLOPRAMIDE HYDROCHLORIDE					
		INJECTABLE; INJECTION					
		METOCLOPRAMIDE HCL					
>D>	AP	ABBOTT	EQ 5MG BASE/ML	N70506 001	JUN 22, 1989	MAY	DISC
>A>		@	EQ 5MG BASE/ML	N70506 001	JUN 22, 1989	MAY	DISC
>D>		SOLUTION; INJECTION					
>D>		METOCLOPRAMIDE					
	AA	UDL	EQ 5MG BASE/5ML	N75051 001	JAN 26, 2001	JAN	NEWA
>A>		SOLUTION; ORAL					
>A>	AA	UDL	EQ 5MG BASE/5ML	N75051 001	JAN 26, 2001	MAY	CDFR
		TABLET; ORAL					
		METOCLOPRAMIDE HCL					
	AB	GENEVA PHARMS TECH	EQ 5MG BASE	N74478 001	OCT 05, 1995	JAN	CAHN
	AB		EQ 10MG BASE	N74478 002	OCT 05, 1995	JAN	CAHN
		METOPROLOL SUCCINATE					
		TABLET, EXTENDED RELEASE; ORAL					
		TOPROL-XL					
	+	ASTRAZENECA	EQ 25MG TARTRATE	N19962 004	FEB 05, 2001	FEB	NEWA
		METRONIDAZOLE					
		INJECTABLE; INJECTION					
>D>		METRO I.V.					
>D>	AP +	B BRAUN	500MG/100ML	N18674 001	AUG 31, 1982	MAY	DISC
>A>		@	500MG/100ML	N18674 001	AUG 31, 1982	MAY	DISC
>D>		METRONIDAZOLE					
>D>	AP +	ABBOTT	500MG/100ML	N18889 001	NOV 18, 1983	MAY	DISC
>A>		@	500MG/100ML	N18889 001	NOV 18, 1983	MAY	DISC
>D>	AP +	ELKINS SINN	500MG/100ML	N18907 001	MAR 30, 1984	MAY	DISC
>A>		@	500MG/100ML	N18907 001	MAR 30, 1984	MAY	DISC
		TABLET; ORAL					
		PROTOSTAT					
		@ JOHNSON RW	250MG	N18871 001	MAR 02, 1983	MAR	DISC
		@	500MG	N18871 002	MAR 02, 1983	MAR	DISC
		MEZLOCILLIN SODIUM MONOHYDRATE					
		INJECTABLE; INJECTION					
		MEZLIN					
>D>		BAYER	EQ 1GM BASE/VIAL	N62372 005	JAN 13, 1983	MAY	DISC
>A>		@	EQ 1GM BASE/VIAL	N62372 005	JAN 13, 1983	MAY	DISC
>D>			EQ 2GM BASE/VIAL	N62372 001	MAY 13, 1982	MAY	DISC
>A>		@	EQ 2GM BASE/VIAL	N62372 001	MAY 13, 1982	MAY	DISC
>D>			EQ 3GM BASE/VIAL	N62372 002	MAY 13, 1982	MAY	DISC
>A>		@	EQ 3GM BASE/VIAL	N62372 002	MAY 13, 1982	MAY	DISC
>D>			EQ 4GM BASE/VIAL	N62372 003	MAY 13, 1982	MAY	DISC
>A>		@	EQ 4GM BASE/VIAL	N62372 003	MAY 13, 1982	MAY	DISC
>D>			EQ 20GM BASE/VIAL	N62372 004	MAR 02, 1988	MAY	DISC
>A>		@	EQ 20GM BASE/VIAL	N62372 004	MAR 02, 1988	MAY	DISC

MIDAZOLAM HYDROCHLORIDE
INJECTABLE; INJECTION
MIDAZOLAM HCL

>D>	AP	APOTHECON	EQ 1MG BASE/ML	N75620	001	NOV 01, 2000	MAY	DISC
>A>		@	EQ 1MG BASE/ML	N75620	001	NOV 01, 2000	MAY	DISC
>D>	AP		EQ 5MG BASE/ML	N75620	002	NOV 01, 2000	MAY	DISC
>A>		@	EQ 5MG BASE/ML	N75620	002	NOV 01, 2000	MAY	DISC
>D>	AP		EQ 5MG BASE/ML	N75641	001	OCT 19, 2000	MAY	DISC
>A>		@	EQ 5MG BASE/ML	N75641	001	OCT 19, 2000	MAY	DISC
>D>	AP	ASTRAZENECA	EQ 5MG BASE/ML	N75263	001	JUN 26, 2000	MAY	DISC
>A>		@	EQ 5MG BASE/ML	N75263	001	JUN 26, 2000	MAY	DISC

MINOCYCLINE HYDROCHLORIDE
CAPSULE; ORAL
MINOCIN

	AB	LEDERLE	EQ 75MG BASE	N50649	003	FEB 12, 2001	MAR	NEWA
	AB	+	EQ 100MG BASE	N50649	002	MAY 31, 1990	MAR	CRLD

MINOCYCLINE HCL

	AB	DANBURY PHARMA	EQ 100MG BASE	N63065	001	DEC 30, 1991	MAR	CRLD
	AB	IMPAX LABS	EQ 75MG BASE	N65005	003	APR 18, 2001	APR	NEWA

VECTRIN

>D>	AB	MEDICIS	EQ 75MG BASE	N63067	002	SEP 15, 1999	MAY	DISC
>A>		@	EQ 75MG BASE	N63067	002	SEP 15, 1999	MAY	DISC
>D>	AB		EQ 100MG BASE	N63067	001	JUL 31, 1990	MAY	DISC
>A>		@	EQ 100MG BASE	N63067	001	JUL 31, 1990	MAY	DISC

POWDER, EXTENDED RELEASE; DENTAL
ARESTIN

	+	ORAPHARMA	EQ 1MG BASE	N50781	001	FEB 16, 2001	FEB	NEWA

MIRTAZAPINE
TABLET, ORALLY DISINTEGRATING; ORAL
REMERON SOLTAB

	+	ORGANON INC	15MG	N21208	001	JAN 12, 2001	JAN	NEWA
			30MG	N21208	002	JAN 12, 2001	JAN	NEWA
			45MG	N21208	003	JAN 12, 2001	JAN	NEWA

MORPHINE SULFATE
TABLET, EXTENDED RELEASE; ORAL
MORPHINE SULFATE

	AB	WATSON LABS	100MG	N75656	001	JAN 30, 2001	JAN	NEWA

NADOLOL
TABLET; ORAL
NADOLOL

	AB	GENEVA PHARMS TECH	20MG	N74501	001	NOV 09, 1995	JAN	CAHN
	AB		40MG	N74501	002	NOV 09, 1995	JAN	CAHN
	AB		80MG	N74501	003	NOV 09, 1995	JAN	CAHN

NAFCILLIN SODIUM
INJECTABLE; INJECTION
NAFCILLIN SODIUM

>D>	AP	APOTHECON	EQ 500MG BASE/VIAL	N61984	001	APR 29, 1976	MAY	DISC

>A>		@	EQ 500MG BASE/VIAL	N61984	001	APR 29, 1976	MAY	DISC
>D>	AP		EQ 500MG BASE/VIAL	N62527	001	AUG 02, 1984	MAY	CRLD
>A>	+		EQ 500MG BASE/VIAL	N62527	001	AUG 02, 1984	MAY	CRLD
>D>	AP		EQ 1GM BASE/VIAL	N61984	002	APR 29, 1976	MAY	DISC
>A>		@	EQ 1GM BASE/VIAL	N61984	002	APR 29, 1976	MAY	DISC
>D>	AP		EQ 4GM BASE/VIAL	N61984	005	APR 29, 1976	MAY	DISC
>A>		@	EQ 4GM BASE/VIAL	N61984	005	APR 29, 1976	MAY	DISC
>D>	AP	MARSAM	EQ 500MG BASE/VIAL	N62844	001	OCT 26, 1988	MAY	DISC
>A>		@	EQ 500MG BASE/VIAL	N62844	001	OCT 26, 1988	MAY	DISC
>D>	AP		EQ 1GM BASE/VIAL	N62844	002	OCT 26, 1988	MAY	DISN
>A>		@	EQ 1GM BASE/VIAL	N62844	002	OCT 26, 1988	MAY	DISN
>D>	AP		EQ 2GM BASE/VIAL	N62844	004	OCT 26, 1988	MAY	DISC
>A>		@	EQ 2GM BASE/VIAL	N62844	004	OCT 26, 1988	MAY	DISC
>D>	AP		EQ 10GM BASE/VIAL	N63008	001	SEP 29, 1988	MAY	DISC
>A>		@	EQ 10GM BASE/VIAL	N63008	001	SEP 29, 1988	MAY	DISC
>D>		NALLPEN						
>D>	AP	SMITHKLINE BEECHAM	EQ 500MG BASE/VIAL	N61999	001	JUL 10, 1978	MAY	DISC
>A>		@	EQ 500MG BASE/VIAL	N61999	001	JUL 10, 1978	MAY	DISC
>D>	AP		EQ 1GM BASE/VIAL	N61999	002	JUL 10, 1978	MAY	DISC
>A>		@	EQ 1GM BASE/VIAL	N61999	002	JUL 10, 1978	MAY	DISC
>D>	AP		EQ 2GM BASE/VIAL	N61999	003	JUL 10, 1978	MAY	DISC
>A>		@	EQ 2GM BASE/VIAL	N61999	003	JUL 10, 1978	MAY	DISC
>D>	AP		EQ 10GM BASE/VIAL	N61999	004	JUL 17, 1978	MAY	DISC
>A>		@	EQ 10GM BASE/VIAL	N61999	004	JUL 17, 1978	MAY	DISC
>D>		UNIPEN						
>D>	AP +	WYETH AYERST	EQ 500MG BASE/VIAL	N50320	001	JUN 23, 1970	MAY	DISC
>A>		@	EQ 500MG BASE/VIAL	N50320	001	JUN 23, 1970	MAY	DISC
>D>	AP		EQ 500MG BASE/VIAL	N62717	001	DEC 16, 1986	MAY	DISC
>A>		@	EQ 500MG BASE/VIAL	N62717	001	DEC 16, 1986	MAY	DISC
>D>	AP +		EQ 1GM BASE/VIAL	N62717	002	DEC 16, 1986	MAY	DISC
>A>		@	EQ 1GM BASE/VIAL	N62717	002	DEC 16, 1986	MAY	DISC
>D>	AP +		EQ 2GM BASE/VIAL	N50320	003	JUN 23, 1970	MAY	DISC
>A>		@	EQ 2GM BASE/VIAL	N50320	003	JUN 23, 1970	MAY	DISC
>D>	AP		EQ 2GM BASE/VIAL	N62717	004	DEC 16, 1986	MAY	DISC
>A>		@	EQ 2GM BASE/VIAL	N62717	004	DEC 16, 1986	MAY	DISC
>D>	AP +		EQ 4GM BASE/VIAL	N50320	004	JUN 23, 1970	MAY	DISC
>A>		@	EQ 4GM BASE/VIAL	N50320	004	JUN 23, 1970	MAY	DISC
>D>	AP		EQ 10GM BASE/VIAL	N50320	005	DEC 21, 1978	MAY	DISC
>A>		@	EQ 10GM BASE/VIAL	N50320	005	DEC 21, 1978	MAY	DISC
		UNIPEN IN PLASTIC CONTAINER						
>D>	AP	WYETH AYERST	EQ 1GM BASE/VIAL	N50320	002	JUN 23, 1970	MAY	DISC
>A>		@	EQ 1GM BASE/VIAL	N50320	002	JUN 23, 1970	MAY	DISC

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE

	@ WYETH AYERST	0.02MG/ML	N70188	001	SEP 24, 1986	JAN	DISC
	@	0.02MG/ML	N70189	001	SEP 24, 1986	JAN	DISC
	@	0.4MG/ML	N70190	001	SEP 24, 1986	JAN	DISC
	@	0.4MG/ML	N70191	001	SEP 24, 1986	JAN	DISC

NAPHAZOLINE HYDROCHLORIDE
SOLUTION/DROPS; OPHTHALMIC
VASOCON

AT		NOVARTIS	0.1%	N80235	002	MAR 24, 1983	FEB	CAHN

NAPROXEN
TABLET, EXTENDED RELEASE; ORAL
NAPROXEN

AB	+	ALPHAPHARM	375MG	N75390	001	APR 19, 2001	APR	NEWA
AB	+		500MG	N75390	002	APR 19, 2001	APR	NEWA

NAPROXEN SODIUM
TABLET; ORAL
NAPROXEN SODIUM

AB		GENEVA PHARMS TECH	EQ 250MG BASE	N74495	001	DEC 05, 1994	JAN	CAHN
AB			EQ 500MG BASE	N74495	002	DEC 05, 1994	JAN	CAHN

NEFAZODONE HYDROCHLORIDE
TABLET; ORAL
SERZONE

		BRISTOL MYERS SQUIBB	50MG	N20152	001	DEC 22, 1994	APR	CTEC

NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SOLUTION; IRRIGATION

>D>		NEOMYCIN AND POLYMYXIN B SULFATES						
>D>	AT	STERIS	EQ 40MG BASE/ML;200,000 UNITS/ML	N62664	001	APR 08, 1986	MAY	DISC
>A>		@	EQ 40MG BASE/ML;200,000 UNITS/ML	N62664	001	APR 08, 1986	MAY	DISC
		NEOSPORIN G.U. IRRIGANT						
>D>	AT	MONARCH PHARMS	EQ 40MG BASE/ML;200,000 UNITS/ML	N60707	001	JUN 28, 1966	MAY	CTEC
>A>			EQ 40MG BASE/ML;200,000 UNITS/ML	N60707	001	JUN 28, 1966	MAY	CTEC

NETILMICIN SULFATE

>D>		INJECTABLE; INJECTION						
>D>		NETROMYCIN						
>D>	+	SCHERING	EQ 100MG BASE/ML	N50544	003	FEB 28, 1983	MAY	DISC
>A>		@	EQ 100MG BASE/ML	N50544	003	FEB 28, 1983	MAY	DISC

NIFEDIPINE
CAPSULE; ORAL
NIFEDIPINE

		@ CHASE LABS NJ	10MG	N72409	001	JUL 04, 1990	FEB	WDRP
		@	20MG	N73421	001	JUN 19, 1991	FEB	WDRP

TABLET, EXTENDED RELEASE; ORAL
ADALAT CC

AB1		BAYER	30MG	N20198	001	APR 21, 1993	APR	CTEC

NIFEDIPINE

AB2		BIOVAIL	30MG	N75289	002	FEB 06, 2001	FEB	NEWA

PROCARDIA XL

NIFEDIPINE
TABLET, EXTENDED RELEASE; ORAL
PROCARDIA XL

AB2	+	PFIZER	30MG	N19684 001	SEP 06, 1989	FEB	CTEC

NITROFURAZONE
OINTMENT; TOPICAL
NITROFURAZONE

>D>	AT	+	CLAY PARK	0.2%	N84968 001	JAN 25, 1978	MAY DISC
>A>			@	0.2%	N84968 001	JAN 25, 1978	MAY DISC

POWDER; TOPICAL
FURACIN

			@ ROBERTS LABS	0.2%	N83791 001	OCT 17, 1975	FEB WDRP

SOLUTION; TOPICAL
NITROFURAZONE

>D>	AT	+	CLAY PARK	0.2%	N85130 001	NOV 02, 1978	MAY DISC
>A>			@	0.2%	N85130 001	NOV 02, 1978	MAY DISC
>D>	AT		WENDT	0.2%	N87081 001	JUL 22, 1981	MAY CTEC
>A>		+		0.2%	N87081 001	JUL 22, 1981	MAY CTEC

NITROGLYCERIN
AEROSOL; SUBLINGUAL
NITROLINGUAL

			@ POHL BOSKAMP	0.4MG/SPRAY	N18705 001	OCT 31, 1985	APR DISC

NORETHINDRONE ACETATE
TABLET; ORAL
NORETHINDRONE ACETATE

>A>	AB		BARR	5MG	N75951 001	MAY 25, 2001	MAY NEWA

NYSTATIN
CREAM; TOPICAL
NILSTAT

>D>	AT		LEDERLE	100,000 UNITS/GM	N61445 001	APR 02, 1971	MAY DISC
>A>			@	100,000 UNITS/GM	N61445 001	APR 02, 1971	MAY DISC

NYSTATIN

>D>	AT		TEVA	100,000 UNITS/GM	N61966 001	MAY 25, 1976	MAY DISC
>A>			@	100,000 UNITS/GM	N61966 001	MAY 25, 1976	MAY DISC

OINTMENT; TOPICAL
>D> NILSTAT

>D>	AT	+	LEDERLE	100,000 UNITS/GM	N61444 001	MAR 29, 1971	MAY DISC
>A>			@	100,000 UNITS/GM	N61444 001	MAR 29, 1971	MAY DISC

NYSTATIN

>D>	AT		ALTANA	100,000 UNITS/GM	N62124 002	SEP 23, 1982	MAY CTEC
>A>	AT	+		100,000 UNITS/GM	N62124 002	SEP 23, 1982	MAY CTEC

SUSPENSION; ORAL

>D>	AA		ROXANE	100,000 UNITS/ML	N62832 001	DEC 27, 1991	MAY DISC
>A>			@	100,000 UNITS/ML	N62832 001	DEC 27, 1991	MAY DISC
>D>	AA		TEVA	100,000 UNITS/ML	N62670 001	JUN 18, 1987	MAY DISC
>A>			@	100,000 UNITS/ML	N62670 001	JUN 18, 1987	MAY DISC
>D>	AA			100,000 UNITS/ML	N62776 001	DEC 17, 1987	MAY DISC
>A>			@	100,000 UNITS/ML	N62776 001	DEC 17, 1987	MAY DISC

TABLET; ORAL

NYSTATIN

TABLET; ORAL

NYSTATIN

>D>	AA	EON	500,000 UNITS	N62065 001	JUL 22, 1977	MAY	DISC
>A>		@	500,000 UNITS	N62065 001	JUL 22, 1977	MAY	DISC
>D>	AA	ROSEMONT	500,000 UNITS	N62524 001	NOV 26, 1985	MAY	DISC
>A>		@	500,000 UNITS	N62524 001	NOV 26, 1985	MAY	DISC

TABLET; VAGINAL

KOROSTATIN

		@ HOLLAND RANTOS	100,000 UNITS	N61718 001	SEP 30, 1974	FEB	WDRP

NYSTATIN; TRIAMCINOLONE ACETONIDE

OINTMENT; TOPICAL

MYCO-TRIACET II

>D>	AT	TEVA	100,000 UNITS/GM;0.1%	N62045 002	NOV 26, 1985	MAY	DISC
>A>		@	100,000 UNITS/GM;0.1%	N62045 002	NOV 26, 1985	MAY	DISC

NYSTATIN AND TRIAMCINOLONE ACETONIDE

>D>	AT	CLAY PARK	100,000 UNITS/GM;0.1%	N62280 002	OCT 10, 1985	MAY	DISC
>A>		@	100,000 UNITS/GM;0.1%	N62280 002	OCT 10, 1985	MAY	DISC

OXACILLIN SODIUM

INJECTABLE; INJECTION

BACTOCILL

		@ SMITHKLINE BEECHAM	EQ 1GM BASE/VIAL	N62736 001	DEC 19, 1986	FEB	DISC
		@	EQ 2GM BASE/VIAL	N62736 002	DEC 19, 1986	FEB	DISC

OXACILLIN SODIUM

	AP	+ APOTHECON	EQ 1GM BASE/VIAL	N61490 003	APR 08, 1971	FEB	CRLD
	AP	+	EQ 2GM BASE/VIAL	N62737 002	DEC 23, 1986	FEB	CRLD
>D>		IBI	EQ 125MG BASE/VIAL	N62798 003	DEC 11, 1995	MAY	DISC
>A>		@	EQ 125MG BASE/VIAL	N62798 003	DEC 11, 1995	MAY	DISC
>D>	AP		EQ 250MG BASE/VIAL	N62798 004	DEC 11, 1995	MAY	DISC
>A>		@	EQ 250MG BASE/VIAL	N62798 004	DEC 11, 1995	MAY	DISC
>D>	AP		EQ 500MG BASE/VIAL	N62798 005	DEC 11, 1995	MAY	DISC
>A>		@	EQ 500MG BASE/VIAL	N62798 005	DEC 11, 1995	MAY	DISC
>D>	AP		EQ 1GM BASE/VIAL	N62798 001	DEC 11, 1995	MAY	DISC
>A>		@	EQ 1GM BASE/VIAL	N62798 001	DEC 11, 1995	MAY	DISC
>D>	AP		EQ 2GM BASE/VIAL	N62798 002	DEC 11, 1995	MAY	DISC
>A>		@	EQ 2GM BASE/VIAL	N62798 002	DEC 11, 1995	MAY	DISC

OXAPROZIN

TABLET; ORAL

DAYPRO

	AB	+ SEARLE	600MG	N18841 004	OCT 29, 1992	JAN	CFTG

OXAPROZIN

	AB	DR REDDYS LABS LTD	600MG	N75855 001	JAN 31, 2001	JAN	NEWA
	AB	EON	600MG	N75845 001	JAN 31, 2001	JAN	NEWA
	AB	GENEVA PHARMS	600MG	N75850 001	APR 27, 2001	APR	NEWA
	AB	GENPHARM	600MG	N75847 001	FEB 28, 2001	FEB	NEWA
	AB	INVAMED	600MG	N75842 001	APR 12, 2001	APR	NEWA
	AB	WATSON LABS	600MG	N75848 001	FEB 09, 2001	FEB	NEWA

		OXCARBAZEPINE						
>A>		SUSPENSION; ORAL						
>A>		TRILEPTAL						
>A>	+	NOVARTIS	300MG/5ML	N21285 001	MAY 25, 2001	MAY	NEWA	
		OXYTETRACYCLINE HYDROCHLORIDE						
		CAPSULE; ORAL						
>D>		OXYTETRACYCLINE HCL						
		@ IMPAX LABS	EQ 250MG BASE	N60760 001	AUG 09, 1967	FEB	DISC	
		@ PROTER	EQ 250MG BASE	N60869 001	JAN 29, 1964	FEB	WDRP	
>D>	AB	WEST WARD	EQ 250MG BASE	N60770 001	SEP 29, 1967	MAY	DISC	
>A>		@	EQ 250MG BASE	N60770 001	SEP 29, 1967	MAY	DISC	
		TERRAMYCIN						
>D>	AB +	PFIZER	EQ 250MG BASE	N50286 002	SEP 08, 1964	MAY	CTEC	
>A>	+		EQ 250MG BASE	N50286 002	SEP 08, 1964	MAY	CTEC	
		PACLITAXEL						
		INJECTABLE; INJECTION						
		PACLITAXEL						
	AP	ZENITH GOLDLINE	6MG/ML	N75297 001	MAR 27, 2001	MAR	NEWA	
		PAMIDRONATE DISODIUM						
		INJECTABLE; INJECTION						
		AREDIA						
	AP +	NOVARTIS	30MG/VIAL	N20036 001	OCT 31, 1991	APR	CFTG	
	AP +		90MG/VIAL	N20036 004	MAY 06, 1993	APR	CFTG	
		PAMIDRONATE DISODIUM						
	AP	BEDFORD	30MG/VIAL	N75290 001	APR 30, 2001	APR	NEWA	
	AP		90MG/VIAL	N75290 003	APR 30, 2001	APR	NEWA	
		PANTOPRAZOLE SODIUM						
		INJECTABLE; IV (INFUSION)						
		PROTONIX IV						
	+	WYETH AYERST	EQ 40MG BASE/VIAL	N20988 001	MAR 22, 2001	MAR	NEWA	
		PEMOLINE						
		TABLET; ORAL						
		PEMOLINE						
	AB	MALLINCKRODT	18.75MG	N75726 003	MAR 30, 2001	MAR	NEWA	
	AB		37.5MG	N75726 002	MAR 30, 2001	MAR	NEWA	
	AB		75MG	N75726 001	MAR 30, 2001	MAR	NEWA	
		PENICILLIN G POTASSIUM						
		TABLET; ORAL						
		PENICILLIN G POTASSIUM						
>D>	AB	TEVA	200,000 UNITS	N60306 001	JUN 01, 1964	MAY	DISC	
>A>		@	200,000 UNITS	N60306 001	JUN 01, 1964	MAY	DISC	
>D>	AB		250,000 UNITS	N60306 002	JUN 01, 1964	MAY	DISC	
>A>		@	250,000 UNITS	N60306 002	JUN 01, 1964	MAY	DISC	
>D>	AB		400,000 UNITS	N60306 003	JUN 01, 1964	MAY	DISC	
>A>		@	400,000 UNITS	N60306 003	JUN 01, 1964	MAY	DISC	
>D>	AB		500,000 UNITS	N60306 004	JUN 26, 1979	MAY	DISC	

	>A>		@		500,000 UNITS	N60306 004	JUN 26, 1979	MAY	DISC
			PENICILLIN G PROCAINE						
			INJECTABLE; INJECTION						
MAY NEWA	>D>		PENICILLIN G PROCAINE						
	>D>		PFIZER		300,000 UNITS/VIAL	N60099 001	NOV 10, 1948	MAY	DISC
	>A>		@		300,000 UNITS/VIAL	N60099 001	NOV 10, 1948	MAY	DISC
	>D>		+		1,500,000 UNITS/VIAL	N60099 002	NOV 10, 1948	MAY	DISC
	>A>		@		1,500,000 UNITS/VIAL	N60099 002	NOV 10, 1948	MAY	DISC
FEB DISC	>D>		PFIZERPEN-AS						
FEB WDRP	>D>	AP	+	PFIZER	300,000 UNITS/ML	N60286 001	NOV 01, 1950	MAY	DISC
MAY DISC	>A>		@		300,000 UNITS/ML	N60286 001	NOV 01, 1950	MAY	DISC
MAY DISC	>D>	AP	+		600,000 UNITS/ML	N60286 002	NOV 01, 1950	MAY	DISC
	>A>		@		600,000 UNITS/ML	N60286 002	NOV 01, 1950	MAY	DISC
MAY CTEC			WYCILLIN						
MAY CTEC	>D>	AP		KING PHARMS	300,000 UNITS/ML	N60101 002	APR 26, 1948	MAY	CTEC
	>A>		+		300,000 UNITS/ML	N60101 002	APR 26, 1948	MAY	CTEC
	>D>	AP			600,000 UNITS/ML	N60101 001	APR 26, 1948	MAY	CTEC
	>A>		+		600,000 UNITS/ML	N60101 001	APR 26, 1948	MAY	CTEC
MAR NEWA			PENICILLIN G SODIUM						
			INJECTABLE; IM-IV						
			PENICILLIN G SODIUM						
			+	BIOCHEMIE	5,000,000 UNITS/VIAL	N65068 001	FEB 26, 2001	FEB	NEWA
			@	MARSAM	5,000,000 UNITS/VIAL	N63014 001	SEP 13, 1988	FEB	DISC
APR CFTG									
APR CFTG			PENICILLIN V POTASSIUM						
			FOR SOLUTION; ORAL						
APR NEWA			PENICILLIN V POTASSIUM						
APR NEWA	>D>	AA		MYLAN	EQ 125MG BASE/5ML	N61624 002	AUG 07, 1972	MAY	DISC
	>A>		@		EQ 125MG BASE/5ML	N61624 002	AUG 07, 1972	MAY	DISC
	>D>	AA			EQ 250MG BASE/5ML	N61624 001	JUN 05, 1972	MAY	DISC
	>A>		@		EQ 250MG BASE/5ML	N61624 001	JUN 05, 1972	MAY	DISC
	>D>		V-CILLIN K						
MAR NEWA	>D>	AA		LILLY	EQ 125MG BASE/5ML	N60004 001	AUG 21, 1958	MAY	DISC
	>A>		@		EQ 125MG BASE/5ML	N60004 001	AUG 21, 1958	MAY	DISC
	>D>	AA			EQ 250MG BASE/5ML	N60004 002	APR 07, 1967	MAY	DISC
	>A>		@		EQ 250MG BASE/5ML	N60004 002	APR 07, 1967	MAY	DISC
			TABLET; ORAL						
MAR NEWA			PEN-VEE K						
MAR NEWA	>D>	AB		WYETH AYERST	EQ 500MG BASE	N60006 003	JAN 13, 1958	MAY	CRLD
MAR NEWA	>A>	AB	+		EQ 500MG BASE	N60006 003	JAN 13, 1958	MAY	CRLD
			PENICILLIN V POTASSIUM						
	>D>	AB		BIOCHEMIE	EQ 500MG BASE	N64071 002	NOV 30, 1995	MAY	CTEC
	>A>	AB	+		EQ 500MG BASE	N64071 002	NOV 30, 1995	MAY	CTEC
	>D>	AB		MYLAN	EQ 250MG BASE	N61530 001	NOV 18, 1971	MAY	DISC
MAY DISC	>A>		@		EQ 250MG BASE	N61530 001	NOV 18, 1971	MAY	DISC
MAY DISC	>D>	AB			EQ 500MG BASE	N61530 002	MAR 20, 1972	MAY	DISC
MAY DISC	>A>		@		EQ 500MG BASE	N61530 002	MAR 20, 1972	MAY	DISC
MAY DISC	>D>		V-CILLIN K						
MAY DISC	>D>			LILLY	EQ 125MG BASE	N60003 001	SEP 17, 1957	MAY	DISC
MAY DISC	>A>		@		EQ 125MG BASE	N60003 001	SEP 17, 1957	MAY	DISC
MAY DISC	>D>	AB			EQ 250MG BASE	N60003 002	SEP 17, 1957	MAY	DISC

>A>		@	EQ 250MG BASE	N60003	002	SEP 17, 1957	MAY	DISC
>D>	AB	+	EQ 500MG BASE	N60003	003	SEP 17, 1957	MAY	DISC
>A>		@	EQ 500MG BASE	N60003	003	SEP 17, 1957	MAY	DISC
		PERPHENAZINE						
>A>		CONCENTRATE; ORAL						
>A>		PERPHENAZINE						
>A>		+ PHARM ASSOC	16MG/5ML	N40360	001	MAY 25, 2001	MAY	NEWA
		TRILAFON						
		@ SCHERING	16MG/5ML	N11557	001	DEC 12, 1958	MAR	DISC
		PHENDIMETRAZINE TARTRATE						
		CAPSULE; ORAL						
		PHENDIMETRAZINE TARTRATE						
>D>	AA	EON	35MG	N85694	001	JUN 05, 1978	MAY	DISC
>A>		@	35MG	N85694	001	JUN 05, 1978	MAY	DISC
		TABLET; ORAL						
>D>		PHENAZINE-35						
>D>	AA	ABC HOLDING	35MG	N85512	001	MAY 06, 1977	MAY	DISC
>A>		@	35MG	N85512	001	MAY 06, 1977	MAY	DISC
		PHENDIMETRAZINE TARTRATE						
>D>	AA	EON	35MG	N85402	001	MAY 19, 1978	MAY	DISC
>A>		@	35MG	N85402	001	MAY 19, 1978	MAY	DISC
>D>	AA		35MG	N85497	001	AUG 19, 1977	MAY	DISC
>A>		@	35MG	N85497	001	AUG 19, 1977	MAY	DISC
>D>	AA	ROSEMONT	35MG	N84399	001	MAY 28, 1981	MAY	DISC
>A>		@	35MG	N84399	001	MAY 28, 1981	MAY	DISC
		PHENTERMINE HYDROCHLORIDE						
		CAPSULE; ORAL						
		PHENTERMINE HCL						
>D>	AA	ABC HOLDING	30MG	N85411	001	SEP 10, 1980	MAY	DISC
>A>		@	30MG	N85411	001	SEP 10, 1980	MAY	DISC
>D>	AA	ROSEMONT	30MG	N84487	001	APR 09, 1982	MAY	DISC
>A>		@	30MG	N84487	001	APR 09, 1982	MAY	DISC
		TABLET; ORAL						
>D>		@ EON	30MG	N88605	001	SEP 28, 1987	MAY	CMFD
>A>		+	30MG	N88605	001	SEP 28, 1987	MAY	CMFD
		PHENYTOIN						
		SUSPENSION; ORAL						
		PHENYTOIN						
	AB	UDL	125MG/5ML	N40342	001	JAN 31, 2001	JAN	NEWA
		PIPERAZINE CITRATE						
		SYRUP; ORAL						
		PIPERAZINE CITRATE						
>D>	AA	LANNETT	EQ 500MG BASE/5ML	N80963	001	JUL 25, 1974	MAY	DISC
>A>		@	EQ 500MG BASE/5ML	N80963	001	JUL 25, 1974	MAY	DISC
>D>		TABLET; ORAL						
>D>		PIPERAZINE CITRATE						
>D>		+ IMPAX LABS	EQ 250MG BASE	N80874	001	JUL 19, 1973	MAY	DISC
>A>		@	EQ 250MG BASE	N80874	001	JUL 19, 1973	MAY	DISC

		POTASSIUM CHLORIDE						
		TABLET, EXTENDED RELEASE; ORAL						
		K-DUR 10						
	AB	KEY PHARMS	10MEQ	N19439	002	JUN 13, 1986	APR	CTEC
		PREDNICARBATE						
		OINTMENT; TOPICAL						
		DERMATOP						
	+	AVENTIS PHARMS	0.1%	N19568	001	SEP 23, 1991	MAR	CMFD
		PREDNISOLONE						
		TABLET; ORAL						
		PREDNISOLONE						
>D>	BX	CHELSEA LABS	5MG	N85085	002	FEB 23, 1977	MAY	DISC
>A>		@	5MG	N85085	002	FEB 23, 1977	MAY	DISC
		PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM						
		OINTMENT; OPHTHALMIC						
		VASOCIDIN						
	AT	NOVARTIS	0.5%;10%	N88791	001	OCT 05, 1984	FEB	CAHN
		SUSPENSION/DROPS; OPHTHALMIC						
		METIMYD						
	+	SCHERING	0.5%;10%	N10210	001	FEB 24, 1956	FEB	CTEC
		PREDAMIDE						
		@ AKORN	0.5%;10%	N88059	001	JUL 29, 1983	FEB	WDRP
		SULPHRIN						
		@ BAUSCH AND LOMB	0.5%;10%	N88089	001	DEC 28, 1982	FEB	WDRP
		PREDNISOLONE SODIUM PHOSPHATE						
		SOLUTION/DROPS; OPHTHALMIC						
		INFLAMASE FORTE						
	AT +	NOVARTIS	EQ 0.9% PHOSPHATE	N80751	002	DEC 19, 1973	FEB	CAHN
		INFLAMASE MILD						
	AT +	NOVARTIS	EQ 0.11% PHOSPHATE	N80751	001	DEC 19, 1973	FEB	CAHN
		PREDNISOLONE SODIUM PHOSPHATE						
		@ AKORN	EQ 0.11% PHOSPHATE	N83358	001	AUG 21, 1974	FEB	WDRP
		@	EQ 0.9% PHOSPHATE	N83358	002	AUG 21, 1974	FEB	WDRP
>D>	AT	ALCON UNIVERSAL	EQ 0.11% PHOSPHATE	N81043	001	OCT 24, 1991	MAY	DISC
>A>		@	EQ 0.11% PHOSPHATE	N81043	001	OCT 24, 1991	MAY	DISC
>D>	AT		EQ 0.9% PHOSPHATE	N81044	001	OCT 24, 1991	MAY	DISC
>A>		@	EQ 0.9% PHOSPHATE	N81044	001	OCT 24, 1991	MAY	DISC
		PREDNISONE						
		TABLET; ORAL						
		PREDNISONE						
>D>	AB	CHELSEA LABS	5MG	N85084	002	DEC 15, 1981	MAY	DISC
>A>		@	5MG	N85084	002	DEC 15, 1981	MAY	DISC
>D>	AB	GENEVA PHARMS	5MG	N80336	002	JUL 29, 1976	MAY	DISC
>A>		@	5MG	N80336	002	JUL 29, 1976	MAY	DISC
>D>	BX	LANNETT	20MG	N84275	001	JUN 27, 1974	MAY	DISC
>A>		@	20MG	N84275	001	JUN 27, 1974	MAY	DISC

PRIMIDONE
TABLET; ORAL

		MYSOLINE						
>D>		ELAN PHARMA	50MG	N09170 003	MAR 08, 1954	MAY	CFTG
>A>	AB		50MG	N09170 003	MAR 08, 1954	MAY	CFTG
		PRIMIDONE						
>A>	AB	LANNETT	50MG	N84903 002	MAY 24, 2001	MAY	NEWA

PROCHLORPERAZINE MALEATE
TABLET; ORAL

	PROCHLORPERAZINE MALEATE						
AB	GENEVA PHARMS TECH	EQ 5MG BASE	N40101 001	JUL 19, 1996	JAN	CAHN
AB		EQ 10MG BASE	N40101 002	JUL 19, 1996	JAN	CAHN
AB		EQ 25MG BASE	N40101 003	JUL 19, 1996	JAN	CAHN

PROGESTERONE
INJECTABLE; INJECTION

	PROGESTERONE						
AO	AM PHARM PARTNERS	50MG/ML	N75906 001	APR 25, 2001	APR	NEWA
AO +	STERIS	50MG/ML	N17362 002	MAY 08, 1978	APR	CFTG

PROMETHAZINE HYDROCHLORIDE
SUPPOSITORY; RECTAL

	PROMETHACON						
>D>	BR	POLYMEDICA	50MG	N84902 001	OCT 05, 1981	MAY	DISC
>A>		@	50MG	N84902 001	OCT 05, 1981	MAY	DISC

TABLET; ORAL

	PHENERGAN						
>D>	BP	WYETH AYERST	12.5MG	N07935 002	MAR 29, 1951	MAY	CTEC
>A>			12.5MG	N07935 002	MAR 29, 1951	MAY	CTEC
	PROMETHAZINE HCL						
>D>	BP	LANNETT	12.5MG	N80949 001	JUL 28, 1976	MAY	DISC
>A>		@	12.5MG	N80949 001	JUL 28, 1976	MAY	DISC
>D>	BP		25MG	N80949 002	JUN 28, 1976	MAY	DISC
>A>		@	25MG	N80949 002	JUN 28, 1976	MAY	DISC
>D>	BP		50MG	N80949 003	JUN 28, 1976	MAY	DISC
>A>		@	50MG	N80949 003	JUN 28, 1976	MAY	DISC
>D>	BP	PVT FORM	25MG	N83658 001	OCT 01, 1976	MAY	DISC
>A>		@	25MG	N83658 001	OCT 01, 1976	MAY	DISC

PROPOXYPHENE HYDROCHLORIDE
CAPSULE; ORAL

	PROPOXYPHENE HCL						
>D>	AA	GENEVA PHARMS	65MG	N83125 002	APR 14, 1976	MAY	DISC
>A>		@	65MG	N83125 002	APR 14, 1976	MAY	DISC
>D>	AA	IMPAX LABS	65MG	N83317 001	OCT 23, 1973	MAY	DISC
>A>		@	65MG	N83317 001	OCT 23, 1973	MAY	DISC

PROPRANOLOL HYDROCHLORIDE
TABLET; ORAL

	PROPRANOLOL HCL						
>D>	AB	LEDERLE	10MG	N70125 001	JUL 30, 1985	MAY	DISC

>A>		@	10MG	N70125 001	JUL 30, 1985	MAY	DISC
>D>	AB	WATSON LABS	20MG	N70549 001	APR 11, 1986	MAY	DISC
>A>		@	20MG	N70549 001	APR 11, 1986	MAY	DISC

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

PROTRIPTYLINE HCL

AB	ODYSSEY PHARMS	5MG	N73644 001	AUG 24, 1995	JAN	CAHN
AB		10MG	N73645 001	AUG 24, 1995	JAN	CAHN

VIVACTIL

AB	ODYSSEY PHARMS	5MG	N73644 001	AUG 24, 1995	MAR	CTNA
AB +		10MG	N73645 001	AUG 24, 1995	MAR	CTNA
	@ SIDMAK LABS	5MG	N16012 001	SEP 27, 1967	MAR	DISC
	@	10MG	N16012 002	SEP 27, 1967	MAR	DISC

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

TRILITRON

	@ NEWTRON PHARMS	30MG/5ML;1.25MG/5ML	N88474 001	FEB 12, 1985	FEB	WDRP

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE; ORAL

QUINAGLUTE

BX +	BERLEX LABS	324MG	N16647 001	DEC 08, 1969	MAR	CTEC

QUINIDINE GLUCONATE

BX	DANBURY PHARMA	324MG	N87810 001	SEP 29, 1982	MAR	CTEC
	@ GENEVA PHARMS	324MG	N89894 001	DEC 15, 1988	MAR	DISC
BX	MUTUAL PHARM	324MG	N89338 001	FEB 11, 1987	MAR	CTEC

QUINIDINE SULFATE

TABLET; ORAL

QUINIDINE SULFATE

	@ IMPAX LABS	200MG	N83347 001	DEC 08, 1976	FEB	DISC
>D>	AB	MUTUAL PHARM	300MG	N81031 001	APR 14, 1989	MAY	DISC
>A>		@	300MG	N81031 001	APR 14, 1989	MAY	DISC
>D>	AB	WEST WARD	200MG	N83862 001	SEP 02, 1976	MAY	DISC
>A>		@	200MG	N83862 001	SEP 02, 1976	MAY	DISC

RIFAMPIN

CAPSULE; ORAL

RIFAMPIN

AB	VERSAPHARM	150MG	N65028 001	MAR 14, 2001	MAR	NEWA
AB		300MG	N65028 002	MAR 14, 2001	MAR	NEWA

RISPERIDONE

TABLET; ORAL

RISPERDAL

	JANSSEN	0.5MG	N20272 007	JAN 27, 1999	APR	CRLD
+		1MG	N20272 001	DEC 29, 1993	APR	CRLD
		4MG	N20272 004	DEC 29, 1993	APR	CRLD

		SECOBARBITAL SODIUM					
		CAPSULE; ORAL					
		SECOBARBITAL SODIUM					
		@ ICN	100MG	N85477 001	DEC 10, 1981	FEB	WDRP
		SILVER SULFADIAZINE					
		DRESSING; TOPICAL					
>D>		SILDIMAC					
>D>		@ QUESTCOR PHARM	1%	N19608 001	NOV 30, 1989	MAY	CTNA
>A>		SILDAFLO					
>A>		@ QUESTCOR PHARMS	1%	N19608 001	NOV 30, 1989	MAY	CTNA
		SIMVASTATIN					
		TABLET; ORAL					
		ZOCOR					
		MERCK	5MG	N19766 001	DEC 23, 1991	APR	CTEC
		SODIUM POLYSTYRENE SULFONATE					
		SUSPENSION; ORAL, RECTAL					
		SPS					
>D>	AA	CAROLINA MEDCL	15GM/60ML	N87859 001	DEC 08, 1982	MAY	CRLD
>A>	AA +		15GM/60ML	N87859 001	DEC 08, 1982	MAY	CRLD
		SOTALOL HYDROCHLORIDE					
		TABLET; ORAL					
		SORINE					
	AB	UPSHER SMITH	80MG	N75500 001	APR 27, 2001	APR	NEWA
	AB		120MG	N75500 004	APR 27, 2001	APR	NEWA
	AB		160MG	N75500 002	APR 27, 2001	APR	NEWA
	AB		240MG	N75500 003	APR 27, 2001	APR	NEWA
		STREPTOMYCIN SULFATE					
		INJECTABLE; INJECTION					
>D>		STREPTOMYCIN SULFATE					
>D>	AP +	PFIZER	EQ 5GM BASE/VIAL	N60076 001	FEB 18, 1946	MAY	DISC
>A>		@	EQ 5GM BASE/VIAL	N60076 001	FEB 18, 1946	MAY	DISC
>D>		+	EQ 5GM BASE/VIAL	N60076 002	FEB 18, 1946	MAY	DISC
>A>		@	EQ 5GM BASE/VIAL	N60076 002	FEB 18, 1946	MAY	DISC
>D>	AP	PHARMA TEK	EQ 1GM BASE/VIAL	N64210 001	JUN 30, 1998	MAY	CTEC
>A>		+	EQ 1GM BASE/VIAL	N64210 001	JUN 30, 1998	MAY	CTEC
		SULFACETAMIDE SODIUM					
		OINTMENT; OPHTHALMIC					
>D>		BLEPH-10					
>D>	AT	ALLERGAN	10%	N84015 001	JAN 07, 1975	MAY	DISC
>A>		@	10%	N84015 001	JAN 07, 1975	MAY	DISC
		CETAMIDE					
>D>	AT	ALCON	10%	N80021 001	SEP 27, 1972	MAY	CTEC
>A>	AT +		10%	N80021 001	SEP 27, 1972	MAY	CTEC
>D>		SODIUM SULAMYD					
>D>	AT +	SCHERING	10%	N05963 002	NOV 26, 1947	MAY	DISC
>A>		@	10%	N05963 002	NOV 26, 1947	MAY	DISC
		SOLUTION/DROPS; OPHTHALMIC					

		SULFACETAMIDE SODIUM						
		SOLUTION/DROPS; OPHTHALMIC						
		BLEPH-10						
>D>	AT	ALLERGAN	10%	N80028 001	MAY 25, 1971	MAY	CRLD	
>A>	AT +		10%	N80028 001	MAY 25, 1971	MAY	CRLD	
		BLEPH-30						
>D>	AT	ALLERGAN	30%	N80028 002	MAY 25, 1971	MAY	CRLD	
>A>	AT +		30%	N80028 002	MAY 25, 1971	MAY	CRLD	
>D>		SODIUM SULAMYD						
>D>	AT +	SCHERING	10%	N05963 001	AUG 01, 1946	MAY	DISC	
>A>		@	10%	N05963 001	AUG 01, 1946	MAY	DISC	
>D>	AT +		30%	N05963 003	NOV 26, 1947	MAY	DISC	
>A>		@	30%	N05963 003	NOV 26, 1947	MAY	DISC	
		SULF-10						
		@ NOVARTIS	10%	N80025 001	JUN 03, 1971	FEB	CAHN	
		SULF-15						
	AT	NOVARTIS	15%	N89047 001	OCT 31, 1995	FEB	CAHN	
		SULTEN-10						
		@ BAUSCH AND LOMB	10%	N87818 001	FEB 03, 1983	FEB	WDRP	
		SULFAMETHOXAZOLE						
		TABLET; ORAL						
		GANTANOL						
>D>	AB +	ROCHE	500MG	N12715 002	NOV 17, 1961	MAY	CTEC	
>A>	+		500MG	N12715 002	NOV 17, 1961	MAY	CTEC	
>D>		SULFAMETHOXAZOLE						
>D>	AB	GENEVA PHARMS	500MG	N85844 001	MAR 23, 1978	MAY	DISC	
>A>		@	500MG	N85844 001	MAR 23, 1978	MAY	DISC	
		SULFAMETHOXAZOLE; TRIMETHOPRIM						
		SUSPENSION; ORAL						
		TRIMETH/SULFA						
		@ NASKA	200MG/5ML;40MG/5ML	N72399 001	MAY 23, 1988	FEB	WDRP	
		TABLET; ORAL						
		SULFAMETHOXAZOLE AND TRIMETHOPRIM						
>D>	AB	TEVA	400MG;80MG	N18242 001	MAY 19, 1981	MAY	DISC	
>A>		@	400MG;80MG	N18242 001	MAY 19, 1981	MAY	DISC	
>D>	AB		800MG;160MG	N18242 002	MAY 19, 1981	MAY	DISC	
>A>		@	800MG;160MG	N18242 002	MAY 19, 1981	MAY	DISC	
		SULFANILAMIDE						
		CREAM; VAGINAL						
		AVC						
	AT +	NOVAVAX	15%	N06530 003	JAN 27, 1987	JAN	CAHN	
		SUPPOSITORY; VAGINAL						
		+ NOVAVAX	1.05GM	N06530 004	JAN 27, 1987	JAN	CAHN	
		TECHNETIUM TC-99M APCITIDE						
		INJECTABLE; INJECTION						
		ACUTECT						
>A>		BERLEX LABS	N/A	N20887 001	SEP 14, 1998	MAY	CAHN	
>D>		DIATIDE RES LABS	N/A	N20887 001	SEP 14, 1998	MAY	CAHN	
			N/A	N20887 001	SEP 14, 1998	APR	CAHN	

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HCL

AB	TORPHARM	EQ 1MG BASE	N75498 001	APR 12, 2001	APR	NEWA
AB		EQ 2MG BASE	N75498 002	APR 12, 2001	APR	NEWA
AB		EQ 5MG BASE	N75498 003	APR 12, 2001	APR	NEWA
AB		EQ 10MG BASE	N75498 004	APR 12, 2001	APR	NEWA
AB	ZENITH GOLDLINE	EQ 1MG BASE	N75614 002	JAN 30, 2001	JAN	NEWA
AB		EQ 2MG BASE	N75614 001	JAN 30, 2001	JAN	NEWA
AB		EQ 5MG BASE	N75614 003	JAN 30, 2001	JAN	NEWA
AB		EQ 10MG BASE	N75614 004	JAN 30, 2001	JAN	NEWA

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

PANMYCIN

>D>	AB	PHARMACIA AND UPJOHN	250MG	N60347 001	SEP 28, 1954	MAY	DISC
>A>		@	250MG	N60347 001	SEP 28, 1954	MAY	DISC

ROBITET

>D>	AB	WYETH AYERST	250MG	N61734 001	JUN 06, 1973	MAY	DISC
>A>		@	250MG	N61734 001	JUN 06, 1973	MAY	DISC
>D>	AB		500MG	N61734 002	JUN 06, 1973	MAY	DISC
>A>		@	500MG	N61734 002	JUN 06, 1973	MAY	DISC

TETRACYCLINE HCL

>D>	AB	DANBURY PHARMA	250MG	N62343 001	OCT 02, 1981	MAY	DISC
>A>		@	250MG	N62343 001	OCT 02, 1981	MAY	DISC
>D>	AB		500MG	N62343 002	OCT 02, 1981	MAY	DISC
>A>		@	500MG	N62343 002	OCT 02, 1981	MAY	DISC
>D>	AB	EON	250MG	N61471 001	OCT 28, 1971	MAY	DISC
>A>		@	250MG	N61471 001	OCT 28, 1971	MAY	DISC
>D>	AB	WEST WARD	250MG	N60768 001	AUG 24, 1964	MAY	DISC
>A>		@	250MG	N60768 001	AUG 24, 1964	MAY	DISC
>D>	AB		500MG	N60768 002	NOV 07, 1977	MAY	DISC
>A>		@	500MG	N60768 002	NOV 07, 1977	MAY	DISC

THIOTEPA

INJECTABLE; INJECTION

THIOPLEX

AP	+	IMMUNEX	15MG/VIAL	N20058 001	DEC 22, 1994	APR	CFTG

THIOTEPA

AP		BEDFORD	15MG/VIAL	N75547 001	APR 02, 2001	APR	NEWA
AP		GENSIA SICOR PHARMS	15MG/VIAL	N75730 001	APR 20, 2001	APR	NEWA
	+		30MG/VIAL	N75730 002	APR 20, 2001	APR	NEWA
		@ IMMUNEX	15MG/VIAL	N11683 001	FEB 19, 1959	APR	DISC

THYROGLOBULIN

TABLET; ORAL

THYROGLOBULIN

		@ IMPAX LABS	64.8MG	N80151 001	AUG 07, 1973	FEB	DISC

TICARCILLIN DISODIUM
INJECTABLE; INJECTION
TICAR

>D>		SMITHKLINE BEECHAM	EQ 3GM BASE/VIAL	N62690	001	DEC 19, 1986	MAY	DISC
>A>		@	EQ 3GM BASE/VIAL	N62690	001	DEC 19, 1986	MAY	DISC

TOBRAMYCIN
SOLUTION/DROPS; OPHTHALMIC
TOBRAMYCIN

>D>	AT	ALCON UNIVERSAL	0.3%	N63176	001	MAY 25, 1994	MAY	DISC
>A>		@	0.3%	N63176	001	MAY 25, 1994	MAY	DISC

TOBRAMYCIN SULFATE
INJECTABLE; INJECTION
TOBRAMYCIN SULFATE

>D>	AP	ASTRAZENECA	EQ 40MG BASE/ML	N63121	001	OCT 31, 1994	MAY	DISC
>A>		@	EQ 40MG BASE/ML	N63121	001	OCT 31, 1994	MAY	DISC
>D>	AP	ELKINS SINN	EQ 10MG BASE/ML	N63128	001	NOV 27, 1991	MAY	DISC
>A>		@	EQ 10MG BASE/ML	N63128	001	NOV 27, 1991	MAY	DISC
>D>	AP		EQ 40MG BASE/ML	N63127	001	NOV 27, 1991	MAY	DISC
>A>		@	EQ 40MG BASE/ML	N63127	001	NOV 27, 1991	MAY	DISC
>D>	AP	LEDERLE	EQ 10MG BASE/ML	N63113	001	APR 26, 1991	MAY	DISC
>A>		@	EQ 10MG BASE/ML	N63113	001	APR 26, 1991	MAY	DISC

TOPIRAMATE
TABLET; ORAL
TOPAMAX

	+	JOHNSON RW	25MG	N20505	004	DEC 24, 1996	MAR	CRLD
			200MG	N20505	002	DEC 24, 1996	MAR	CRLD

TRAVOPROST
SOLUTION/DROPS; OPHTHALMIC
TRAVATAN

	+	ALCON UNIVERSAL	0.004%	N21257	001	MAR 16, 2001	MAR	NEWA

TRIAMCINOLONE
TABLET; ORAL
TRIAMCINOLONE

		@ IMPAX LABS	4MG	N84340	001	APR 22, 1975	FEB	DISC

TRIAMCINOLONE ACETONIDE
CREAM; TOPICAL
TRIAMCINOLONE ACETONIDE

>D>	AT	TARO	0.025%	N40038	001	OCT 26, 1994	MAY	DISC
>A>		@	0.025%	N40038	001	OCT 26, 1994	MAY	DISC
		@ TOPIDERM	0.025%	N89274	001	FEB 21, 1989	FEB	WDRP
		@	0.1%	N89275	001	FEB 21, 1989	FEB	WDRP
		@	0.5%	N89276	001	FEB 21, 1989	FEB	WDRP

		TRICHLORMETHIAZIDE					
		TABLET; ORAL					
>D>		TRICHLOREX					
>D>	BP	LANNETT	4MG	N83436 001	AUG 11, 1980	MAY	DISC
>A>		@	4MG	N83436 001	AUG 11, 1980	MAY	DISC
		@	4MG	N85630 001	MAY 16, 1977	FEB	WDRP
		TRIFLUOPERAZINE HYDROCHLORIDE					
		CONCENTRATE; ORAL					
>D>		TRIFLUOPERAZINE HCL					
>D>	AA	GENEVA PHARMS	EQ 10MG BASE/ML	N85787 001	APR 15, 1982	MAY	DISC
>A>		@	EQ 10MG BASE/ML	N85787 001	APR 15, 1982	MAY	DISC
		TABLET; ORAL					
	AB	GENEVA PHARMS TECH	EQ 1MG BASE	N40153 001	OCT 25, 1996	JAN	CAHN
	AB		EQ 2MG BASE	N40153 002	OCT 25, 1996	JAN	CAHN
	AB		EQ 5MG BASE	N40153 003	OCT 25, 1996	JAN	CAHN
	AB		EQ 10MG BASE	N40153 004	OCT 25, 1996	JAN	CAHN
		VALGANCICLOVIR HYDROCHLORIDE					
		TABLET; ORAL					
		VALCYTE					
	+	SYNTEX (USA) INC LLC	EQ 450MG BASE	N21304 001	MAR 29, 2001	MAR	NEWA
		VALPROIC ACID					
		CAPSULE; ORAL					
		VALPROIC ACID					
>D>	AB	PAR PHARM	250MG	N70431 001	FEB 28, 1986	MAY	DISC
>A>		@	250MG	N70431 001	FEB 28, 1986	MAY	DISC
		VANCOMYCIN HYDROCHLORIDE					
		INJECTABLE; INJECTION					
		VANCOMYCIN HCL					
>D>	AP	ELKINS SINN	EQ 500MG BASE/VIAL	N62879 001	AUG 02, 1988	MAY	DISC
>A>		@	EQ 500MG BASE/VIAL	N62879 001	AUG 02, 1988	MAY	DISC
>D>	AP		EQ 1GM BASE/VIAL	N62879 002	AUG 02, 1988	MAY	DISC
>A>		@	EQ 1GM BASE/VIAL	N62879 002	AUG 02, 1988	MAY	DISC
		VINBLASTINE SULFATE					
		INJECTABLE; INJECTION					
>D>		VELBAN					
>D>	AP +	LILLY	10MG/VIAL	N12665 001	MAR 06, 1961	MAY	DISC
>A>		@	10MG/VIAL	N12665 001	MAR 06, 1961	MAY	DISC
		VINBLASTINE SULFATE					
>D>	AP	BEDFORD	10MG/VIAL	N89395 001	APR 09, 1987	MAY	CRLD
>A>	AP +		10MG/VIAL	N89395 001	APR 09, 1987	MAY	CRLD
		VITAMIN A PALMITATE					
		CAPSULE; ORAL					
		VITAMIN A					
		@ WEST WARD	EQ 50,000 UNITS BASE	N80967 001	MAY 04, 1973	FEB	WDRP

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

GEODON

PFIZER	20MG	N20825 001	FEB 05, 2001	FEB	NEWA
	40MG	N20825 002	FEB 05, 2001	FEB	NEWA
	60MG	N20825 003	FEB 05, 2001	FEB	NEWA
+	80MG	N20825 004	FEB 05, 2001	FEB	NEWA

ZOLMITRIPTAN

TABLET, ORALLY DISINTEGRATING; ORAL

ZOMIG-ZMT

ASTRAZENECA	2.5MG	N21231 001	FEB 13, 2001	FEB	NEWA

ACETAMINOPHEN
SUPPOSITORY; RECTAL
ACETAMINOPHEN

	ALPHARMA US PHARM	120MG	N18337 003	SEP 12, 1983	MAR	CAHN
		325MG	N18337 002	AUG 21, 1981	MAR	CAHN
+		650MG	N18337 001	APR 22, 1980	MAR	CAHN
	INFANTS' FEVERALL					
	ALPHARMA US PHARM	80MG	N18337 004	AUG 26, 1992	MAR	CAHN

ACETAMINOPHEN; CLEMASTINE FUMARATE; PSEUDOEPHEDRINE HYDROCHLORIDE
TABLET; ORAL
TAVIST ALLERGY/SINUS/HEADACHE

+	NOVARTIS	500MG;EQ 0.25MG BASE;30MG	N21082 001	MAR 01, 2001	MAR	NEWA

CLEMASTINE FUMARATE; PHENYLPROPANOLAMINE HYDROCHLORIDE
TABLET, EXTENDED RELEASE; ORAL
TAVIST-D

@	NOVARTIS	1.34MG;75MG	N18298 002	AUG 21, 1992	JAN	DISC
@		1.34MG;75MG	N20640 001	AUG 09, 1996	JAN	DISC

FAMOTIDINE
TABLET; ORAL
FAMOTIDINE

>A>	TEVA	10MG	N75312 001	MAY 31, 2001	MAY	NEWA

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE
TABLET; ORAL
IBUPROHM COLD AND SINUS

	OHM LABS	200MG;30MG	N74567 001	APR 17, 2001	APR	NEWA

INSULIN PURIFIED PORK
INJECTABLE; INJECTION
REGULAR PURIFIED PORK INSULIN

>D>	NOVO NORDISK	100 UNITS/ML	N18381 001	MAR 17, 1980	MAY	CTEC
>A>	+	100 UNITS/ML	N18381 001	MAR 17, 1980	MAY	CTEC

INSULIN RECOMBINANT HUMAN
INJECTABLE; INJECTION
NOVOLIN R

>D>	NOVO NORDISK	100 UNITS/ML	N19938 001	JUN 25, 1991	MAY	CTEC
>A>	+	100 UNITS/ML	N19938 001	JUN 25, 1991	MAY	CTEC

INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN
INJECTABLE; INJECTION
HUMULIN 50/50

>D>	LILLY	50 UNITS/ML;50 UNITS/ML	N20100 001	APR 29, 1992	MAY	CTEC
>A>	+	50 UNITS/ML;50 UNITS/ML	N20100 001	APR 29, 1992	MAY	CTEC
	NOVOLIN 70/30					
>D>	NOVO NORDISK	30 UNITS/ML;70 UNITS/ML	N19991 001	JUN 25, 1991	MAY	CTEC
>A>	+	30 UNITS/ML;70 UNITS/ML	N19991 001	JUN 25, 1991	MAY	CTEC

MICONAZOLE NITRATE

>D>	CREAM; TOPICAL						
>D>	MONISTAT 3 COMBINATION PACK						
>D>	+ PERSONAL PRODS	2%;4%	N21261 001	FEB 02, 2001	MAY	CDFR	
	+ PERSONAL PRODS	2%;4%	N21261 001	FEB 02, 2001	FEB	NEWA	
>A>	CREAM; TOPICAL, VAGINAL						
>A>	MONISTAT 3 COMBINATION PACK						
>A>	+ PERSONAL PRODS	2%,4%	N21261 001	FEB 02, 2001	MAY	CDFR	

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 5 MAY '01

NO MAY 2001 APPROVALS

This data is provided to the Division of Data Management and Services from the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Products Designations and Approvals List
May 2001

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
9-nitro-20-(S)-camptothecin TN=Camvirex	Treatment of pediatric HIV infection/AIDS	NovoMed Pharmaceuticals, Inc. P.O. Box 900 Germantown MD 20875-0900 DD= 5/15/01 MA=
Alendronate disodium TN=Fosamax	Treatment of the bone manifestations of Gaucher disease	Richard J. Wenstrup, M.D. Division of Human Genetics Children's Hospital Research Cincinnati OH 45229-3039 DD= 2/13/01 MA=
B Lymphocyte Stimulator TN=BLyS	Treatment of common variable immunodeficiency (CVID)	Human Genome Sciences, Inc. 9410 Key West Avenue Rockville MD 20850 DD= 2/21/01 MA=
Busulfan TN=Spartajet-Busulfan	Intrathecal therapy for neoplastic meningitis	The Brain Tumor Center at Duke Duke University Medical Center Room 047, Baker House, South Durham NC 27710 DD= 3/5/01 MA=
Coenzyme Q10 TN=	For the treatrment of Huntington's disease	Vitaline Corporation 385 Williamson Way Ashland OR 97520 DD= 3/5/01 MA=
docosahexanoic acid-paclitaxel TN=Taxoprexin	Treatment of hormone-refractory prostate cancer.	Protarga, Inc. 1100 East Hector Street Suite 450 Conshohocken PA 19428-2377 DD= 3/5/01 MA=

Orphan Products Designations and Approvals List
May 2001

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
h5G1.1mAb TN=	Idiopathic membranous glomerular nephropathy	Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire CT 06410 DD= 3/5/01 MA=
Hsp E7 TN=	Treatment of recurrent respiratory papillomatosis (RRP)	StressGen Biotechnologies, Inc. 409 2nd Avenue Suite 201 Collegeville PA 19426-2655 DD= 3/19/01 MA=
human gammaglobulin TN=	Treatment for juvenile rheumatoid arthritis	Protein Therapeutics, Inc 9040 S. Rita Rd., Suite 1100 Tucson AZ 84747 DD= 5/25/01 MA=
Imatinib TN=Gleevec	Treatment of chronic myelogenous leukemia	Novartis Pharmaceuticals 59 Route 10 East Hanover NJ 07936-1080 DD= 1/31/01 MA= 5/10/01
Interferon-alfa-1b TN=	Treatment of multiple myeloma	Ernest C.Borden Center for Cancer Drud Discovery 9500 Euclid Avenue Clevland OH 44195 DD= 4/17/01 MA=
Medroxyprogesterone acetate TN=Hematrol	Treatment of immune thrombocytopenic purpura.	InKine Pharmaceutical Company, 1787 Sentry Parkway West Building 18, Suite 440 Blue Bell PA 19422 DD= 2/22/01 MA=

Orphan Products Designations and Approvals List
May 2001

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
MTC-DOX for Injection TN=	Treatment of hepatocellular carcinoma	FeRx Incorporated 4330 La Jolla Village Drive Suite #250 San Diego CA 92122 DD= 1/3/01 MA=
Nitroprusside TN=	Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.	Thomas, MD, Jeffrey Evan Thomas Jefferson University and 834 Walnut Street, Suite 650 Philadelphia PA 19107-5102 DD= 2/21/01 MA=
Novel Acting Thrombolytic (NAT) TN=	Treatment of peripheral arterial occlusion (PAO)	Amgen, Inc. One Amgen Center Drive Thousand Oaks CA 91320-1799 DD= 1/26/01 MA=
NZ-1002 TN=	Enzyme replacement therapy in patients with all subtypes of Mucopolysaccharidosis I.	Novazyme Pharmaceuticals, Inc. 800 Research Parkway Suite 200 Oklahoma City OK 73104 DD= 4/11/01 MA=

Orphan Products Designations and Approvals List
May 2001

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
p1-(uridine 5'-)-p4-(2'-deoxycytidine 5'-) tetraphosphate, tetrasodium salt TN=	For the treatment of cystic fibrosis	Inspire Pharmaceuticals, Inc. 4222 Emperor Blvd. Suite 470 Durham NC 27703 DD= 3/7/01 MA=
Perflubron TN=LiquiVent	Treatment of acute respiratory distress disease (ARDS) in adults	Alliance Pharmaceutical Corp. 3040 Science Park Road San Diego CA 92191 DD= 4/26/01 MA=
Polyethylene glycol (PEG)-uricase TN=	To control the clinical consequences of hyperuricemia in patients with severe gout in whom conventional therapy is contraindicated or has been ineffective.	Bio-Technology General Corporation 70 Wood Avenue South Iselin NJ 08830 DD= 2/21/01 MA=
Pyruvate TN=	Treatment of interstitial lung disease.	Cellular Sciences, Inc 84 park Avenue P.O. Box 968 Flemington NJ 08822 DD= 2/21/01 MA=
Recombinant Human Alpha-Fetoprotein TN=	Treatment of myasthenia gravis	Atlantic Biopharmaceuticals, Inc. 50 Church Street 5th floor Cambridge MA 02138 DD= 2/22/01 MA=
squalamine lactate TN=	Treatment of ovarian cancer refractory or resistant to standard chemotherapy	Genaera Corporation 5110 Campus Drive Plymouth Meeting PA 19462 DD= 5/11/01 MA=

Orphan Products Designations and Approvals List
May 2001

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Synthetic Human Parathyroid Hormone 1-34 TN=	Treatment of hypoparathyroidism	Orphan Pharmaceuticals, U.S., Inc. 1101 Kermit Drive, Suite 608 Nashville TN 37217 DD= 1/26/01 MA=
Unconjugated Chimeric (human-murine) G250 IgG monoclonal antibody TN=	Treatment of renal cell carcinoma.	Wilex Biotechnology GmbH Grillparzerstrasse 10B 81675 Munich Germany DE DD= 3/22/01 MA=
Vasoactive intestinal peptide TN=	Treatment of Acute Respiratory Distress Syndrome.	Sami I. Said, M.D. State University of New York at Health Sciences Center T17, 040 Stony Brook NY 11794-8172 DD= 3/9/01 MA=
Virulizin TN=Virulizin	Treatment of pancreatic cancer.	Lorus Therapeutics Inc. 7100 Woodbine Avenue, Suite 215 Markham, ON L3R 5J2 Canada DD= 2/1/01 MA=

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO MAY 2001 ADDITIONS

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021205 001	ABACAVIR SULFATE;TRIZIVIR	6180639	JAN 30, 2018	U-248		
	021082 001	ACETAMINOPHEN;TAVIST ALLERGY/SINUS				NC	MAR 01, 2004
	020760 001	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE	6194429	JUL 23, 2018			
	020760 002	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE	6194429	JUL 23, 2018		NCE	DEC 18, 2002
	020949 001	ALBUTEROL SULFATE;ACCUNEB				NP	APR 30, 2004
	020949 002	ALBUTEROL SULFATE;ACCUNEB				NP	APR 30, 2004
	020950 001	ALBUTEROL SULFATE;DUONEB				NP	MAR 21, 2004
>ADD>	020983 001	ALBUTEROL SULFATE;VENTOLIN HFA	6251368	DEC 04, 2012		I-235	SEP 23, 2001
						I-262	JUN 02, 2002
	021074 001	ALCOHOL;AVAGARD	5897031	JUN 21, 2016		NC	JUN 07, 2004
	020560 001	ALENDRONATE SODIUM;FOSAMAX	6194004	DEC 02, 2012			
	020560 004	ALENDRONATE SODIUM;FOSAMAX	6225294	JUL 17, 2018			
	020560 005	ALENDRONATE SODIUM;FOSAMAX	6225294	JUL 17, 2018			
	021001 001	ALMOTRIPTAN MALATE;AXERT				NCE	MAY 07, 2006
	021001 002	ALMOTRIPTAN MALATE;AXERT				NCE	MAY 07, 2006
	021107 001	ALOSETRON HYDROCHLORIDE;LOTRONEX	5360800	FEB 02, 2010			
	021078 001	ATOVAQUONE;MALARONE	6166046	NOV 25, 2013		NC	JUL 14, 2003
			5053432	OCT 01, 2008			
	021078 002	ATOVAQUONE;MALARONE PEDIATRIC	5053432	OCT 01, 2008		NC	JUL 14, 2003
	019408 002	BETAMETHASONE DIPROPIONATE;DIPROLENE	4489070	MAY 13, 2003			
>ADD>	021056 001	BEXAROTENE;TARGRETIN	5780676	JUL 14, 2015		ODE	DEC 29, 2006
			5962731	OCT 05, 2016			
			5466861	NOV 14, 2012			
>ADD>	020498 001	BICALUTAMIDE;CASODEX	1712251	SEP 18, 2001	U-391		
>ADD>			5712251	SEP 18, 2001	U-391		
	021275 001	BIMATOPROST;LUMIGAN	5688819	SEP 21, 2012		NCE	MAR 16, 2006
	021262 001	BRIMONIDINE TARTRATE;ALPHAGAN P				NP	MAY 16, 2004
	074253 001	BUSPIRONE HYDROCHLORIDE;BUSPIRONE HCL				PC	SEP 26, 2001
	074253 002	BUSPIRONE HYDROCHLORIDE;BUSPIRONE HCL				PC	SEP 26, 2001
	075272 003	BUSPIRONE HYDROCHLORIDE;BUSPIRONE HCL				PC	SEP 24, 2001
	075467 002	BUSPIRONE HYDROCHLORIDE;BUSPIRONE HCL				PC	SEP 26, 2001
	018874 001	CALCITRIOL;CALCIJEX	4308264	JAN 28, 2001			
			6051567	AUG 02, 2019			
			4308264*PED	JUL 28, 2001			
			6051567*PED	FEB 02, 2020			
	018874 002	CALCITRIOL;CALCIJEX	4308264	JAN 28, 2001			
			6051567	AUG 02, 2019			
			4308264*PED	JUL 28, 2001			
			6051567*PED	FEB 02, 2020			
	019976 001	CALCIUM ACETATE;PHOSLO	4870105	APR 07, 2007	U-381		
	021160 001	CALCIUM ACETATE;PHOSLO	4870105	APR 07, 2007	U-381		
	021160 002	CALCIUM ACETATE;PHOSLO	4870105	APR 07, 2007	U-381		
	020896 001	CAPECITABINE;XELODA				I-323	APR 30, 2004
	020896 002	CAPECITABINE;XELODA				I-323	APR 30, 2004

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021227 001	CASPOFUNGIN ACETATE;CANCIDAS	5952300	MAR 28, 2017		NCE	JAN 26, 2006
			5378804	MAR 16, 2013			
			5514650	MAR 16, 2013			
			5792746	MAR 16, 2013			
			6136783	MAR 28, 2017			
	021227 002	CASPOFUNGIN ACETATE;CANCIDAS	5952300	MAR 28, 2017		NCE	JAN 26, 2006
			5378804	MAR 16, 2013			
			5514650	MAR 16, 2013			
			5792746	MAR 16, 2013			
			6136783	MAR 28, 2017			
	019111 001	CHLORPHENIRAMINE POLISTIREX;TUSSIONEX	4762709	AUG 09, 2005			
	021022 001	CICLOPIROX;PENLAC	4957730	SEP 18, 2007	U-379		
	020705 001	DELAVIRDINE MESYLATE;RESCRIPTOR	6177101	JUN 11, 2018			
>ADD>	020607 001	DICLOFENAC SODIUM;ARTHROTEC	5698225	MAY 03, 2010	U-392		
>ADD>	020607 002	DICLOFENAC SODIUM;ARTHROTEC	5698225	MAY 03, 2010	U-392		
	021005 001	DICLOFENAC SODIUM;SOLARAZE				NP	OCT 16, 2003
	020154 002	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
			5254539	AUG 29, 2006	U-248		
			5880106	JUL 22, 2011			
	020154 003	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
			5254539	AUG 29, 2006	U-248		
			5880106	JUL 22, 2011			
	020154 004	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
			5254539	AUG 29, 2006	U-248		
			5880106	JUL 22, 2011			
	020154 005	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
			5254539	AUG 29, 2006	U-248		
			5880106	JUL 22, 2011			
	020154 006	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
			5254539	AUG 29, 2006	U-248		
			5880106	JUL 22, 2011			
	020155 003	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
			5254539	AUG 29, 2006	U-248		
	020155 004	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
			5254539	AUG 29, 2006	U-248		
	020155 005	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
			5254539	AUG 29, 2006	U-248		
	020156 001	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
			5254539	AUG 29, 2006	U-248		
	021183 001	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248		
			5254539	AUG 29, 2006	U-248		
	021183 002	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248		
			5254539	AUG 29, 2006	U-248		
	021183 003	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248		
			5254539	AUG 29, 2006	U-248		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021183 004	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248		
			5254539	AUG 29, 2006	U-248		
	020623 001	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011			
	020623 002	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011			
	020624 001	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011			
>ADD>	020690 001	DONEPEZIL HYDROCHLORIDE;ARICEPT	6245911	DEC 01, 2018			
>ADD>	020690 002	DONEPEZIL HYDROCHLORIDE;ARICEPT	6245911	DEC 01, 2018			
>ADD>	020869 001	DORZOLAMIDE HYDROCHLORIDE;COSOPT	6248735	APR 17, 2011			
	021098 001	DROSPIRENONE;YASMIN				NC	MAY 11, 2004
	018998 001	ENALAPRIL MALEATE;VASOTEC				M-7	DEC 13, 2004
	018998 002	ENALAPRIL MALEATE;VASOTEC				M-7	DEC 13, 2004
	018998 003	ENALAPRIL MALEATE;VASOTEC				M-7	DEC 13, 2004
	018998 005	ENALAPRIL MALEATE;VASOTEC				M-7	DEC 13, 2004
	020164 002	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
			4692435	DEC 24, 2004	U-123		
			5389618	FEB 14, 2012			
	020164 003	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
			4692435	DEC 24, 2004	U-123		
			5389618	FEB 14, 2012			
	020164 004	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
			4692435	DEC 24, 2004	U-123		
			5389618	FEB 14, 2012			
	020164 005	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
			4692435	DEC 24, 2004	U-123		
			5389618	FEB 14, 2012			
	020164 006	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001			
			4692435	DEC 24, 2004	U-123		
			5389618	FEB 14, 2012			
	020164 007	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
			4692435	DEC 24, 2004	U-123		
			5389618	FEB 14, 2012			
	020164 008	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
			4692435	DEC 24, 2004	U-123		
			5389618	FEB 14, 2012			
	020718 001	EPTIFIBATIDE;INTEGRILIN				D-66	JUN 08, 2004
	020718 002	EPTIFIBATIDE;INTEGRILIN				D-66	JUN 08, 2004
	021153 001	ESOMEPRAZOLE MAGNESIUM;NEXIUM	4255431	APR 05, 2001	U-373	NP	FEB 20, 2004
			4738974	APR 19, 2005	U-373		
			4636499	MAY 30, 2005	U-373		
			5900424	MAY 04, 2016	U-373		
			4786505	APR 20, 2007	U-373		
			4853230	APR 20, 2007	U-373		
			5714504	FEB 03, 2015	U-373		
			5877192	MAY 27, 2014	U-373		
			5093342	FEB 02, 2010	U-373		
			5599794	FEB 04, 2014	U-373		
			5629305	FEB 04, 2014	U-373		
			5690960	NOV 25, 2014	U-373		
			6147103	OCT 09, 2018			
			6166213	OCT 09, 2018			
			6191148	OCT 09, 2018			
			4508905	FEB 20, 2001			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021153 002	ESOMEPRAZOLE MAGNESIUM;NEXIUM	4255431	APR 05, 2001	U-373	NP	FEB 20, 2004
		4738974	APR 19, 2005	U-373		
		4636499	MAY 30, 2005	U-373		
		5900424	MAY 04, 2016	U-373		
		4786505	APR 20, 2007	U-373		
		4853230	APR 20, 2007	U-373		
		5714504	FEB 03, 2015	U-373		
		5877192	MAY 27, 2014	U-373		
		5093342	FEB 02, 2010	U-373		
		5599794	FEB 04, 2014	U-373		
		5629305	FEB 04, 2014	U-373		
		5690960	NOV 25, 2014	U-373		
		6147103	OCT 09, 2018			
		6166213	OCT 09, 2018			
		6191148	OCT 09, 2018			
		4508905	FEB 20, 2001			
020538 005	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014			
		5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
020538 006	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014			
		5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
020538 007	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014			
		5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
020538 008	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014			
		5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
020946 001	ETHINYL ESTRADIOL;PREVEN EMERGENCY CON	6156742	DEC 05, 2020	U-374		
020584 001	ETODOLAC;LODINE XL				I-321	AUG 11, 2003
020584 002	ETODOLAC;LODINE XL				I-321	AUG 11, 2003
020584 003	ETODOLAC;LODINE XL				I-321	AUG 11, 2003
020902 001	FAMOTIDINE;PEPCID AC				D-47	NOV 09, 2001
					PED	MAY 09, 2002
020625 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6187791	MAY 11, 2012	U-138		
020872 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6187791	MAY 11, 2012	U-138		
020872 002	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6187791	MAY 11, 2012	U-138		
020872 004	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6187791	MAY 11, 2012	U-138		
020786 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA-D	6187791	MAY 11, 2012	U-138		
020985 001	FLUOROURACIL;CARAC	4690825	OCT 04, 2005			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021235 001	FLUOXETINE HYDROCHLORIDE;PROZAC WEEKLY				NDF	FEB 26, 2004
	018936 007	FLUOXETINE HYDROCHLORIDE;SARAFEM				PED	JAN 06, 2004
	021077 001	FLUTICASONE PROPIONATE;ADVAIR DISKUS 100/50	5270305	SEP 07, 2010	U-387		
			5290815	MAR 01, 2011	U-386		
	021077 002	FLUTICASONE PROPIONATE;ADVAIR DISKUS 250/50	5270305	SEP 07, 2010	U-387		
			5290815	MAR 01, 2011	U-386		
	021077 003	FLUTICASONE PROPIONATE;ADVAIR DISKUS 500/50	5270305	SEP 07, 2010	U-387		
			5290815	MAR 01, 2011	U-386		
	020831 001	FORMOTEROL FUMARATE;FORADIL				NCE	FEB 16, 2006
	021169 001	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
	021169 002	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
	021169 003	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
	021224 001	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
	020387 001	HYDROCHLOROTHIAZIDE;HYZAAR	5608075	MAR 04, 2014			
	020387 002	HYDROCHLOROTHIAZIDE;HYZAAR	5608075	MAR 04, 2014			
	020402 002	IBUPROFEN POTASSIUM;ADVIL MIGRAINE LIQUI				NP	MAR 16, 2003
	021128 001	IBUPROFEN;CHILDREN'S MOTRIN CO	6211246	JUN 10, 2019			
	021335 002	IMATINIB MESYLATE;GLEEVEC				NCE	MAY 10, 2006
						ODE	MAY 10, 2008
	021081 001	INSULIN GLARGINE;LANTUS	5656722	SEP 12, 2014			
	020394 001	IPRATROPIUM BROMIDE;ATROVENT				I-327	OCT 27, 2003
	018662 002	ISOTRETINOIN;ACCUTANE	4464394	AUG 07, 2001			
			4464394*PED	FEB 07, 2002			
	018662 003	ISOTRETINOIN;ACCUTANE	4464394	AUG 07, 2001			
			4464394*PED	FEB 07, 2002			
	018662 004	ISOTRETINOIN;ACCUTANE	4464394	AUG 07, 2001			
			4464394*PED	FEB 07, 2002			
	020857 001	LAMIVUDINE;COMBIVIR	6180639	JAN 30, 2018	U-248		
	020564 001	LAMIVUDINE;EPIVIR	6180639	JAN 30, 2018	U-248		
	020596 001	LAMIVUDINE;EPIVIR	6180639	JAN 30, 2018	U-248		
	021281 001	LANSOPRAZOLE;PREVACID				I-316	NOV 30, 2003
						M-1	JUL 06, 2002
						D-42	JUL 20, 2001
	021281 002	LANSOPRAZOLE;PREVACID				I-316	NOV 30, 2003
						M-1	JUL 06, 2002
						D-42	JUL 20, 2001
	020905 001	LEFLUNOMIDE;ARAVA	4284786	DEC 13, 2001			
	020905 002	LEFLUNOMIDE;ARAVA	4284786	DEC 13, 2001			
	020905 003	LEFLUNOMIDE;ARAVA	4284786	DEC 13, 2001			
	021088 001	LEUPROLIDE ACETATE;VIADUR	6235712	JUN 13, 2017			
	021226 001	LOPINAVIR;KALETRA	6232333	NOV 07, 2017			
	020386 001	LOSARTAN POTASSIUM;COZAAR	5608075	MAR 04, 2014			
	020386 002	LOSARTAN POTASSIUM;COZAAR	5608075	MAR 04, 2014			
>ADD>	019643 002	LOVASTATIN;MEVACOR	4231938	JUN 15, 2001		I-250	MAR 11, 2002
>ADD>			4231938*PED	DEC 15, 2001		PED	SEP 11, 2002

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	019643 003	LOVASTATIN;MEVACOR	4231938	JUN 15, 2001		I-250	MAR 11, 2002
>ADD>			4231938*PED	DEC 15, 2001		PED	SEP 11, 2002
>ADD>	019643 004	LOVASTATIN;MEVACOR	4231938	JUN 15, 2001		I-250	MAR 11, 2002
>ADD>			4231938*PED	DEC 15, 2001		PED	SEP 11, 2002
	020357 001	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
	020357 002	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
	020357 003	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
	020357 004	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
	020357 005	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
	021121 001	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	4783337	SEP 16, 2003	U-372		
	021121 002	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	4783337	SEP 16, 2003	U-372		
	021121 003	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	4783337	SEP 16, 2003	U-372	NP	AUG 01, 2003
	019962 001	METOPROLOL SUCCINATE;TOPROL-XL	4927640	MAY 22, 2007		I-194	FEB 05, 2004
			5246714	SEP 21, 2010			
	019962 002	METOPROLOL SUCCINATE;TOPROL-XL	4927640	MAY 22, 2007		I-194	FEB 05, 2004
			5246714	SEP 21, 2010			
	019962 003	METOPROLOL SUCCINATE;TOPROL-XL	4927640	MAY 27, 2007		I-194	FEB 05, 2004
			5246714	SEP 21, 2010			
	019962 004	METOPROLOL SUCCINATE;TOPROL-XL	4957745	SEP 18, 2007	U-107	NS	FEB 05, 2004
			5001161	MAR 19, 2008	U-107	I-194	FEB 05, 2004
			5081154	JAN 14, 2009	U-107		
			4927640	MAY 22, 2007			
			5246714	SEP 21, 2010			
			6153635	NOV 28, 2020			
>ADD>	021308 001	MICONAZOLE NITRATE;MONISTAT 1 COMBINATI	5514698	MAR 21, 2014			
>ADD>			5178878	JAN 12, 2010		NCE	JUN 14, 2001
	021208 001	MIRTAZAPINE;REMERON SOLTAB	5178878	JAN 12, 2010		NCE	JUN 14, 2001
	021208 002	MIRTAZAPINE;REMERON SOLTAB	5178878	JAN 12, 2010		NCE	JUN 14, 2001
	021208 003	MIRTAZAPINE;REMERON SOLTAB	4617319	JUN 13, 2005	U-390	I-324	OCT 13, 2003
	019297 001	MITOXANTRONE HYDROCHLORIDE;NOVANTRONE	5565473	FEB 03, 2012	U-228		
	020829 002	MONTELUKAST SODIUM;SINGULAIR	5565473	FEB 03, 2012	U-228		
	020830 001	MONTELUKAST SODIUM;SINGULAIR	5565473	FEB 03, 2012	U-228		
	020830 002	MONTELUKAST SODIUM;SINGULAIR				I-329	APR 27, 2004
	021085 001	MOXIFLOXACIN HYDROCHLORIDE;AVELOX	RE34878	MAR 28, 2006			
	021204 001	NATEGLINIDE;STARLIX	5463116	OCT 21, 2012			
			5488150	JAN 30, 2013			
	021204 002	NATEGLINIDE;STARLIX	RE34878	MAR 28, 2006			
			5463116	OCT 21, 2012			
			5488150	JAN 30, 2013			
	020165 004	NICOTINE;NICODERM CQ	6165497	JUN 14, 2008	U-388		
			5633008	JUN 14, 2008	U-389		
	020165 005	NICOTINE;NICODERM CQ	5633008	JUN 14, 2008	U-389		
			6165497	JUN 14, 2008	U-388		
	020165 006	NICOTINE;NICODERM CQ	5633008	JUN 14, 2008	U-389		
			6165497	JUN 14, 2008	U-388		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	075269 001	NIFEDIPINE;NIFEDIPINE				PC	JUN 05, 2001
	075269 002	NIFEDIPINE;NIFEDIPINE				PC	JUN 05, 2001
	021008 001	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5753618	JUL 08, 2008			
	021008 002	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5753618	JUL 08, 2008			
	021008 003	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5753618	JUL 08, 2008			
	020592 005	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	U-149	NCE	SEP 30, 2001
			5605897	FEB 25, 2014	U-176		
>ADD>	021086 001	OLANZAPINE;ZYPREXA ZYDIS	6251895	SEP 23, 2017			
			6020487	SEP 23, 2017			
>ADD>	021086 002	OLANZAPINE;ZYPREXA ZYDIS	6251895	SEP 23, 2017			
			6020487	SEP 23, 2017			
>ADD>	021086 003	OLANZAPINE;ZYPREXA ZYDIS	6251895	SEP 23, 2017			
			6020487	SEP 23, 2017			
>ADD>	021086 004	OLANZAPINE;ZYPREXA ZYDIS	6251895	SEP 23, 2017			
			6020487	SEP 23, 2017			
	019810 001	OMEPRAZOLE;PRILOSEC	6150380	NOV 10, 2018		PED	DEC 29, 2001
			6147103	OCT 09, 2018			
			6166213	OCT 09, 2018			
			6191148	OCT 09, 2018			
			4255431*PED	OCT 05, 2001	U-108		
			4636499*PED	JAN 30, 2006			
			4786505*PED	OCT 20, 2007	U-108		
			4853230*PED	OCT 20, 2007	U-108		
			5093342*PED	AUG 02, 2010	U-166		
			5599794*PED	AUG 04, 2014	U-166		
			5629305*PED	AUG 04, 2014	U-188		
			6147103*PED	APR 09, 2019			
			6150380*PED	MAY 10, 2019			
			6166213*PED	APR 09, 2018			
			6191148*PED	APR 09, 2019			
			4508905	APR 02, 2002			
	019810 002	OMEPRAZOLE;PRILOSEC	6150380	NOV 10, 2018		PED	DEC 29, 2001
			6147103	OCT 09, 2018			
			6166213	OCT 09, 2018			
			6191148	OCT 09, 2018			
			4255431*PED	OCT 05, 2001	U-108		
			4636499*PED	JAN 30, 2006			
			4786505*PED	OCT 20, 2007	U-108		
			4853230*PED	OCT 20, 2007	U-108		
			5093342*PED	AUG 02, 2010	U-166		
			5599794*PED	AUG 04, 2014			
			5629305*PED	AUG 04, 2014	U-166		
			6147103*PED	APR 09, 2019	U-188		
			6150380*PED	MAY 10, 2019			
			6166213*PED	APR 09, 2018			
			6191148*PED	APR 09, 2019			
			4508905	APR 02, 2002			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	019810 003	OMEPRAZOLE;PRILOSEC	6150380	NOV 10, 2018		I-229	JUN 29, 2001
			6147103	OCT 09, 2018		PED	DEC 29, 2001
			6166213	NOV 10, 2018			
			6191148	OCT 09, 2018			
			4255431*PED	OCT 05, 2001	U-108		
			4636499*PED	JAN 30, 2006			
			4786505*PED	OCT 20, 2007	U-108		
			4853230*PED	OCT 20, 2007	U-108		
			5093342*PED	AUG 02, 2010	U-166		
			5599794*PED	AUG 04, 2014	U-166		
			5629305*PED	AUG 04, 2014	U-188		
			6147103*PED	APR 09, 2019			
			6150380*PED	MAY 10, 2019			
			6166213*PED	APR 09, 2018			
			6191148*PED	APR 09, 2019			
			4508905	APR 02, 2002			
	021246 001	OSELTAMIVIR PHOSPHATE;TAMIFLU	5763483	DEC 27, 2016	U-376	I-317	NOV 17, 2003
			5866601	FEB 02, 2016		NDF	DEC 14, 2003
			5952375	FEB 02, 2016		NCE	OCT 27, 2004
	020897 001	OXYBUTYNIN CHLORIDE;DITROPAN XL	6124355	MAY 22, 2015	U-378		
	020897 002	OXYBUTYNIN CHLORIDE;DITROPAN XL	6124355	MAY 22, 2015	U-378		
	020897 003	OXYBUTYNIN CHLORIDE;DITROPAN XL	6124355	MAY 22, 2015	U-378		
>ADD>	020553 004	OXYCODONE HYDROCHLORIDE;OXYCONTIN	4861598	AUG 29, 2006			
>ADD>			4970075	NOV 13, 2007			
>ADD>			5266331	FEB 05, 2008			
>ADD>			5549912	FEB 05, 2008			
>ADD>	020553 005	OXYCODONE HYDROCHLORIDE;OXYCONTIN	4861598	AUG 29, 2006			
>ADD>			4970075	NOV 13, 2007			
>ADD>			5266331	FEB 05, 2008			
>ADD>			5549912	FEB 05, 2008			
>ADD>			5508042	APR 16, 2013			
>ADD>			5656295	FEB 05, 2008			
>ADD>			6150398	MAY 08, 2011	U-380		
	020262 001	PACLITAXEL;TAXOL				I-330	JUN 12, 2004
	020987 001	PANTOPRAZOLE SODIUM;PROTONIX	4758579	JUL 19, 2005		NDF	MAR 22, 2004
	020988 001	PANTOPRAZOLE SODIUM;PROTONIX IV				NCE	FEB 02, 2005
						I-326	APR 13, 2004
	020031 001	PAROXETINE HYDROCHLORIDE;PAXIL				I-326	APR 13, 2004
	020031 002	PAROXETINE HYDROCHLORIDE;PAXIL				I-326	APR 13, 2004
	020031 003	PAROXETINE HYDROCHLORIDE;PAXIL				I-326	APR 13, 2004
	020031 004	PAROXETINE HYDROCHLORIDE;PAXIL				I-326	APR 13, 2004
	020031 005	PAROXETINE HYDROCHLORIDE;PAXIL					
	020936 003	PAROXETINE HYDROCHLORIDE;PAXIL CR	4721723	DEC 29, 2006			
			4839177	JUN 13, 2006			
			5422123	JUN 06, 2012			
			5789449	JAN 06, 2009	U-286		
			5872132	MAY 19, 2015			
			5900423	MAY 19, 2015			
			6063927	APR 23, 2019			
			6080759	MAY 19, 2015			
			6121291	MAR 17, 2017	U-286		
			6133289	MAY 19, 2015	U-286		
			6172233	JAN 15, 2018			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020667 005	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	MAR 25, 2011			
	019627 002	PROPOFOL;DIPRIVAN				I-322	FEB 20, 2004
	020973 002	RABEPRAZOLE SODIUM;ACIPHEX	5045552	SEP 03, 2008	U-385		
			5035899	APR 04, 2009	U-385		
	020815 001	RALOXIFENE HYDROCHLORIDE;EVISTA	4418068	APR 03, 2002			
>ADD>	019901 001	RAMIPRIL;ALTACE	5061722	OCT 19, 2008			
>ADD>	019901 002	RAMIPRIL;ALTACE	5061722	OCT 19, 2008			
>ADD>	019901 003	RAMIPRIL;ALTACE	5061722	OCT 19, 2008			
>ADD>	019901 004	RAMIPRIL;ALTACE	5061722	OCT 19, 2008			
	020903 001	RIBAVIRIN;REBETOL	6172046	SEP 21, 2017	U-377	PED	JUN 09, 2002
			5767097*PED	JUL 23, 2016	U-235	PED	DEC 03, 2001
			5914128*PED	JUN 22, 2018			
			6051252*PED	JUN 22, 2018			
			6063772*PED	JUL 23, 2017	U-375		
			6172046*PED	MAR 21, 2018	U-377		
	020945 001	RITONAVIR;NORVIR	6232333	NOV 07, 2017			
	021042 001	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266		
			5691374	NOV 25, 2017			
			6239173	JUN 24, 2013			
	021042 002	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266		
			5691374	NOV 25, 2017			
			6239173	JUN 24, 2013			
	021042 003	ROFECOXIB;VIOXX	6239173	JUN 24, 2013			
			5474995	JUN 24, 2013	U-266		
			5691374	NOV 25, 2017			
	021052 001	ROFECOXIB;VIOXX	6239173	JUN 24, 2013			
	021052 002	ROFECOXIB;VIOXX	6239173	JUN 24, 2013			
	020632 001	SIBUTRAMINE HYDROCHLORIDE;MERIDIA				D-65	FEB 16, 2004
	020632 002	SIBUTRAMINE HYDROCHLORIDE;MERIDIA				D-65	FEB 16, 2004
	020632 003	SIBUTRAMINE HYDROCHLORIDE;MERIDIA				D-65	FEB 16, 2004
	020280 001	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	JUN 11, 2018			
	020280 002	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	JUN 11, 2018			
	020280 003	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	JUN 11, 2018			
	020280 005	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	JUN 11, 2018			
	020280 008	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	JUN 11, 2018			
	020280 009	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	JUN 11, 2018			
	021151 001	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
						PED	AUG 22, 2003
	021151 002	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
						PED	AUG 22, 2003
	021151 003	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
						PED	AUG 22, 2003
>ADD>	020330 001	TIMOLOL MALEATE;TIMOPTIC-XE	4861760	SEP 25, 2006			
>ADD>	020330 002	TIMOLOL MALEATE;TIMOPTIC-XE	4861760	SEP 25, 2006			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021257 001	TRAVOPROST;TRAVATAN	6011062	DEC 22, 2014	U-382	NCE	MAR 16, 2006
			5631287	DEC 22, 2014	U-382		
			5849792	DEC 22, 2014	U-383		
			5889052	AUG 03, 2013	U-383		
			6235781	JUN 15, 2019	U-382		
>ADD>	019963 001	TRETINOIN;RENOVA	RE36068	JUL 29, 2003	U-131		
>ADD>	021108 001	TRETINOIN;RENOVA	RE36068	JUL 29, 2003	U-131		
>ADD>			4603146	JUL 29, 2003	U-131		
	020475 001	TRETINOIN;RETIN-A MICRO	5955109	SEP 21, 2016	U-134		
	020468 001	TRIAMCINOLONE ACETONIDE;NASACORT AQ	6143329	JUL 03, 2016			
	020759 001	TROVAFLOXACIN MESYLATE;TROVAN	6187341	JAN 20, 2019			
	020759 002	TROVAFLOXACIN MESYLATE;TROVAN	6187341	JAN 20, 2019			
	021304 001	VALGANCICLOVIR HYDROCHLORIDE;VALCYTE	6083953	JUL 28, 2014	U-384	NE	MAR 29, 2004
	020151 001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR				I-325	MAY 02, 2004
	020151 002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR				I-325	MAY 02, 2004
	020151 003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR				I-325	MAY 02, 2004
	020151 004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR				I-325	MAY 02, 2004
	020151 005	VENLAFAXINE HYDROCHLORIDE;EFFEXOR				I-325	MAY 02, 2004
	020151 006	VENLAFAXINE HYDROCHLORIDE;EFFEXOR				I-325	MAY 02, 2004
	020699 001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR				I-325	MAY 02, 2004
	020699 002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR				I-325	MAY 02, 2004
	020699 004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR				I-328	SEP 17, 2002
	020547 001	ZAFIRLUKAST;ACCOLATE				I-328	SEP 17, 2002
	020547 003	ZAFIRLUKAST;ACCOLATE				M-8	FEB 22, 2004
	020859 001	ZALEPLON;SONATA				M-8	FEB 22, 2004
	020859 002	ZALEPLON;SONATA				NCE	FEB 05, 2006
	020825 001	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007			
			5312925	SEP 01, 2012			
	020825 002	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
			5312925	SEP 01, 2012			
	020825 003	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
			5312925	SEP 01, 2012			
	020825 004	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
			5312925	SEP 01, 2012			
	021231 001	ZOLMITRIPTAN;ZOMIG-ZMT				NDF	FEB 13, 2004

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 21ST EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION.

ABBREVIATIONS

REFERENCES

NEW DOSING SCHEDULE

D-47	PREVENTION OF HEARTBURN SYMPTOMS WHEN ADMINISTERED FROM 15 MINUTES UP TO, BUT NOT INCLUDING, 1 HOUR PRIOR TO A PROVOCATIVE MEAL
D-65	CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS
D-66	DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI

NEW INDICATION

I-321	JUVENILE RHEUMATOID ARTHRITIS
I-322	USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS
I-323	COLORECTAL CANCER
I-324	REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING RELAPSING-REMITTING MULTIPLE SCLEROSIS
I-325	PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION
I-326	GENERALIZED ANXIETY DISORDER
I-327	SYMPTOMATIC RELIEF OF RHINOORRHEA ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN PATIENTS 5 YEARS AND OLDER
I-328	PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 5-6 YEARS OF AGE
I-329	UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
I-330	MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND CONTROL OF DAYTIME AND NIGHTTIME HEARTBURN SYSTOMS IN PATIENTS WITH GERD

MISCELLANEOUS EXCLUSIVITY CODES

M-6	ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUOPHAGE/GLYBURIDE COMBINATION ADDED TO CLIN PHARM AND DOSING AND ADMIN
M-7	CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION INFORMATION
M-8	ADDITIONAL INFORMATION FOR THE USE OF SONATA CAPSULES FOR UP TO 5 WEEKS (35 NIGHTS) OF TREATMENT IN A CONTROLLED TRIAL SETTING

PATENT AND EXCLUSIVITY TERMS

REFERENCES
PATENT USE CODE

U-267 PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE FOOD/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE

U-372 METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...

U-373 GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING "PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OFGERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE

U-374 KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX

U-375 METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C

U-376 TREATMENT OF INFLUENZA

U-377 METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS

U-378 METHOD FOR TREATING INCONTINENCE

U-379 METHOD OF TREATING ONYCHROMYCOSIS

U-380 COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS

U-381 TREATMENT OF HYPERPHOSPHATEMIA

U-382 METHOD OF STABLIZING PROSTAGLANDIN

U-383 METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION

U-384 TREATMENT OF CMV RETINITIS

U-385 TREATMENT OF PEPTIC ULCERS

U-386 TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA

U-387 TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS

U-388 SMOKING CESSATION AID APPLIED TO THE SKIN

U-389 SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS

U-390 METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS)

U-391 USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE CANCER

U-392 TREATMENT OF PATIENTS FOR INFLAMMATION

*U.S. Government Printing Office: 2001 — 472-432/21012

New 21st Edition

APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

21ST EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 8367

Charge your order. It's easy!

MasterCard VISA

☐ **Yes,** enter my subscription as follows:

_subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $101.00 per year.

The total cost of my order is $_____. Price includes regular shipping and handling and is subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account ☐☐☐☐☐☐–☐

☐ VISA or MasterCard
☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

_____
(Credit card expiration date)

Thank you for your order!

_____
(Authorizing Signature)

(10/00)

_____
Company or personal name

_____
Additional address/attention line

_____
Street address

_____
City, State, ZIP Code

(____)_____
Daytime phone including area code

_____
Purchase Order No. (optional)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2250.
To charge your subscription call (202) 512-1800.

Approved drug products with therapeutic equivalence